Phenylketonuria

🏷

Classifications

Harrison's Chapter

🔗

Mappings

MONDO

MONDO:0009861 phenylketonuria

Orphanet ORPHA:716 lists MONDO:0009861 as an exact cross-reference for phenylketonuria.

📘

Definitions

1

Orphanet phenylketonuria definition

A rare inborn error of amino acid metabolism with elevated blood phenylalanine and low or absent phenylalanine hydroxylase enzyme activity, causing mild to severe mental disability if not detected early or left untreated.

OTHER

Show evidence (1 reference)

ORPHA:716 SUPPORT Other

"A rare inborn error of amino acid metabolism characterized by elevated blood phenylalanine and low levels or absence of phenylalanine hydroxylase enzyme."

Orphanet's definition supports the disease-level biochemical characterization.

👪

Inheritance

1

Autosomal Recessive HP:0000007

Biallelic pathogenic PAH variants are required for disease expression.

Autosomal recessive inheritance

Show evidence (2 references)

PMID:21555948 SUPPORT Human Clinical

"Phenylalanine hydroxylase deficiency is an autosomal recessive disorder that results in intolerance to the dietary intake of the essential amino acid phenylalanine."

Confirms autosomal recessive inheritance for PAH deficiency (PKU).

ORPHA:716 SUPPORT Other

"Autosomal recessive"

Orphanet independently classifies ORPHA:716 as autosomal recessive.

◆

Subtypes

3

Classic PKU

Severe PAH deficiency with blood Phe greater than 1200 micromol/L untreated.

Show evidence (1 reference)

PMID:21555948 SUPPORT Human Clinical

"Deficiency of this enzyme produces a spectrum of disorders including classic phenylketonuria, mild phenylketonuria, and mild hyperphenylalaninemia."

GeneReviews describes classic PKU as part of the PAH deficiency spectrum.

Mild PKU

Moderate PAH deficiency with blood Phe 600-1200 micromol/L untreated.

Show evidence (1 reference)

PMID:21555948 SUPPORT Human Clinical

"Deficiency of this enzyme produces a spectrum of disorders including classic phenylketonuria, mild phenylketonuria, and mild hyperphenylalaninemia."

Same source supports mild PKU as a recognized subtype in the PAH deficiency spectrum.

BH4-Responsive PKU

Responds to tetrahydrobiopterin supplementation.

Show evidence (1 reference)

PMID:34017006 SUPPORT Human Clinical

"Pharmacological treatments are available, such as tetrahydrobiopterin, which is effective in only a minority of patients (usually those with milder PKU)"

Supports a BH4-responsive subgroup among PKU patients.

◈

Mechanistic Hypotheses

1

Canonical PAH Deficiency and Phenylalanine Neurotoxicity Model

canonical_pah_deficiency_phenylalanine_neurotoxicity_model CANONICAL

Biallelic loss-of-function variants in PAH reduce hepatic phenylalanine hydroxylase activity, blocking conversion of phenylalanine to tyrosine. The resulting hyperphenylalaninemia exposes the developing and adult brain to neurotoxic phenylalanine levels, with downstream perturbation of large-neutral-amino-acid (LNAA) transport across the blood-brain barrier, depletion of cerebral tyrosine, tryptophan, and dopamine/serotonin neurotransmitter pools, impaired myelination, and oxidative stress. Severity is graded by residual PAH activity (classic PKU vs mild PKU vs non-PKU hyperphenylalaninemia) and the BH4-responsive subset; phenylalanine restriction, BH4 sapropterin, and pegvaliase (phenylalanine ammonia lyase) all act on this canonical axis.

Retained as CANONICAL. The 2026 falcon hypothesis-search report (kb/hypotheses/Phenylketonuria/canonical_pah_deficiency_phenylalanine_neurotoxicity_model; openscientist timed out) confirms biallelic PAH loss-of- function → hyperphenylalaninemia → neurotoxicity as the core mechanism, supported by phenylalanine-restricted diet efficacy, BH4 sapropterin response in cofactor-responsive variants, and pegvaliase (PAL enzyme substitution) approval. Three refinements: (1) the BBB neurotoxicity mechanism is multifactorial — LNAA transporter competition, depletion of cerebral tyrosine/tryptophan, reduced dopamine/serotonin synthesis, impaired myelin lipid composition, and oxidative stress all contribute, rather than direct Phe-toxicity alone; (2) maternal PKU teratogenicity (embryonic Phe exposure causing microcephaly, congenital heart disease, intellectual disability in offspring) operates through a distinct developmental mechanism; (3) executive dysfunction, attention deficits, and mood disorders persist in early-treated PKU adults even with good metabolic control, suggesting subtle developmental neurotoxicity beyond what current Phe targets capture.

Deep research

Falcon citations 31 citations 2026-05-23T19:13:32.173686

Show evidence (1 reference)

PMID:35854334 SUPPORT Human Clinical

"PKU, an autosomal recessive disease, is an inborn error of phenylalanine (Phe) metabolism"

Canonical mechanism review used as the seed reference for the hypothesis-search deep-research run.

⚙

Pathophysiology

17

Biallelic PAH Pathogenic Variant Burden

Homozygous or compound heterozygous pathogenic PAH variant combinations initiate PKU by reducing phenylalanine hydroxylase activity, with variant severity determining whether the downstream biochemical phenotype is classic PKU, mild PKU, or mild hyperphenylalaninemia.

PAH hgnc:8582 ↓ DECREASED

Genetic context functional_impact: loss_of_function_or_hypomorphic

Biallelic pathogenic PAH variant combinations.

Downstream

Near-Complete PAH Activity Loss Severe PAH genotypes converge on complete or near-complete enzyme deficiency.

Residual PAH Activity and BH4 Responsiveness Residual-function PAH variants create milder phenotypes and possible BH4 response.

Show evidence (2 references)

PMID:35854334 SUPPORT Human Clinical

"PKU, an autosomal recessive disease, is an inborn error of phenylalanine (Phe) metabolism caused by pathogenic variants in the phenylalanine hydroxylase (PAH) gene."

Establishes PAH pathogenic variants as the upstream genetic lesion.

PMID:21555948 SUPPORT Human Clinical

"Deficiency of this enzyme produces a spectrum of disorders including classic phenylketonuria, mild phenylketonuria, and mild hyperphenylalaninemia."

Supports variant-severity-dependent disease spectrum downstream of PAH deficiency.

Near-Complete PAH Activity Loss

Severe PAH variant combinations produce complete or near-complete hepatic PAH activity loss, defining the classic PKU branch with the highest untreated phenylalanine burden and greatest neurotoxicity risk.

PAH hgnc:8582 ↓ DECREASED

Genetic context allele_type: null_or_severe_hypomorphic functional_impact: complete_or_near_complete_loss_of_PAH_activity

Severe biallelic PAH variant combinations.

L-phenylalanine catabolic process GO:0006559 ↓ DECREASED

phenylalanine 4-monooxygenase activity GO:0004505 ↓ DECREASED

Downstream

Hepatic PAH Enzyme Deficiency Complete or near-complete PAH activity loss is the severe end of hepatic PAH enzyme deficiency.

Show evidence (1 reference)

PMID:21555948 SUPPORT Human Clinical

"Classic phenylketonuria is caused by a complete or near-complete deficiency of phenylalanine hydroxylase activity and without dietary restriction of phenylalanine most children will develop profound and irreversible intellectual disability."

Defines the severe enzymatic branch and its untreated neurodevelopmental consequence.

Residual PAH Activity and BH4 Responsiveness

Hypomorphic PAH variant combinations retain some enzyme activity, producing milder hyperphenylalaninemia/PKU phenotypes and enabling a subset of patients to respond to tetrahydrobiopterin or sapropterin.

PAH hgnc:8582 ↓ DECREASED

Genetic context allele_type: hypomorphic_or_residual_function functional_impact: partial_loss_of_PAH_activity

PAH variant combinations retaining pharmacologically activatable residual activity.

L-phenylalanine catabolic process GO:0006559 ↓ DECREASED

phenylalanine 4-monooxygenase activity GO:0004505 ↓ DECREASED

Downstream

Hepatic PAH Enzyme Deficiency Residual-function alleles still reduce hepatic PAH activity, but less completely than classic PKU genotypes.

Show evidence (2 references)

PMID:34017006 SUPPORT Human Clinical

"Pharmacological treatments are available, such as tetrahydrobiopterin, which is effective in only a minority of patients (usually those with milder PKU)"

Supports BH4 responsiveness as enriched in milder PKU phenotypes.

PMID:21555948 SUPPORT Human Clinical

"Mild phenylketonuria and mild hyperphenylalaninemia are associated with lower risk of impaired cognitive development in the absence of treatment."

Supports residual-function phenotypes with less severe untreated neurodevelopmental risk.

Hepatic PAH Enzyme Deficiency

Pathogenic PAH variants reduce hepatic phenylalanine hydroxylase activity.

hepatocyte CL:0000182

PAH hgnc:8582 ↓ DECREASED

L-phenylalanine catabolic process GO:0006559 ↓ DECREASED

phenylalanine 4-monooxygenase activity GO:0004505 ↓ DECREASED

liver UBERON:0002107

Computational models

Recon3D with PAH knockout GENOME SCALE METABOLIC COBRApy PAH knockout in Recon3D models the primary PAH-deficiency reaction defect.

Harvey Whole-Body PKU Model GENOME SCALE METABOLIC Whole-body PAH absence models the inherited metabolic block across organs.

Downstream

Hyperphenylalaninemia Reduced PAH activity impairs phenylalanine clearance from blood.

Relative Tyrosine Deficiency Blocked conversion of phenylalanine to tyrosine reduces tyrosine availability.

Show evidence (3 references)

PMID:29025426 SUPPORT Human Clinical

"Phenylketonuria (PKU) is an autosomal recessive inborn error of phenylalanine metabolism caused by deficiency in the enzyme phenylalanine hydroxylase that converts phenylalanine into tyrosine."

Defines PAH deficiency as the primary molecular lesion in PKU.

PMID:31076506 SUPPORT In Vitro

"a tractable C29S variant of hPAH (C29S) yielded a 3.06 Å resolution crystal structure of the tetrameric resting-state conformation."

Experimental X-ray crystallography and SEC-SAXS provide structural support for PAH quaternary-state mechanisms relevant to enzyme dysfunction.

PMID:27049649 SUPPORT In Vitro

"a disease-associated PAH mutant impaired in Phe binding disrupts the monomer:dimer equilibrium of PAH-RD."

Experimental structural and biophysical data connect disease-associated PAH mutation effects to impaired allosteric regulatory-domain dimerization.

Hyperphenylalaninemia

Phenylalanine accumulates in blood and tissues when PAH-dependent metabolism is impaired.

L-phenylalanine metabolic process GO:0006558 ↕ DYSREGULATED

Computational models

Recon3D with PAH knockout GENOME SCALE METABOLIC COBRApy PAH knockout is used to simulate the metabolic consequence of impaired phenylalanine clearance.

Harvey Whole-Body PKU Model GENOME SCALE METABOLIC Whole-body modeling is used for inherited metabolic disease biomarker prediction, including phenylalanine-related biomarkers.

Downstream

Blood Phenylalanine Elevated blood phenylalanine is the direct biochemical readout of impaired PAH-dependent phenylalanine clearance.

Phenylalanine to Tyrosine Ratio Hyperphenylalaninemia contributes to an elevated phenylalanine-to-tyrosine ratio.

Competitive Large Neutral Amino Acid Transport at the Blood-Brain Barrier Excess phenylalanine competitively perturbs transport of other neutral amino acids into brain.

Brain Phenylalanine Toxicity Persistent systemic hyperphenylalaninemia increases brain phenylalanine burden and toxicity.

Phenylketone Accumulation Excess phenylalanine is diverted to alternative metabolites, including phenylketones.

Protein Insufficiency During Dietary Therapy Chronic hyperphenylalaninemia requires phenylalanine-restricted medical nutrition; inadequate protein status during therapy can impair linear growth.

Reduced Bone Mineral Density in PKU PKU and its long-term phenylalanine-restricted medical nutrition context are associated with lower bone mineral density in some cohorts.

Maternal Hyperphenylalaninemia Teratogenicity Elevated maternal phenylalanine during early gestation creates a fetal teratogenic exposure associated with congenital heart defects.

Show evidence (2 references)

PMID:24385074 SUPPORT Human Clinical

"Phenylalanine hydroxylase deficiency, traditionally known as phenylketonuria, results in the accumulation of phenylalanine in the blood of affected individuals and was the first inborn error of metabolism to be identified through population screening."

Clinical guideline abstract confirms blood phenylalanine accumulation in PKU.

PMID:21216643 SUPPORT Human Clinical

"Phenylketonuria (PKU) is caused by mutations in the phenylalanine hydroxylase gene (PAH) with consequent elevation of blood phenylalanine (Phe), reduction in tyrosine (Tyr) and elevation of Phe/Tyr ratio (P/T)."

Independent clinical study confirms elevated blood phenylalanine in PKU.

Protein Insufficiency During Dietary Therapy

Phenylalanine-restricted therapy depends on carefully balanced natural protein and Phe-free protein substitutes; inadequate protein sufficiency, reflected by low plasma prealbumin, is associated with impaired linear growth in treated children with PKU.

negative regulation of multicellular organism growth GO:0040015 ↑ INCREASED

Downstream

Growth Delay Protein insufficiency during PKU dietary therapy can manifest as growth delay or linear growth impairment.

Plasma Prealbumin Plasma prealbumin is a monitoring readout for protein sufficiency during phenylalanine-restricted therapy.

Show evidence (2 references)

PMID:12183721 SUPPORT Human Clinical

"There is a strong relation between protein insufficiency, as determined by plasma prealbumin levels, and linear growth impairment."

Directly supports protein insufficiency as a mechanism for impaired linear growth in treated PKU children.

PMID:12183721 SUPPORT Human Clinical

"We suggest that a plasma prealbumin level of at least 20 mg/dL is necessary for optimal growth in children with PKU."

Supports plasma prealbumin as a protein-sufficiency threshold tied to growth outcome.

Reduced Bone Mineral Density in PKU

Adults and children with PKU have repeatedly been reported to have lower bone mineral density, with mechanisms still uncertain and likely involving diet composition, metabolic control, and other modifiers.

bone mineralization GO:0030282 ↓ DECREASED

Downstream

Osteopenia Reduced bone mineral density is the quantitative substrate for osteopenia in the PKU phenotype spectrum.

Bone Mineral Density Z-score Bone mineral density Z-score is a quantitative readout of reduced bone density in PKU cohorts.

Show evidence (2 references)

PMID:25758373 SUPPORT Human Clinical

"Patients with Phenylketonuria (PKU) reportedly have decreased bone mineral density (BMD)."

Systematic review directly supports reduced BMD as a bone-health abnormality in PKU.

PMID:25758373 SUPPORT Human Clinical

"Ten out of 11 articles found BMD was significantly lower in patients with PKU."

Summarizes the direction of BMD findings across included PKU studies.

Maternal Hyperphenylalaninemia Teratogenicity

In women with PKU or hyperphenylalaninemia, poor phenylalanine control during early pregnancy creates a fetal teratogenic exposure that is associated with congenital heart defects and other maternal PKU syndrome outcomes.

heart development GO:0007507 ⚠ ABNORMAL

Downstream

Abnormal Cardiovascular System Morphology Maternal PKU teratogenicity can cause congenital heart defects in offspring.

Show evidence (2 references)

PMID:10636975 SUPPORT Human Clinical

"None of the women whose offspring had CHDs had blood Phe levels in control during the first 8 weeks of gestation."

Directly supports poor early gestational phenylalanine control as the maternal PKU context for congenital heart defects.

PMID:12193940 SUPPORT Human Clinical

"A significantly increased incidence of congenital heart defects was observed in offspring of mothers with hyperphenylalaninemia who had an elevated blood phenylalanine level >10 mg/dL at 0 to 8 weeks of gestation and a protein intake of < or = 50% of the recommended dietary allowance (P <.0013)."

Supports the combined high-phenylalanine and maternal nutrition risk context for fetal cardiac malformations.

Relative Tyrosine Deficiency

Decreased PAH flux lowers endogenous tyrosine generation from phenylalanine.

tyrosine metabolic process GO:0006570 ↓ DECREASED

Downstream

Blood Tyrosine Reduced PAH-mediated conversion of phenylalanine to tyrosine is reflected by decreased blood tyrosine.

Phenylalanine to Tyrosine Ratio Reduced tyrosine availability contributes to the elevated phenylalanine-to-tyrosine ratio.

Impaired Melanin Biosynthesis Reduced tyrosine supply limits melanin production.

Reduced Dopamine Biosynthesis Lower tyrosine availability reduces substrate supply for catecholamine synthesis.

Show evidence (2 references)

PMID:29025426 SUPPORT Human Clinical

"Phenylketonuria (PKU) is an autosomal recessive inborn error of phenylalanine metabolism caused by deficiency in the enzyme phenylalanine hydroxylase that converts phenylalanine into tyrosine."

Impaired conversion from phenylalanine to tyrosine implies substrate deficiency downstream.

PMID:21216643 SUPPORT Human Clinical

"Phenylketonuria (PKU) is caused by mutations in the phenylalanine hydroxylase gene (PAH) with consequent elevation of blood phenylalanine (Phe), reduction in tyrosine (Tyr) and elevation of Phe/Tyr ratio (P/T)."

Human PKU cohort data directly reports reduced tyrosine associated with hyperphenylalaninemia.

Competitive Large Neutral Amino Acid Transport at the Blood-Brain Barrier

Large neutral amino acids, including phenylalanine, share competitive brain-entry transport.

neutral amino acid transport GO:0015804 ↕ DYSREGULATED

blood brain barrier UBERON:0000120

Computational models

Multi-compartment PKU FBA Model FLUX BALANCE ANALYSIS The FBA model explicitly represents shared BBB aromatic amino acid transport.

Downstream

Reduced Serotonin Biosynthesis Lower brain tryptophan availability contributes to impaired serotonin synthesis.

Reduced Dopamine Biosynthesis Lower brain tyrosine availability contributes to impaired dopamine synthesis.

Show evidence (1 reference)

PMID:987768 SUPPORT Model Organism

"The LNAA group of amino acids--phenylalanine, tyrosine, tryptophan, leucine, isoleucine, and valine--compete with each other for entry into brain by a common transport mechanism."

Provides mechanistic support for competitive BBB amino acid transport.

Reduced Serotonin Biosynthesis

High phenylalanine states inhibit serotonin production pathways.

serotonin biosynthetic process GO:0042427 ↓ DECREASED

Computational models

Multi-compartment PKU FBA Model FLUX BALANCE ANALYSIS The FBA model includes serotonin synthesis as a brain-function objective affected by PKU metabolic constraints.

Downstream

Neurocognitive Dysfunction Monoamine deficits contribute to attention, executive, and behavioral impairment.

Show evidence (1 reference)

PMID:6119011 SUPPORT Human Clinical

"In classical PKU, the serotonin and dopamine biosynthesis is inhibited by high L-phenylalanine in blood and tissues."

Human PKU data support reduced serotonin synthesis under high phenylalanine conditions.

Reduced Dopamine Biosynthesis

High phenylalanine states inhibit dopamine production pathways.

dopamine biosynthetic process GO:0042416 ↓ DECREASED

Computational models

Multi-compartment PKU FBA Model FLUX BALANCE ANALYSIS The FBA model includes dopamine synthesis as a brain-function objective affected by PKU metabolic constraints.

Downstream

Neurocognitive Dysfunction Dopaminergic dysfunction contributes to executive and cognitive deficits.

Hypertonia Biogenic amine disruption in classical PKU can contribute to hypertonicity and spasticity.

Show evidence (1 reference)

PMID:6119011 SUPPORT Human Clinical

"In classical PKU, the serotonin and dopamine biosynthesis is inhibited by high L-phenylalanine in blood and tissues."

Human PKU data support reduced dopamine synthesis under high phenylalanine conditions.

Brain Phenylalanine Toxicity

Elevated phenylalanine in the CNS drives diffuse brain dysfunction.

nervous system development GO:0007399 ⚠ ABNORMAL

brain UBERON:0000955

Downstream

White Matter and Subcortical Structural Injury Brain phenylalanine toxicity contributes to persistent white-matter and subcortical abnormalities.

Microcephaly Untreated high-phenylalanine neurotoxicity can impair brain growth and cause acquired microcephaly.

Neurocognitive Dysfunction Brain dysfunction manifests clinically as cognitive impairment and executive deficits.

Encephalopathy Severe phenylalanine-mediated brain dysfunction can manifest as encephalopathy.

EEG Abnormality Phenylalanine-mediated brain dysfunction can be reflected by abnormal EEG findings.

Tremor PKU brain dysfunction can include tremor as a motor manifestation.

Ataxia PKU neurologic involvement can include ataxia.

Show evidence (1 reference)

PMID:34017006 SUPPORT Human Clinical

"Phenylketonuria (PKU; also known as phenylalanine hydroxylase (PAH) deficiency) is an autosomal recessive disorder of phenylalanine metabolism, in which especially high phenylalanine concentrations cause brain dysfunction."

Confirms high phenylalanine concentrations as a direct driver of brain dysfunction.

White Matter and Subcortical Structural Injury

Treated adults still exhibit white-matter damage and subcortical volume loss associated with phenylalanine burden.

oligodendrocyte CL:0000128

myelination GO:0042552 ⚠ ABNORMAL

white matter UBERON:0002316

Downstream

Neurocognitive Dysfunction Structural brain injury is associated with lower cognitive performance.

Abnormal Cerebral White Matter Morphology Persistent white-matter injury is the mechanistic counterpart of the HPO white-matter morphology phenotype.

Lower Limb Spasticity White-matter and subcortical motor-pathway injury can contribute to lower-limb spasticity.

Cerebral Visual Impairment Cerebral visual impairment is represented as an occasional neurologic manifestation downstream of brain structural injury.

Show evidence (2 references)

PMID:37265600 SUPPORT Human Clinical

"In conclusion, our findings demonstrate that white matter alterations in early-treated phenylketonuria persist into adulthood, are most prominent in the posterior white matter and are likely to be driven by axonal damage."

Supports persistent white matter injury in adults with early-treated PKU.

PMID:38907189 SUPPORT Human Clinical

"Moreover, these patients showed reduced global white matter volume as well as reductions in the volume of several subcortical grey matter structures, which might be related to the existence of underlying neurodevelopmental alterations."

Independently confirms white matter and subcortical structural abnormalities.

Neurocognitive Dysfunction

PKU causes global and executive cognitive impairment, especially when metabolic control is poor or untreated.

neuron CL:0000540

Downstream

Intellectual Disability Severe or untreated neurotoxicity can progress to intellectual disability.

Seizures Severe untreated neurotoxicity can present with epilepsy/seizures.

Global Developmental Delay Untreated or poorly controlled PKU neurotoxicity can manifest as global developmental delay.

Specific Learning Disability Persistent cognitive and executive dysfunction can manifest as specific learning disability.

Short Attention Span Adult PKU neurocognitive effects include attention and executive-function impairment.

Atypical Behavior PKU brain dysfunction can present with behavioral problems.

Anxiety Neuropsychiatric effects of PKU include anxiety in the phenotype spectrum.

Depression Neuropsychiatric effects of PKU include depression in the phenotype spectrum.

Dementia Severe chronic neurocognitive deterioration can manifest as dementia in some PKU patients.

Show evidence (1 reference)

PMID:38907189 SUPPORT Human Clinical

"Adult patients with early-treated PKU showed significantly lower global intelligence than HC."

Demonstrates measurable cognitive impairment in early-treated adult PKU cohorts.

Impaired Melanin Biosynthesis

Reduced tyrosine availability limits melanin synthesis in untreated or poorly controlled disease.

melanin biosynthetic process GO:0042438 ↓ DECREASED

Downstream

Hypopigmentation Reduced melanin production leads to fair skin and lighter pigmentation phenotypes.

Show evidence (1 reference)

PMID:30570999 SUPPORT Human Clinical

"These signs can include musty odor from skin and urine, fair skin, eczema, seizures, tremors, and hyperactivity."

Fair skin in PKU is consistent with reduced pigmentation downstream of tyrosine deficit.

Phenylketone Accumulation

Alternative phenylalanine metabolism increases phenylketones such as phenylpyruvate.

Downstream

Musty Odor Phenylketone byproducts contribute to characteristic musty body odor.

Eczema Eczematous dermatitis is associated with untreated or poorly controlled PKU through incompletely defined skin effects of PAH deficiency.

Phenylalaninuria Urinary phenylalanine and phenylketone excretion reflects overflow alternative phenylalanine metabolism.

Phenylpyruvic Acid Phenylpyruvic acid is a measured urinary readout of phenylketone accumulation.

Show evidence (1 reference)

PMID:21565303 SUPPORT Human Clinical

"The urinary metabolic marker compounds, namely phenylpyruvic acid (PPA), 2-hydroxyphenylacetic acid (oOPAA), 4-hydroxyphenylacetic acid (pOPAA), phenyllactic acid (PLA) and phenylacetic acid (PAA) of phenylketonuric individuals were detected"

Confirms phenylketone metabolite accumulation in PKU urine profiles.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

26

Head and Neck 1

Microcephaly FREQUENT Microcephaly HP:0000252

Result of impaired brain development

Show evidence (3 references)

PMID:17092471 SUPPORT Human Clinical

"In addition to well-known findings such as mental retardation, autistic features, microcephaly, and tremor, motor retardation was common and responded promptly to dietary treatment."

Pediatric PKU case series documents microcephaly among established neurologic manifestations.

PMID:35854334 SUPPORT Human Clinical

"Untreated PKU, also known as PAH deficiency, results in severe and irreversible intellectual disability, epilepsy, behavioral disorders, and clinical features such as acquired microcephaly, seizures, psychological signs, and generalized hypopigmentation of skin (including hair and eyes)."

Review abstract independently supports acquired microcephaly in untreated PKU.

ORPHA:716 SUPPORT Other

"HP:0000252 | Microcephaly | Frequent (79-30%)"

Orphanet's curated HPO frequency annotation supports microcephaly as frequent in PKU.

Immune 1

Eczema FREQUENT Eczematoid dermatitis HP:0000964

Show evidence (2 references)

PMID:30570999 SUPPORT Human Clinical

"These signs can include musty odor from skin and urine, fair skin, eczema, seizures, tremors, and hyperactivity."

Clinical overview explicitly lists eczema among PKU manifestations.

ORPHA:716 SUPPORT Other

"HP:0000964 | Eczematoid dermatitis | Frequent (79-30%)"

Orphanet's curated HPO frequency annotation supports eczematoid dermatitis as frequent in PKU.

Integument 1

Hypopigmentation FREQUENT Hypopigmentation of the skin HP:0001010

Fair skin, light hair, blue eyes due to melanin deficiency

Show evidence (3 references)

PMID:35854334 SUPPORT Human Clinical

"Untreated PKU, also known as PAH deficiency, results in severe and irreversible intellectual disability, epilepsy, behavioral disorders, and clinical features such as acquired microcephaly, seizures, psychological signs, and generalized hypopigmentation of skin (including hair and eyes)."

Supports generalized skin, hair, and eye hypopigmentation as a PKU phenotype.

PMID:30570999 SUPPORT Human Clinical

"These signs can include musty odor from skin and urine, fair skin, eczema, seizures, tremors, and hyperactivity."

Fair skin in PKU is consistent with clinical hypopigmentation.

ORPHA:716 SUPPORT Other

"HP:0001010 | Hypopigmentation of the skin | Frequent (79-30%)"

Orphanet's curated HPO frequency annotation supports hypopigmentation as frequent in PKU.

Musculoskeletal 2

Hypertonia OCCASIONAL Hypertonia HP:0001276

Reported in untreated/poorly controlled disease; less frequent than hypotonia in pediatric series.

Show evidence (2 references)

PMID:17092471 SUPPORT Human Clinical

"Hypotonia and diminished reflexes were more frequent findings than hypertonia."

Confirms hypertonia occurs in PKU while indicating lower relative frequency.

PMID:2516176 SUPPORT Human Clinical

"Dietary therapy reduced serum phenylalanine levels, improved symptoms of hypertonicity, and cerebrospinal fluid neurotransmitter metabolites became normal."

Adult PKU report supports clinically significant hypertonicity as a neurologic manifestation.

Osteopenia FREQUENT Osteopenia HP:0000938

Show evidence (2 references)

ORPHA:716 SUPPORT Other

"HP:0000938 | Osteopenia | Frequent (79-30%)"

Orphanet's curated HPO annotation supports osteopenia as frequent in PKU.

PMID:25758373 SUPPORT Human Clinical

"Ten out of 11 articles found BMD was significantly lower in patients with PKU."

Systematic review evidence supports lower BMD as the clinical substrate for osteopenia in PKU.

Nervous System 12

Intellectual Disability VERY_FREQUENT Intellectual disability HP:0001249

Develops in untreated PKU and is preventable with early dietary treatment. The Orphanet phenotype row documents severe intellectual disability as frequent, while this general phenotype entry retains VERY_FREQUENT for untreated intellectual disability risk.

Show evidence (3 references)

PMID:34017006 SUPPORT Human Clinical

"If untreated, this brain dysfunction results in severe intellectual disability, epilepsy and behavioural problems."

The Nature Reviews Primer confirms severe intellectual disability as a key untreated phenotype.

PMID:38907189 PARTIAL Human Clinical

"Adult patients with PKU showed significantly lower performance than HC in Full Scale IQ"

Even early-treated adults show lower IQ compared to healthy controls.

ORPHA:716 SUPPORT Other

"HP:0010864 | Intellectual disability, severe | Frequent (79-30%)"

Orphanet's HPO annotation supports severe intellectual disability as frequent in PKU; the broader intellectual disability phenotype remains very frequent for untreated disease.

Seizures FREQUENT Seizure HP:0001250

Common in untreated patients

Show evidence (2 references)

PMID:29025426 SUPPORT Human Clinical

"If left untreated, PKU results in increased phenylalanine concentrations in blood and brain, which cause severe intellectual disability, epilepsy and behavioural problems."

European guidelines confirm epilepsy as a major untreated manifestation.

ORPHA:716 SUPPORT Other

"HP:0001250 | Seizure | Frequent (79-30%)"

Orphanet's curated HPO frequency annotation supports seizures as frequent in PKU.

Abnormal Cerebral White Matter Morphology FREQUENT Abnormal cerebral white matter morphology HP:0002500

White-matter abnormalities are reported in PKU, including early-treated adults.

Show evidence (1 reference)

ORPHA:716 SUPPORT Other

"HP:0002500 | Abnormal cerebral white matter morphology | Frequent (79-30%)"

Orphanet's HPO annotation supports cerebral white-matter abnormality as frequent in PKU.

EEG Abnormality FREQUENT EEG abnormality HP:0002353

Show evidence (1 reference)

ORPHA:716 SUPPORT Other

"HP:0002353 | EEG abnormality | Frequent (79-30%)"

Orphanet's HPO annotation supports EEG abnormality as frequent in PKU.

Global Developmental Delay FREQUENT Global developmental delay HP:0001263

Show evidence (1 reference)

ORPHA:716 SUPPORT Other

"HP:0001263 | Global developmental delay | Frequent (79-30%)"

Orphanet's curated HPO annotation supports global developmental delay as a frequent PKU phenotype.

Atypical Behavior FREQUENT Atypical behavior HP:0000708

Show evidence (1 reference)

ORPHA:716 SUPPORT Other

"HP:0000708 | Atypical behavior | Frequent (79-30%)"

Orphanet's curated HPO annotation supports atypical behavior as frequent in PKU.

Ataxia OCCASIONAL Ataxia HP:0001251

Show evidence (1 reference)

ORPHA:716 SUPPORT Other

"HP:0001251 | Ataxia | Occasional (29-5%)"

Orphanet's curated HPO annotation supports ataxia as an occasional PKU phenotype.

Tremor OCCASIONAL Tremor HP:0001337

Show evidence (1 reference)

ORPHA:716 SUPPORT Other

"HP:0001337 | Tremor | Occasional (29-5%)"

Orphanet's curated HPO annotation supports tremor as an occasional PKU phenotype.

Anxiety OCCASIONAL Anxiety HP:0000739

Show evidence (1 reference)

ORPHA:716 SUPPORT Other

"HP:0000739 | Anxiety | Occasional (29-5%)"

Orphanet's curated HPO annotation supports anxiety as an occasional PKU phenotype.

Depression OCCASIONAL Depression HP:0000716

Show evidence (1 reference)

ORPHA:716 SUPPORT Other

"HP:0000716 | Depression | Occasional (29-5%)"

Orphanet's curated HPO annotation supports depression as an occasional PKU phenotype.

Dementia OCCASIONAL Dementia HP:0000726

Show evidence (1 reference)

ORPHA:716 SUPPORT Other

"HP:0000726 | Dementia | Occasional (29-5%)"

Orphanet's curated HPO annotation supports dementia as an occasional PKU phenotype.

Encephalopathy OCCASIONAL Encephalopathy HP:0001298

Show evidence (1 reference)

ORPHA:716 SUPPORT Other

"HP:0001298 | Encephalopathy | Occasional (29-5%)"

Orphanet's curated HPO annotation supports encephalopathy as an occasional PKU phenotype.

Constitutional 1

Musty Odor FREQUENT Musty odor HP:0410021

Due to phenylacetic acid in sweat and urine

Show evidence (2 references)

PMID:30570999 SUPPORT Human Clinical

"These signs can include musty odor from skin and urine, fair skin, eczema, seizures, tremors, and hyperactivity."

Clinical overview directly supports musty body odor as a characteristic PKU sign.

ORPHA:716 SUPPORT Other

"HP:0410021 | Musty odor | Frequent (79-30%)"

Orphanet's curated HPO frequency annotation supports musty odor as frequent in PKU.

Growth 1

Growth Delay FREQUENT Growth delay HP:0001510

Show evidence (2 references)

ORPHA:716 SUPPORT Other

"HP:0001510 | Growth delay | Frequent (79-30%)"

Orphanet's curated HPO annotation supports growth delay as frequent in PKU.

PMID:12183721 SUPPORT Human Clinical

"There is a strong relation between protein insufficiency, as determined by plasma prealbumin levels, and linear growth impairment."

Human PKU cohort data support linear growth impairment tied to protein insufficiency.

Other 7

Phenylalaninuria VERY_FREQUENT Phenylalaninuria HP:0032351

Urinary phenylalanine/phenylketone abnormality reflected in the disease name.

Show evidence (1 reference)

ORPHA:716 SUPPORT Other

"HP:0032351 | Phenylalaninuria | Very frequent (99-80%)"

Orphanet's HPO annotation classifies phenylalaninuria as very frequent in PKU.

Hyperphenylalaninemia FREQUENT Hyperphenylalaninemia HP:0004923

Elevated blood phenylalanine is the defining biochemical abnormality.

Show evidence (1 reference)

ORPHA:716 SUPPORT Other

"HP:0004923 | Hyperphenylalaninemia | Frequent (79-30%)"

Orphanet's HPO annotation supports hyperphenylalaninemia as a frequent PKU phenotype.

Specific Learning Disability FREQUENT Specific learning disability HP:0001328

Show evidence (1 reference)

ORPHA:716 SUPPORT Other

"HP:0001328 | Specific learning disability | Frequent (79-30%)"

Orphanet's curated HPO annotation supports specific learning disability as frequent in PKU.

Short Attention Span OCCASIONAL Short attention span HP:0000736

Show evidence (1 reference)

ORPHA:716 SUPPORT Other

"HP:0000736 | Short attention span | Occasional (29-5%)"

Orphanet's curated HPO annotation supports short attention span as an occasional PKU phenotype.

Lower Limb Spasticity OCCASIONAL Lower limb spasticity HP:0002061

Show evidence (1 reference)

ORPHA:716 SUPPORT Other

"HP:0002061 | Lower limb spasticity | Occasional (29-5%)"

Orphanet's curated HPO annotation supports lower limb spasticity as an occasional PKU phenotype.

Cerebral Visual Impairment OCCASIONAL Cerebral visual impairment HP:0100704

Show evidence (1 reference)

ORPHA:716 SUPPORT Other

"HP:0100704 | Cerebral visual impairment | Occasional (29-5%)"

Orphanet's curated HPO annotation supports cerebral visual impairment as an occasional PKU phenotype.

Abnormal Cardiovascular System Morphology OCCASIONAL Abnormal cardiovascular system morphology HP:0030680

In PKU, cardiac malformations arise primarily in offspring of mothers with poorly controlled PKU (maternal PKU syndrome), rather than as a direct phenotype of affected individuals. Orphanet annotates this phenotype at occasional frequency.

Show evidence (2 references)

ORPHA:716 SUPPORT Other

"HP:0030680 | Abnormal cardiovascular system morphology | Occasional (29-5%)"

Orphanet's curated HPO annotation records abnormal cardiovascular system morphology at occasional frequency; the clinical context for PKU is primarily maternal PKU syndrome, as noted above.

PMID:10636975 SUPPORT Human Clinical

"Thirty-one offspring had CHDs; of these, 17 also had microcephaly."

Human maternal PKU cohort evidence supports congenital heart defects as the cardiovascular morphology context for this phenotype.

🧬

Genetic Associations

1

PAH (Causative)

Gene: PAH hgnc:8582

Show evidence (3 references)

PMID:35854334 SUPPORT Human Clinical

"PKU, an autosomal recessive disease, is an inborn error of phenylalanine (Phe) metabolism caused by pathogenic variants in the phenylalanine hydroxylase (PAH) gene."

Directly supports PAH as the causative gene in classical PKU.

PMID:35952926 SUPPORT Human Clinical

"Thirty-three PAH variants and five PTS variants were detected in HPA patients; 80.6 % PAH variants and 100 % PTS variants were classified as pathogenic or likely pathogenic."

Provides cohort-level evidence for multiple pathogenic PAH variants in HPA/PKU.

CGGV:assertion_5a617cb4-94ec-4f34-b97e-10d9808a1581-2020-04-24T160000.000Z SUPPORT Other

ClinGen classifies the PAH-phenylketonuria gene-disease relationship as definitive with autosomal recessive inheritance.

💊

Medical Actions

5

Phenylalanine-Restricted Diet

Action: dietary intervention MAXO:0000088

Diet: restrict mammalian meat food product FOODON:00001006 restrict milk FOODON:03302116 restrict nut FOODON:03303171

Lifelong dietary restriction of phenylalanine intake, mainstay of treatment.

Mechanism Target:

INHIBITS Hyperphenylalaninemia — Restricting dietary phenylalanine lowers and maintains blood phenylalanine concentrations.

Show evidence (1 reference)

PMID:35854334 SUPPORT Human Clinical

"Dietary treatment, including natural protein restriction and Phe-free supplements, must be used to maintain blood Phe concentrations of 120-360 μmol/L throughout the life span."

Supports dietary phenylalanine restriction as acting on the hyperphenylalaninemia node.

Show evidence (2 references)

PMID:34017006 SUPPORT Human Clinical

"Dietary restriction of phenylalanine has been the mainstay of treatment for over 60 years and has been highly successful, although outcomes are still suboptimal and patients can find the treatment difficult to adhere to."

Confirms diet as the primary and long-standing treatment approach.

PMID:21555948 SUPPORT Human Clinical

"The mainstay of treatment for hyperphenylalaninemia involves a low-protein diet and use of a phenylalanine-free medical formula."

Independent clinical review confirms low-protein dietary treatment as standard of care.

Medical Formula

Action: dietary intervention MAXO:0000088

Phenylalanine-free amino acid supplements to provide protein needs.

Mechanism Target:

MODULATES Hyperphenylalaninemia — Phenylalanine-free formula supports protein requirements while limiting phenylalanine burden.

Show evidence (1 reference)

PMID:21555948 SUPPORT Human Clinical

"The mainstay of treatment for hyperphenylalaninemia involves a low-protein diet and use of a phenylalanine-free medical formula."

GeneReviews supports phenylalanine-free medical formula as part of hyperphenylalaninemia management.

Show evidence (2 references)

PMID:21555948 SUPPORT Human Clinical

"The mainstay of treatment for hyperphenylalaninemia involves a low-protein diet and use of a phenylalanine-free medical formula."

Directly supports phenylalanine-free medical formula as standard PKU therapy.

PMID:35854334 SUPPORT Human Clinical

"Dietary treatment, including natural protein restriction and Phe-free supplements, must be used to maintain blood Phe concentrations of 120-360 μmol/L throughout the life span."

Independent review confirms ongoing use of Phe-free supplementation in PKU management.

Sapropterin (Kuvan)

Action: Pharmacotherapy NCIT:C15986

Agent: sapropterin CHEBI:59560

BH4 cofactor replacement for responsive patients, allows dietary liberalization.

Mechanism Target:

ACTIVATES Residual PAH Activity and BH4 Responsiveness — Sapropterin/BH4 activates residual PAH activity in responsive patients.

Show evidence (1 reference)

PMID:35854334 SUPPORT Human Clinical

"The synthetic BH4 analog, sapropterin hydrochloride (i.e., Kuvan®, BioMarin), is another potential treatment that activates residual PAH, thus decreasing Phe concentrations in the blood of PKU patients."

Directly supports residual PAH activation as the mechanism targeted by sapropterin.

Show evidence (2 references)

PMID:34017006 SUPPORT Human Clinical

"Pharmacological treatments are available, such as tetrahydrobiopterin, which is effective in only a minority of patients (usually those with milder PKU)"

Confirms sapropterin (BH4) effectiveness in a subset of patients with milder disease.

PMID:17693179 SUPPORT Human Clinical

"In some patients with phenylketonuria who are responsive to BH4, sapropterin treatment to reduce blood phenylalanine could be used as an adjunct to a restrictive low-phenylalanine diet, and might even replace the diet in some instances."

Phase III trial evidence supports sapropterin efficacy in BH4-responsive PKU.

Pegvaliase (Palynziq)

Action: Pharmacotherapy NCIT:C15986

Agent: pegvaliase NCIT:C174744

Enzyme substitution therapy using PEGylated phenylalanine ammonia lyase.

Mechanism Target:

INHIBITS Hyperphenylalaninemia — Pegvaliase reduces blood phenylalanine concentrations by substituting an alternative phenylalanine-catabolizing enzyme activity.

Show evidence (1 reference)

PMID:29628378 SUPPORT Human Clinical

"Results from this study confirmed the efficacy of pegvaliase in maintaining reduced blood Phe concentrations with a manageable safety profile for most participants."

Supports pegvaliase as acting on the hyperphenylalaninemia node by maintaining reduced blood phenylalanine.

Show evidence (2 references)

PMID:34017006 PARTIAL Human Clinical

"pegylated phenylalanine ammonia lyase, which requires daily subcutaneous injections and causes adverse immune responses"

Confirms pegvaliase as an available treatment, noting its route and immunogenicity concerns.

PMID:29628378 SUPPORT Human Clinical

"Results from this study confirmed the efficacy of pegvaliase in maintaining reduced blood Phe concentrations with a manageable safety profile for most participants."

Pivotal Phase 3 trial independently supports pegvaliase efficacy and tolerability profile.

Large Neutral Amino Acids

Action: dietary intervention MAXO:0000088

Compete with phenylalanine for brain transport, adjunctive therapy.

Mechanism Target:

MODULATES Competitive Large Neutral Amino Acid Transport at the Blood-Brain Barrier — Large neutral amino acid supplementation competes with phenylalanine transport into brain.

Show evidence (1 reference)

PMID:35854334 SUPPORT Human Clinical

"Additional treatments include the casein glycomacropeptide (GMP), which contains very limited aromatic amino acids and may improve immunological function, and large neutral amino acid (LNAA) supplementation to prevent plasma Phe transport into the brain."

Supports LNAA supplementation as targeting the BBB neutral amino acid transport mechanism.

Show evidence (2 references)

PMID:987768 SUPPORT Model Organism

"Increasing the serum concentrations of amino acids competitive with phenylalanine for transport across the blood brain barrier might form an alternative approach to effective dietary treatment of PKU."

Supports LNAA supplementation rationale as an adjunctive PKU dietary strategy.

PMID:35854334 SUPPORT Human Clinical

"Additional treatments include the casein glycomacropeptide (GMP), which contains very limited aromatic amino acids and may improve immunological function, and large neutral amino acid (LNAA) supplementation to prevent plasma Phe transport into the brain."

Human PKU review independently supports LNAA supplementation as an adjunctive treatment strategy.

🌍

Environmental Factors

5

Dietary Phenylalanine

Primary determinant of metabolic control

Show evidence (2 references)

PMID:24385074 SUPPORT Human Clinical

"Treatment has predominantly been dietary manipulation, and use of low protein and phenylalanine medical foods is likely to remain a major component of therapy for the immediate future."

Supports that phenylalanine intake control through diet is central to metabolic management.

PMID:35854334 SUPPORT Human Clinical

"Dietary treatment, including natural protein restriction and Phe-free supplements, must be used to maintain blood Phe concentrations of 120-360 μmol/L throughout the life span."

Independent review supports dietary phenylalanine restriction as a central environmental determinant of metabolic control.

Mammalian Meat Intake

Representative high-protein phenylalanine-rich food source requiring restriction

Dairy Intake

Milk and related dairy foods contribute to dietary phenylalanine burden

Nut Intake

Nuts are concentrated protein sources that contribute to dietary phenylalanine burden

Aspartame

Contains phenylalanine, must be avoided

Show evidence (2 references)

PMID:33672234 SUPPORT Human Clinical

"Aspartame is a phenylalanine containing sweetener, added to foods and drinks, which is avoided in phenylketonuria (PKU)."

Directly supports aspartame avoidance as a relevant environmental exposure issue in PKU.

PMID:3291200 SUPPORT Human Clinical

"Persons suffering from phenylketonuria (PKU-homozygotes) on a phenylalanine-restricted diet should avoid consumption of aspartame."

Independent review supports specific aspartame avoidance guidance in PKU.

🔬

Biochemical Markers

7

Blood Phenylalanine (Elevated)

Context: Greater than 120 micromol/L, often greater than 1200 micromol/L in classic PKU

Pathograph Readouts

Readout Of Hyperphenylalaninemia Positive Diagnostic

Elevated blood phenylalanine reports impaired PAH-dependent phenylalanine clearance.

Readout Of Maternal Hyperphenylalaninemia Teratogenicity Positive Prognostic

Elevated maternal blood phenylalanine during early gestation predicts fetal congenital-heart-defect risk in maternal PKU syndrome.

Show evidence (2 references)

PMID:24385074 SUPPORT Human Clinical

"Phenylalanine hydroxylase deficiency, traditionally known as phenylketonuria, results in the accumulation of phenylalanine in the blood of affected individuals and was the first inborn error of metabolism to be identified through population screening."

Supports elevated blood phenylalanine as the defining biochemical abnormality.

PMID:21216643 SUPPORT Human Clinical

"Phenylketonuria (PKU) is caused by mutations in the phenylalanine hydroxylase gene (PAH) with consequent elevation of blood phenylalanine (Phe), reduction in tyrosine (Tyr) and elevation of Phe/Tyr ratio (P/T)."

Independent human cohort evidence confirms elevated blood phenylalanine in PKU.

Treatment-Induced Plasma Phenylalanine Reduction (Treatment-induced)

Context: Plasma phenylalanine concentration measured during pharmacotherapy with phenylalanine hydroxylase activators (sapropterin) or phenylalanine- metabolizing enzyme therapy (pegvaliase). Distinct from baseline diagnostic hyperphenylalaninemia. Plasma phenylalanine is recognized by the FDA as a validated surrogate endpoint supporting traditional approval of PKU drugs.

Pathograph Readouts

Pharmacodynamic Marker Of Hyperphenylalaninemia Negative Pharmacodynamic

Reductions in plasma phenylalanine during treatment with phenylalanine hydroxylase activators (sapropterin) or phenylalanine-metabolizing enzyme therapy (pegvaliase) report pharmacodynamic correction at the hyperphenylalaninemia node and underpin the FDA surrogate-endpoint basis for traditional approval of PKU drugs.

FDA-SE-adult-noncancer-087 FDA

Plasma phenylalanine

Traditional Validated Surrogate Endpoint

1. Patients with hyperphenylalaninemia due to tetrahydrobiopterin-responsive PKU 2. Adults with PKU who have uncontrolled plasma Phe>600 micromol/L on existing management 3. Pateints with hyperphenylalaninemia due to sepiapterin-responsive PKU

FDA-SE-pediatric-noncancer-057 FDA

Plasma phenylalanine

Traditional Validated Surrogate Endpoint

Patients with hyperphenylalaninemia due to tetrahydrobiopterin-responsive PKU; Pediatrc pateints with hyperphenylalaninemia due to sepiapterin-responsive PKU

Show evidence (3 references)

PMID:17693179 SUPPORT Human Clinical

"The primary endpoint was mean change from baseline in concentration of phenylalanine in blood after 6 weeks."

The pivotal randomized placebo-controlled trial of sapropterin used blood phenylalanine concentration as its primary endpoint, establishing plasma Phe as the pharmacodynamic readout for PAH-activator efficacy.

PMID:17693179 SUPPORT Human Clinical

"After 6 weeks of treatment, patients given sapropterin had a decrease in mean blood phenylalanine of 236 (257) micromol/L, compared with a 3 (240) micromol/L increase in the placebo group (p<0.0001)."

Plasma phenylalanine declined significantly with sapropterin therapy versus placebo, confirming Phe as a treatment-responsive pharmacodynamic marker.

PMID:29653686 SUPPORT Human Clinical

"Mean (SD) blood Phe was 1232.7 (386.4) μmol/L at baseline, 564.5 (531.2) μmol/L at 12 months, and 311.4 (427) μmol/L at 24 months, a decrease from baseline of 51.1% and 68.7%, respectively."

PRISM-1/2 pivotal phase 3 trials of pegvaliase report pharmacodynamic reduction of plasma phenylalanine, supporting plasma Phe as the pharmacodynamic readout for phenylalanine-metabolizing enzyme substitution therapy.

Show evidence (2 references)

PMID:17693179 SUPPORT Human Clinical

"We aimed to test the efficacy of sapropterin, a synthetic form of tetrahydrobiopterin (BH4), for reduction of blood phenylalanine concentration."

Establishes plasma phenylalanine reduction as the treatment-effect endpoint for sapropterin in PKU.

PMID:29653686 SUPPORT Human Clinical

"Pegvaliase, PEGylated recombinant Anabaena variabilis phenylalanine ammonia lyase (PAL), converts Phe to trans-cinnamic acid and ammonia, and is a potential enzyme substitution therapy to lower blood Phe in adults with PKU."

Establishes the pharmacodynamic basis: pegvaliase enzymatically degrades phenylalanine, with plasma Phe as the measurable response.

Blood Tyrosine (Decreased)

Context: Low due to blocked conversion from phenylalanine

Pathograph Readouts

Readout Of Relative Tyrosine Deficiency Negative Diagnostic

Lower blood tyrosine reports reduced PAH-mediated conversion of phenylalanine to tyrosine.

Show evidence (2 references)

PMID:30570999 SUPPORT Human Clinical

"Elevated blood Phe levels and decreased Tyr levels characterize PKU."

Directly supports low tyrosine as a characteristic biochemical feature.

PMID:21216643 SUPPORT Human Clinical

"Phenylketonuria (PKU) is caused by mutations in the phenylalanine hydroxylase gene (PAH) with consequent elevation of blood phenylalanine (Phe), reduction in tyrosine (Tyr) and elevation of Phe/Tyr ratio (P/T)."

Independent cohort data explicitly reports reduced tyrosine in PKU.

Phenylalanine to Tyrosine Ratio (Elevated)

Context: Diagnostic marker

Pathograph Readouts

Readout Of Hyperphenylalaninemia Positive Diagnostic

Elevated Phe/Tyr ratio reports combined phenylalanine accumulation and reduced tyrosine production.

Readout Of Relative Tyrosine Deficiency Positive Diagnostic

Elevated Phe/Tyr ratio reports the biochemical imbalance produced by impaired PAH flux.

Show evidence (2 references)

PMID:35952926 SUPPORT Human Clinical

"All patients had elevated Phe and Phe/Tyr levels."

Supports elevation of the phenylalanine:tyrosine index in diagnosed HPA/PKU cohorts.

PMID:21216643 SUPPORT Human Clinical

"Phenylketonuria (PKU) is caused by mutations in the phenylalanine hydroxylase gene (PAH) with consequent elevation of blood phenylalanine (Phe), reduction in tyrosine (Tyr) and elevation of Phe/Tyr ratio (P/T)."

Independent clinical data supports elevated Phe/Tyr ratio as a core PKU biochemical marker.

Phenylpyruvic Acid (Elevated)

Context: Alternative metabolite in urine

Pathograph Readouts

Readout Of Phenylketone Accumulation Positive Diagnostic

Elevated urinary phenylpyruvic acid reports diversion of excess phenylalanine into phenylketone metabolites.

Show evidence (1 reference)

PMID:21565303 SUPPORT Human Clinical

"The urinary metabolic marker compounds, namely phenylpyruvic acid (PPA), 2-hydroxyphenylacetic acid (oOPAA), 4-hydroxyphenylacetic acid (pOPAA), phenyllactic acid (PLA) and phenylacetic acid (PAA) of phenylketonuric individuals were detected"

Supports urinary phenylpyruvic acid elevation as part of the PKU metabolite profile.

Plasma Prealbumin (Decreased)

Context: Low plasma prealbumin marks protein insufficiency during PKU dietary therapy.

Pathograph Readouts

Readout Of Protein Insufficiency During Dietary Therapy Negative Monitoring

Lower plasma prealbumin reports protein insufficiency associated with impaired linear growth in treated PKU children.

Show evidence (1 reference)

PMID:12183721 SUPPORT Human Clinical

"We suggest that a plasma prealbumin level of at least 20 mg/dL is necessary for optimal growth in children with PKU."

Supports plasma prealbumin as a monitoring readout for protein sufficiency and growth risk in children with PKU.

Bone Mineral Density Z-score (Decreased)

Context: Lower BMD Z-scores summarize the quantitative bone-density abnormality reported in PKU cohorts.

Pathograph Readouts

Readout Of Reduced Bone Mineral Density in PKU Negative Monitoring

Decreased BMD Z-score reports reduced bone mineral density in PKU bone-health assessment.

Show evidence (1 reference)

PMID:39267130 SUPPORT Human Clinical

"Adults with PKU had lower BMD Z-scores than the reference (non-PKU) population but < 1 in 10 were below the expected range for age."

Meta-analysis supports lower BMD Z-scores as a quantitative readout of PKU bone mineral density.

🔀

Differential Diagnoses

4

Conditions with similar clinical presentations that must be differentiated from Phenylketonuria:

Hyperphenylalaninemia due to tetrahydrobiopterin deficiency Not Yet Curated MONDO:0016543

Overlapping Features BH4 cofactor defects can present as newborn-screen positive hyperphenylalaninemia and mimic PAH deficiency.

Distinguishing Features

Differential testing is required because BH4 deficiency can present with the same initial hyperphenylalaninemia signal as PKU.
Separation from PAH deficiency relies on pterin studies and DHPR enzyme activity testing.
Patients may develop neurologic abnormalities despite acceptable blood phenylalanine control.

Show evidence (2 references)

PMID:35952926 SUPPORT Human Clinical

"Newborn screening is an effective method for early detection of HPA, but differential diagnosis of BH4D is necessary."

Explicitly states that BH4 deficiency must be differentiated from PAH-related hyperphenylalaninemia.

PMID:8404969 SUPPORT Human Clinical

"We describe a new fully reliable method for the differential diagnosis of tetrahydrobiopterin-dependent hyperphenylalaninaemia (HPA)."

Supports dedicated differential workup for BH4-dependent forms.

Dihydropteridine Reductase Deficiency Not Yet Curated MONDO:0009862

Overlapping Features A BH4 regeneration disorder causing hyperphenylalaninemia with monoamine neurotransmitter deficiency.

Distinguishing Features

DHPR activity testing on dried blood spots is recommended during differential diagnosis.
Distinguishing this disorder from PAH deficiency changes treatment strategy beyond phenylalanine restriction alone.

Show evidence (2 references)

PMID:3930839 SUPPORT Human Clinical

"Measurement of DHPR activity in blood spots on Guthrie cards is recommended."

Confirms DHPR enzyme testing as a key discriminator in hyperphenylalaninemia workup.

PMID:8404969 SUPPORT Human Clinical

"It should be performed together with the measurement of dihydropteridine reductase (DHPR) activity in blood."

Reinforces that differential diagnosis requires specific DHPR testing.

BH4-deficient hyperphenylalaninemia A Not Yet Curated MONDO:0009863

Overlapping Features PTS-related BH4 synthesis deficiency that phenotypically overlaps with PKU on newborn screening.

Distinguishing Features

Caused by BH4 pathway defects (including PTS variants) rather than PAH enzyme deficiency.
Requires BH4-focused biochemical and/or genetic testing to identify correctly.

Show evidence (2 references)

PMID:35952926 SUPPORT Human Clinical

"Of the 296 newborns who tested HPA positive, 56 were diagnosed with HPA, including 47 with phenylalanine hydroxylase deficiency and nine with tetrahydrobiopterin deficiency (BH4D)."

Demonstrates a real newborn-screen cohort where BH4-deficient cases coexist with PAH deficiency and require distinction.

PMID:35952926 SUPPORT Human Clinical

"Thirty-three PAH variants and five PTS variants were detected in HPA patients;"

Supports genetic differentiation between PAH-related PKU and PTS-related BH4 deficiency.

Mild Hyperphenylalaninemia Not Yet Curated MONDO:0019335

Overlapping Features A milder PAH-spectrum condition with lower untreated phenylalanine burden and lower neurologic risk than classic PKU.

Distinguishing Features

Lower baseline phenylalanine elevations and substantially reduced risk of severe cognitive impairment compared with classic PKU.
Phenylalanine thresholds for lifelong intensive treatment differ from classic PKU-range disease.

Show evidence (2 references)

PMID:21555948 SUPPORT Human Clinical

"Mild phenylketonuria and mild hyperphenylalaninemia are associated with lower risk of impaired cognitive development in the absence of treatment."

Supports lower neurodevelopmental risk profile relative to classic untreated PKU.

PMID:39630157 SUPPORT Human Clinical

"treatment for PAH deficiency should be lifelong for individuals with untreated phenylalanine (Phe) levels >360 μmol/L"

Guideline threshold helps distinguish lower-range hyperphenylalaninemia from classic PKU requiring strict lifelong treatment targets.

📊

Related Datasets

3

Whole transcriptome comparison between two groups of PKU patients: Non-carriers vs. Carriers of rs113883650 geo:GSE294755

Transcriptomic profiling dataset comparing PKU carrier/non-carrier groups under differing phenylalanine exposure conditions.

Homo sapiens MICROARRAY n=19

patient-derived cells

Conditions: PKU non-carrier group PKU carrier group (rs113883650) high phenylalanine condition low phenylalanine condition

Findings

High-phenylalanine conditions in this cohort were associated with reduced expression of proteasome pathway genes.

Show evidence (1 reference)

geo:GSE294755 SUPPORT In Vitro

"We demonstrated a decrease of expression of proteasome pathway (KEGG) incells treated with high Phe concentrations."

GEO summary reports pathway-level transcriptomic changes under high phenylalanine exposure.

PMID:41387948

Show evidence (1 reference)

geo:GSE294755 SUPPORT In Vitro

"We demonstrated a decrease of expression of proteasome pathway (KEGG) incells treated with high Phe concentrations."

Dataset-level summary supports relevance to PKU high-phenylalanine cellular response.

Does early treatment of PKU patients with sapropterin dihydrochloride affect brain development? geo:GSE112108

RNA-seq from organotypic rat brain cultures exposed to sepiapterin/BH4 to model developmental effects relevant to early PKU treatment contexts.

Rattus norvegicus BULK RNA SEQ n=23

organotypic brain cell culture

Conditions: sepiapterin-treated untreated control early developmental stage later developmental stage

Findings

Early-stage sepiapterin exposure showed transcriptomic and cellular evidence of disturbed neural development, with increased apoptosis and altered glial/axonal markers.

Show evidence (2 references)

geo:GSE112108 SUPPORT In Vitro

"RNAseq analyses revealed a number of significantly affected genes."

Dataset summary confirms measurable transcriptional perturbations in treated developing brain cultures.

geo:GSE112108 SUPPORT In Vitro

"Immunofluorescence for activated caspase-3 revealed an increased apoptosis rate."

Summary links treatment exposure to increased apoptosis in the early developmental stage.

Show evidence (1 reference)

geo:GSE112108 SUPPORT In Vitro

"RNAseq analyses revealed a number of significantly affected genes."

Supports utility of this dataset for transcriptomic analysis of early PKU-treatment-relevant brain effects.

Mildly compromised tetrahydrobiopterin biosynthesis mouse mutants exhibit abnormal body fat distribution and abdominal obesity geo:GSE55148

Mouse expression profiling study of reduced BH4 biosynthesis (Pts mutant models), relevant to BH4-deficient hyperphenylalaninemia mechanisms.

Mus musculus MICROARRAY n=16

brain tissue liver tissue

Conditions: Pts mutant mice wild-type controls

Findings

BH4-biosynthesis impairment in this model produced metabolic phenotypes relevant to BH4-associated hyperphenylalaninemia.

Show evidence (1 reference)

geo:GSE55148 SUPPORT Model Organism

"BH4 deficiency due to an autosomal recessive defect in its biosynthetic enzyme 6-pyruvoyltetrahydropterin synthase (PTPS, encoded by the PTS gene) leads to a variant form of hyperphenylalaninemia concomitant with severe deficiency of brain monoamine neurotransmitters."

Summary supports translational relevance of BH4-pathway models to differential hyperphenylalaninemia biology.

Show evidence (1 reference)

geo:GSE55148 SUPPORT Model Organism

"BH4 deficiency due to an autosomal recessive defect in its biosynthetic enzyme 6-pyruvoyltetrahydropterin synthase (PTPS, encoded by the PTS gene) leads to a variant form of hyperphenylalaninemia concomitant with severe deficiency of brain monoamine neurotransmitters."

Dataset-level summary supports relevance to BH4-associated hyperphenylalaninemia mechanisms.

🔬

Clinical Trials

3

NCT00838435 PHASE_III COMPLETED

Phase 3b open-label Kuvan study in young children with PKU evaluating safety, neurocognitive outcomes, blood phenylalanine maintenance, and growth.

Target Phenotypes: Intellectual Disability HP:0001249

Show evidence (1 reference)

clinicaltrials:NCT00838435 SUPPORT Human Clinical

"This multicenter, open label study is designed to evaluate the safety of Kuvan® and its effect on neurocognitive function, blood Phe concentration, and growth in children with PKU who are 0-6 years old."

Trial synopsis confirms explicit clinical endpoints relevant to PKU neurocognitive disease burden.

NCT01212744 PHASE_II COMPLETED

Phase 2 open-label trial of daily subcutaneous rAvPAL-PEG evaluating safety, tolerability, and efficacy for blood phenylalanine reduction in PKU.

Target Phenotypes: Intellectual Disability HP:0001249 Seizures HP:0001250

Show evidence (1 reference)

clinicaltrials:NCT01212744 SUPPORT Human Clinical

"The purpose of this study is to evaluate the effect of daily administration of rAvPAL-PEG on the reduction of blood Phe concentrations in subjects with PKU."

Confirms interventional targeting of the core biochemical driver in PKU.

NCT04534842 PHASE_II COMPLETED

Open-label Phase 2 SynPheny-1 trial assessing efficacy and safety of SYNB1618/SYNB1934 oral biotherapeutic regimens in PKU.

Target Phenotypes: Intellectual Disability HP:0001249

Show evidence (1 reference)

clinicaltrials:NCT04534842 SUPPORT Human Clinical

"This Phase 2 study in patients with phenylketonuria (PKU) will be an open-label, dual-arm study of either a SYNB1618 or SYNB1934 dose-ramp regimen."

Confirms active interventional evaluation of novel PKU therapeutics in a defined patient cohort.

🧮

Computational Models

3

Multi-compartment PKU FBA Model FLUX_BALANCE_ANALYSIS

Three-compartment FBA model with explicit blood-brain barrier transport for aromatic amino acids

PMID:36880400 Base model: Recon-derived

Pathograph links

Competitive Large Neutral Amino Acid Transport at the Blood-Brain Barrier The FBA model explicitly represents shared BBB aromatic amino acid transport.

Reduced Dopamine Biosynthesis The FBA model includes dopamine synthesis as a brain-function objective affected by PKU metabolic constraints.

Reduced Serotonin Biosynthesis The FBA model includes serotonin synthesis as a brain-function objective affected by PKU metabolic constraints.

Explains brain-specific pathology and why Phe restriction outperforms Tyr supplementation

Show evidence (1 reference)

PMID:36880400 SUPPORT Computational

"We built a three-compartment model, made the common transport across the BBB explicit, and included dopamine and serotonin synthesis as parts of the brain function to be delivered by FBA."

Directly supports model architecture and PKU-relevant mechanistic scope.

Recon3D with PAH knockout SBML COBRApy GENOME_SCALE_METABOLIC

Human genome-scale metabolic model simulating phenylalanine hydroxylase deficiency

Repository ↗ PMID:29457794 Base model: Recon3D

Pathograph links

Hepatic PAH Enzyme Deficiency PAH knockout in Recon3D models the primary PAH-deficiency reaction defect.

Hyperphenylalaninemia PAH knockout is used to simulate the metabolic consequence of impaired phenylalanine clearance.

Show evidence (1 reference)

PMID:29457794 SUPPORT Computational

"Recon3D represents the most comprehensive human metabolic network model to date, accounting for 3,288 open reading frames (representing 17% of functionally annotated human genes), 13,543 metabolic reactions involving 4,140 unique metabolites, and 12,890 protein structures."

Supports use of Recon3D as a genome-scale computational base model for metabolic disease simulation.

Harvey Whole-Body PKU Model GENOME_SCALE_METABOLIC

Sex-specific whole-body model for organ-resolved IEM biomarker prediction.

Repository ↗ PMID:32463598 Base model: Harvey 1.0

Pathograph links

Hepatic PAH Enzyme Deficiency Whole-body PAH absence models the inherited metabolic block across organs.

Hyperphenylalaninemia Whole-body modeling is used for inherited metabolic disease biomarker prediction, including phenylalanine-related biomarkers.

Whole-body WBM framework supports organ-resolved biomarker prediction in inherited metabolic disease.

Show evidence (2 references)

PMID:32463598 SUPPORT Computational

"We developed a new metabolic network reconstruction approach that used organ-specific information from literature and omics data to generate two sex-specific whole-body metabolic (WBM) reconstructions."

Supports whole-body sex-specific metabolic reconstruction framework underlying Harvey/Harvetta-style models.

PMID:32463598 SUPPORT Computational

"We also illustrate that the WBM models can predict known biomarkers of inherited metabolic diseases in different biofluids."

Supports biomarker prediction capability relevant to PKU and related IEM applications.

{ }

Source YAML

click to show

name: Phenylketonuria
creation_date: '2025-12-19T14:27:56Z'
updated_date: '2026-05-21T18:42:36Z'
category: Genetic
parents:
- Metabolic Disease
- Inborn Error of Metabolism
disease_term:
  preferred_term: phenylketonuria
  term:
    id: MONDO:0009861
    label: phenylketonuria
mappings:
  mondo_mappings:
  - term:
      id: MONDO:0009861
      label: phenylketonuria
    mapping_predicate: skos:exactMatch
    mapping_source: Orphanet ORPHA:716
    mapping_justification: >-
      Orphanet ORPHA:716 lists MONDO:0009861 as an exact cross-reference for
      phenylketonuria.
external_assertions:
- name: Orphanet Phenylketonuria disease record
  source: Orphanet
  assertion_type: structured_disease_record
  external_id: ORPHA:716
  url: http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=716
  description: >-
    Orphanet's ORPHA:716 structured record for Phenylketonuria includes the
    disease-level cross-reference set, inheritance, epidemiology, natural
    history, and HPO phenotype annotations used in this entry.
  notes: >-
    The ORPHA:716 cross-reference table also lists exact mappings to
    ICD-11:5C50.0, MeSH:D010661, MedDRA:10034872, and UMLS:C0031485, and
    narrower mappings to ICD-10:E70.0, ICD-10:E70.1, and OMIM:261600.
  evidence:
  - reference: ORPHA:716
    reference_title: "Phenylketonuria (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "MONDO:0009861 | Exact"
    explanation: Orphanet maps ORPHA:716 to the same MONDO identifier used by this entry.
definitions:
- name: Orphanet phenylketonuria definition
  definition_type: OTHER
  description: >-
    A rare inborn error of amino acid metabolism with elevated blood
    phenylalanine and low or absent phenylalanine hydroxylase enzyme activity,
    causing mild to severe mental disability if not detected early or left
    untreated.
  evidence:
  - reference: ORPHA:716
    reference_title: "Phenylketonuria (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "A rare inborn error of amino acid metabolism characterized by elevated blood phenylalanine and low levels or absence of phenylalanine hydroxylase enzyme."
    explanation: Orphanet's definition supports the disease-level biochemical characterization.
has_subtypes:
- name: Classic PKU
  description: Severe PAH deficiency with blood Phe greater than 1200 micromol/L untreated.
  evidence:
  - reference: PMID:21555948
    reference_title: "Phenylalanine hydroxylase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Deficiency of this enzyme produces a spectrum of disorders including classic phenylketonuria, mild phenylketonuria, and mild hyperphenylalaninemia."
    explanation: GeneReviews describes classic PKU as part of the PAH deficiency spectrum.
- name: Mild PKU
  description: Moderate PAH deficiency with blood Phe 600-1200 micromol/L untreated.
  evidence:
  - reference: PMID:21555948
    reference_title: "Phenylalanine hydroxylase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Deficiency of this enzyme produces a spectrum of disorders including classic phenylketonuria, mild phenylketonuria, and mild hyperphenylalaninemia."
    explanation: Same source supports mild PKU as a recognized subtype in the PAH deficiency spectrum.
- name: BH4-Responsive PKU
  description: Responds to tetrahydrobiopterin supplementation.
  evidence:
  - reference: PMID:34017006
    reference_title: "Phenylketonuria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Pharmacological treatments are available, such as tetrahydrobiopterin, which is effective in only a minority of patients (usually those with milder PKU)"
    explanation: Supports a BH4-responsive subgroup among PKU patients.
inheritance:
- name: Autosomal Recessive
  description: Biallelic pathogenic PAH variants are required for disease expression.
  inheritance_term:
    preferred_term: Autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  evidence:
  - reference: PMID:21555948
    reference_title: "Phenylalanine hydroxylase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Phenylalanine hydroxylase deficiency is an autosomal recessive disorder that results in intolerance to the dietary intake of the essential amino acid phenylalanine."
    explanation: Confirms autosomal recessive inheritance for PAH deficiency (PKU).
  - reference: ORPHA:716
    reference_title: "Phenylketonuria (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Autosomal recessive"
    explanation: Orphanet independently classifies ORPHA:716 as autosomal recessive.
prevalence:
- population: Global neonatal screening cohorts
  percentage: 6.002 per 100,000 neonates
  notes: >-
    A meta-analysis focused on classic PKU found a pooled global prevalence of
    6.002 per 100,000 neonates, with marked regional variation. Broader PAH
    deficiency estimates are similar in magnitude at about 0.64 per 10,000
    births globally.
  evidence:
  - reference: PMID:32024337
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The overall worldwide prevalence of the disease is 6.002 per 100,000 neonates (95% confidence interval, 5.07-6.93)."
    explanation: This systematic review and meta-analysis provides a pooled global neonatal prevalence estimate for classic PKU.
  - reference: PMID:34082800
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "was 0.64 (95% confidence interval 0.53-0.75) per 10,000 births"
    explanation: This meta-analysis of newborn screening studies supports a similar global birth prevalence estimate for the broader PAH deficiency spectrum that includes PKU.
- population: Worldwide Orphanet registry synthesis
  percentage: 1-9 per 100,000
  notes: >-
    Orphanet records worldwide point prevalence and birth prevalence for PKU in
    the 1-9 per 100,000 range.
  evidence:
  - reference: ORPHA:716
    reference_title: "Phenylketonuria (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "1-9 / 100 000 | Worldwide | Point prevalence | PMID:32668217"
    explanation: Orphanet's epidemiology table supports the worldwide point-prevalence range.
  - reference: ORPHA:716
    reference_title: "Phenylketonuria (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "1-9 / 100 000 | Worldwide | Prevalence at birth | PMID:34082800"
    explanation: Orphanet independently records the same worldwide range for prevalence at birth.
progression:
- phase: Infancy onset
  age_range: infancy
  notes: Orphanet records infancy as the age-of-onset category for PKU.
  evidence:
  - reference: ORPHA:716
    reference_title: "Phenylketonuria (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Age of onset: Infancy"
    explanation: Orphanet's natural-history section supplies the disease-level onset category.
mechanistic_hypotheses:
- hypothesis_group_id: canonical_pah_deficiency_phenylalanine_neurotoxicity_model
  hypothesis_label: Canonical PAH Deficiency and Phenylalanine Neurotoxicity Model
  status: CANONICAL
  description: >-
    Biallelic loss-of-function variants in PAH reduce hepatic phenylalanine hydroxylase activity, blocking conversion of phenylalanine to tyrosine. The resulting hyperphenylalaninemia exposes the developing and adult brain to neurotoxic phenylalanine levels, with downstream perturbation of large-neutral-amino-acid (LNAA) transport across the blood-brain barrier, depletion of cerebral tyrosine, tryptophan, and dopamine/serotonin neurotransmitter pools, impaired myelination, and oxidative stress. Severity is graded by residual PAH activity (classic PKU vs mild PKU vs non-PKU hyperphenylalaninemia) and the BH4-responsive subset; phenylalanine restriction, BH4 sapropterin, and pegvaliase (phenylalanine ammonia lyase) all act on this canonical axis.
  notes: >-
    Retained as CANONICAL. The 2026 falcon
    hypothesis-search report
    (kb/hypotheses/Phenylketonuria/canonical_pah_deficiency_phenylalanine_neurotoxicity_model;
    openscientist timed out) confirms biallelic PAH loss-of-
    function → hyperphenylalaninemia → neurotoxicity as the
    core mechanism, supported by phenylalanine-restricted diet
    efficacy, BH4 sapropterin response in cofactor-responsive
    variants, and pegvaliase (PAL enzyme substitution) approval.
    Three refinements: (1) the BBB neurotoxicity mechanism is
    multifactorial — LNAA transporter competition, depletion of
    cerebral tyrosine/tryptophan, reduced dopamine/serotonin
    synthesis, impaired myelin lipid composition, and oxidative
    stress all contribute, rather than direct Phe-toxicity alone;
    (2) maternal PKU teratogenicity (embryonic Phe exposure
    causing microcephaly, congenital heart disease,
    intellectual disability in offspring) operates through a
    distinct developmental mechanism; (3) executive
    dysfunction, attention deficits, and mood disorders persist
    in early-treated PKU adults even with good metabolic
    control, suggesting subtle developmental neurotoxicity
    beyond what current Phe targets capture.
  evidence:
  - reference: PMID:35854334
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "PKU, an autosomal recessive disease, is an inborn error of phenylalanine (Phe) metabolism"
    explanation: >
      Canonical mechanism review used as the seed reference for the
      hypothesis-search deep-research run.
pathophysiology:
- name: Biallelic PAH Pathogenic Variant Burden
  description: >-
    Homozygous or compound heterozygous pathogenic PAH variant combinations
    initiate PKU by reducing phenylalanine hydroxylase activity, with variant
    severity determining whether the downstream biochemical phenotype is classic
    PKU, mild PKU, or mild hyperphenylalaninemia.
  genes:
  - preferred_term: PAH
    term:
      id: hgnc:8582
      label: PAH
    modifier: DECREASED
  genetic_context:
    description: Biallelic pathogenic PAH variant combinations.
    functional_impact: loss_of_function_or_hypomorphic
  evidence:
  - reference: PMID:35854334
    reference_title: "Genetic etiology and clinical challenges of phenylketonuria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "PKU, an autosomal recessive disease, is an inborn error of phenylalanine (Phe) metabolism caused by pathogenic variants in the phenylalanine hydroxylase (PAH) gene."
    explanation: Establishes PAH pathogenic variants as the upstream genetic lesion.
  - reference: PMID:21555948
    reference_title: "Phenylalanine hydroxylase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Deficiency of this enzyme produces a spectrum of disorders including classic phenylketonuria, mild phenylketonuria, and mild hyperphenylalaninemia."
    explanation: Supports variant-severity-dependent disease spectrum downstream of PAH deficiency.
  downstream:
  - target: Near-Complete PAH Activity Loss
    description: Severe PAH genotypes converge on complete or near-complete enzyme deficiency.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:21555948
      reference_title: "Phenylalanine hydroxylase deficiency."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Classic phenylketonuria is caused by a complete or near-complete deficiency of phenylalanine hydroxylase activity"
      explanation: Directly connects the severe activity-loss state to classic PKU.
  - target: Residual PAH Activity and BH4 Responsiveness
    description: Residual-function PAH variants create milder phenotypes and possible BH4 response.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:35854334
      reference_title: "Genetic etiology and clinical challenges of phenylketonuria."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The synthetic BH4 analog, sapropterin hydrochloride (i.e., Kuvan®, BioMarin), is another potential treatment that activates residual PAH, thus decreasing Phe concentrations in the blood of PKU patients."
      explanation: Supports a residual-activity branch that can respond to BH4 pharmacological activation.
- name: Near-Complete PAH Activity Loss
  description: >-
    Severe PAH variant combinations produce complete or near-complete hepatic
    PAH activity loss, defining the classic PKU branch with the highest untreated
    phenylalanine burden and greatest neurotoxicity risk.
  genes:
  - preferred_term: PAH
    term:
      id: hgnc:8582
      label: PAH
    modifier: DECREASED
  molecular_functions:
  - preferred_term: phenylalanine 4-monooxygenase activity
    term:
      id: GO:0004505
      label: phenylalanine 4-monooxygenase activity
    modifier: DECREASED
  subtypes:
  - Classic PKU
  genetic_context:
    allele_type: null_or_severe_hypomorphic
    functional_impact: complete_or_near_complete_loss_of_PAH_activity
    description: Severe biallelic PAH variant combinations.
  biological_processes:
  - preferred_term: L-phenylalanine catabolic process
    term:
      id: GO:0006559
      label: L-phenylalanine catabolic process
    modifier: DECREASED
  evidence:
  - reference: PMID:21555948
    reference_title: "Phenylalanine hydroxylase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Classic phenylketonuria is caused by a complete or near-complete deficiency of phenylalanine hydroxylase activity and without dietary restriction of phenylalanine most children will develop profound and irreversible intellectual disability."
    explanation: Defines the severe enzymatic branch and its untreated neurodevelopmental consequence.
  downstream:
  - target: Hepatic PAH Enzyme Deficiency
    description: Complete or near-complete PAH activity loss is the severe end of hepatic PAH enzyme deficiency.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:21555948
      reference_title: "Phenylalanine hydroxylase deficiency."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Classic phenylketonuria is caused by a complete or near-complete deficiency of phenylalanine hydroxylase activity"
      explanation: Places the severe activity-loss state directly upstream of the shared hepatic PAH deficiency node.
- name: Residual PAH Activity and BH4 Responsiveness
  description: >-
    Hypomorphic PAH variant combinations retain some enzyme activity, producing
    milder hyperphenylalaninemia/PKU phenotypes and enabling a subset of patients
    to respond to tetrahydrobiopterin or sapropterin.
  genes:
  - preferred_term: PAH
    term:
      id: hgnc:8582
      label: PAH
    modifier: DECREASED
  molecular_functions:
  - preferred_term: phenylalanine 4-monooxygenase activity
    term:
      id: GO:0004505
      label: phenylalanine 4-monooxygenase activity
    modifier: DECREASED
  subtypes:
  - Mild PKU
  - BH4-Responsive PKU
  genetic_context:
    allele_type: hypomorphic_or_residual_function
    functional_impact: partial_loss_of_PAH_activity
    description: PAH variant combinations retaining pharmacologically activatable residual activity.
  biological_processes:
  - preferred_term: L-phenylalanine catabolic process
    term:
      id: GO:0006559
      label: L-phenylalanine catabolic process
    modifier: DECREASED
  evidence:
  - reference: PMID:34017006
    reference_title: "Phenylketonuria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Pharmacological treatments are available, such as tetrahydrobiopterin, which is effective in only a minority of patients (usually those with milder PKU)"
    explanation: Supports BH4 responsiveness as enriched in milder PKU phenotypes.
  - reference: PMID:21555948
    reference_title: "Phenylalanine hydroxylase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Mild phenylketonuria and mild hyperphenylalaninemia are associated with lower risk of impaired cognitive development in the absence of treatment."
    explanation: Supports residual-function phenotypes with less severe untreated neurodevelopmental risk.
  downstream:
  - target: Hepatic PAH Enzyme Deficiency
    description: Residual-function alleles still reduce hepatic PAH activity, but less completely than classic PKU genotypes.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:35854334
      reference_title: "Genetic etiology and clinical challenges of phenylketonuria."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The synthetic BH4 analog, sapropterin hydrochloride (i.e., Kuvan®, BioMarin), is another potential treatment that activates residual PAH, thus decreasing Phe concentrations in the blood of PKU patients."
      explanation: Connects residual PAH activity to the shared PAH-deficiency biochemical pathway.
- name: Hepatic PAH Enzyme Deficiency
  description: Pathogenic PAH variants reduce hepatic phenylalanine hydroxylase activity.
  genes:
  - preferred_term: PAH
    term:
      id: hgnc:8582
      label: PAH
    modifier: DECREASED
  molecular_functions:
  - preferred_term: phenylalanine 4-monooxygenase activity
    term:
      id: GO:0004505
      label: phenylalanine 4-monooxygenase activity
    modifier: DECREASED
  cell_types:
  - preferred_term: hepatocyte
    term:
      id: CL:0000182
      label: hepatocyte
  locations:
  - preferred_term: liver
    term:
      id: UBERON:0002107
      label: liver
  biological_processes:
  - preferred_term: L-phenylalanine catabolic process
    term:
      id: GO:0006559
      label: L-phenylalanine catabolic process
    modifier: DECREASED
  pdb_structures:
  - pdb_id: 6N1K
    description: >-
      Full-length human phenylalanine hydroxylase C29S tetramer in the
      resting-state conformation, providing an experimental structural context for
      PAH allostery and disease-associated enzyme dysfunction.
    resolution_angstrom: 3.06
    method: X-ray diffraction
    target_protein: phenylalanine hydroxylase
    publication: PMID:31076506
  - pdb_id: 5FII
    description: >-
      Human PAH N-terminal regulatory domain bound to phenylalanine, showing
      ligand-dependent ACT-domain dimerization at the allosteric regulatory site.
    resolution_angstrom: 1.8
    method: X-ray diffraction
    ligand: L-phenylalanine
    target_protein: phenylalanine hydroxylase regulatory domain
    publication: PMID:27049649
  evidence:
  - reference: PMID:29025426
    reference_title: "The complete European guidelines on phenylketonuria: diagnosis and treatment."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Phenylketonuria (PKU) is an autosomal recessive inborn error of phenylalanine metabolism caused by deficiency in the enzyme phenylalanine hydroxylase that converts phenylalanine into tyrosine."
    explanation: Defines PAH deficiency as the primary molecular lesion in PKU.
  - reference: PMID:31076506
    reference_title: "Biophysical characterization of full-length human phenylalanine hydroxylase provides a deeper understanding of its quaternary structure equilibrium."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "a tractable C29S variant of hPAH (C29S) yielded a 3.06 Å resolution crystal structure of the tetrameric resting-state conformation."
    explanation: Experimental X-ray crystallography and SEC-SAXS provide structural support for PAH quaternary-state mechanisms relevant to enzyme dysfunction.
  - reference: PMID:27049649
    reference_title: "Structural basis for ligand-dependent dimerization of phenylalanine hydroxylase regulatory domain."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "a disease-associated PAH mutant impaired in Phe binding disrupts the monomer:dimer equilibrium of PAH-RD."
    explanation: Experimental structural and biophysical data connect disease-associated PAH mutation effects to impaired allosteric regulatory-domain dimerization.
  downstream:
  - target: Hyperphenylalaninemia
    description: Reduced PAH activity impairs phenylalanine clearance from blood.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:24385074
      reference_title: "Phenylalanine hydroxylase deficiency: diagnosis and management guideline."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Phenylalanine hydroxylase deficiency, traditionally known as phenylketonuria, results in the accumulation of phenylalanine in the blood of affected individuals and was the first inborn error of metabolism to be identified through population screening."
      explanation: Links PAH deficiency directly to elevated blood phenylalanine.
  - target: Relative Tyrosine Deficiency
    description: Blocked conversion of phenylalanine to tyrosine reduces tyrosine availability.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:29025426
      reference_title: "The complete European guidelines on phenylketonuria: diagnosis and treatment."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Phenylketonuria (PKU) is an autosomal recessive inborn error of phenylalanine metabolism caused by deficiency in the enzyme phenylalanine hydroxylase that converts phenylalanine into tyrosine."
      explanation: The blocked PAH reaction mechanistically implies reduced tyrosine production.
- name: Hyperphenylalaninemia
  description: Phenylalanine accumulates in blood and tissues when PAH-dependent metabolism is impaired.
  chemical_entities:
  - preferred_term: L-phenylalanine
    term:
      id: CHEBI:58095
      label: L-phenylalanine zwitterion
    modifier: INCREASED
  biological_processes:
  - preferred_term: L-phenylalanine metabolic process
    term:
      id: GO:0006558
      label: L-phenylalanine metabolic process
    modifier: DYSREGULATED
  evidence:
  - reference: PMID:24385074
    reference_title: "Phenylalanine hydroxylase deficiency: diagnosis and management guideline."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Phenylalanine hydroxylase deficiency, traditionally known as phenylketonuria, results in the accumulation of phenylalanine in the blood of affected individuals and was the first inborn error of metabolism to be identified through population screening."
    explanation: Clinical guideline abstract confirms blood phenylalanine accumulation in PKU.
  - reference: PMID:21216643
    reference_title: "The effect of blood phenylalanine concentration on Kuvan™ response in phenylketonuria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Phenylketonuria (PKU) is caused by mutations in the phenylalanine hydroxylase gene (PAH) with consequent elevation of blood phenylalanine (Phe), reduction in tyrosine (Tyr) and elevation of Phe/Tyr ratio (P/T)."
    explanation: Independent clinical study confirms elevated blood phenylalanine in PKU.
  downstream:
  - target: Blood Phenylalanine
    description: Elevated blood phenylalanine is the direct biochemical readout of impaired PAH-dependent phenylalanine clearance.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:24385074
      reference_title: "Phenylalanine hydroxylase deficiency: diagnosis and management guideline."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Phenylalanine hydroxylase deficiency, traditionally known as phenylketonuria, results in the accumulation of phenylalanine in the blood of affected individuals and was the first inborn error of metabolism to be identified through population screening."
      explanation: Directly supports blood phenylalanine accumulation as the biochemical readout of PKU hyperphenylalaninemia.
  - target: Phenylalanine to Tyrosine Ratio
    description: Hyperphenylalaninemia contributes to an elevated phenylalanine-to-tyrosine ratio.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:21216643
      reference_title: "The effect of blood phenylalanine concentration on Kuvan™ response in phenylketonuria."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Phenylketonuria (PKU) is caused by mutations in the phenylalanine hydroxylase gene (PAH) with consequent elevation of blood phenylalanine (Phe), reduction in tyrosine (Tyr) and elevation of Phe/Tyr ratio (P/T)."
      explanation: Clinical data link elevated phenylalanine with increased Phe/Tyr ratio in PKU.
  - target: Competitive Large Neutral Amino Acid Transport at the Blood-Brain Barrier
    description: Excess phenylalanine competitively perturbs transport of other neutral amino acids into brain.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:987768
      reference_title: "Lowering brain phenylalanine levels by giving other large neutral amino acids. A new experimental therapeutic approach to phenylketonuria."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "The LNAA group of amino acids--phenylalanine, tyrosine, tryptophan, leucine, isoleucine, and valine--compete with each other for entry into brain by a common transport mechanism."
      explanation: Demonstrates the shared competitive transport mechanism driving brain amino-acid imbalance.
  - target: Brain Phenylalanine Toxicity
    description: Persistent systemic hyperphenylalaninemia increases brain phenylalanine burden and toxicity.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:34017006
      reference_title: "Phenylketonuria."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Phenylketonuria (PKU; also known as phenylalanine hydroxylase (PAH) deficiency) is an autosomal recessive disorder of phenylalanine metabolism, in which especially high phenylalanine concentrations cause brain dysfunction."
      explanation: Directly links high phenylalanine levels to brain dysfunction.
  - target: Phenylketone Accumulation
    description: Excess phenylalanine is diverted to alternative metabolites, including phenylketones.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:21565303
      reference_title: "Study on urinary metabolic profile of phenylketonuria by micellar electrokinetic capillary chromatography with dual electrochemical detection--potential clinical application in fast diagnosis of phenylketonuria."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The urinary metabolic marker compounds, namely phenylpyruvic acid (PPA), 2-hydroxyphenylacetic acid (oOPAA), 4-hydroxyphenylacetic acid (pOPAA), phenyllactic acid (PLA) and phenylacetic acid (PAA) of phenylketonuric individuals were detected"
      explanation: Supports accumulation of phenylalanine-derived phenylketone metabolites in PKU.
  - target: Protein Insufficiency During Dietary Therapy
    description: >-
      Chronic hyperphenylalaninemia requires phenylalanine-restricted medical
      nutrition; inadequate protein status during therapy can impair linear
      growth.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - phenylalanine-restricted diet and protein-substitute dependence
    evidence:
    - reference: PMID:35854334
      reference_title: "Genetic etiology and clinical challenges of phenylketonuria."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Dietary treatment, including natural protein restriction and Phe-free supplements, must be used to maintain blood Phe concentrations of 120-360 μmol/L throughout the life span."
      explanation: Supports the treatment dependency linking the hyperphenylalaninemia node to nutrition-sensitive growth outcomes.
    - reference: PMID:12183721
      reference_title: "Protein insufficiency and linear growth restriction in phenylketonuria."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "There is a strong relation between protein insufficiency, as determined by plasma prealbumin levels, and linear growth impairment."
      explanation: Human PKU cohort data support protein insufficiency as the growth-limiting intermediate.
  - target: Reduced Bone Mineral Density in PKU
    description: >-
      PKU and its long-term phenylalanine-restricted medical nutrition context
      are associated with lower bone mineral density in some cohorts.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:39267130
      reference_title: "Meta-analysis of bone mineral density in adults with phenylketonuria."
      supports: PARTIAL
      evidence_source: HUMAN_CLINICAL
      snippet: "Studies have reported low bone mineral density (BMD) in mixed-age PKU populations, possibly related to long-term Phe restriction."
      explanation: The meta-analysis supports an association between PKU dietary management context and lower BMD, while noting causal uncertainty.
  - target: Maternal Hyperphenylalaninemia Teratogenicity
    description: >-
      Elevated maternal phenylalanine during early gestation creates a fetal
      teratogenic exposure associated with congenital heart defects.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:10636975
      reference_title: "Maternal phenylketonuria syndrome: congenital heart defects, microcephaly, and developmental outcomes."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Mean Phe levels at 4 to 8 weeks' gestation predicted CHDs (P <.0001)."
      explanation: Maternal PKU cohort data link early gestational phenylalanine levels to offspring congenital heart defects.
- name: Protein Insufficiency During Dietary Therapy
  description: >-
    Phenylalanine-restricted therapy depends on carefully balanced natural
    protein and Phe-free protein substitutes; inadequate protein sufficiency,
    reflected by low plasma prealbumin, is associated with impaired linear growth
    in treated children with PKU.
  biological_processes:
  - preferred_term: negative regulation of multicellular organism growth
    term:
      id: GO:0040015
      label: negative regulation of multicellular organism growth
    modifier: INCREASED
  evidence:
  - reference: PMID:12183721
    reference_title: "Protein insufficiency and linear growth restriction in phenylketonuria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "There is a strong relation between protein insufficiency, as determined by plasma prealbumin levels, and linear growth impairment."
    explanation: Directly supports protein insufficiency as a mechanism for impaired linear growth in treated PKU children.
  - reference: PMID:12183721
    reference_title: "Protein insufficiency and linear growth restriction in phenylketonuria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We suggest that a plasma prealbumin level of at least 20 mg/dL is necessary for optimal growth in children with PKU."
    explanation: Supports plasma prealbumin as a protein-sufficiency threshold tied to growth outcome.
  downstream:
  - target: Growth Delay
    description: Protein insufficiency during PKU dietary therapy can manifest as growth delay or linear growth impairment.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:12183721
      reference_title: "Protein insufficiency and linear growth restriction in phenylketonuria."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "There is a strong relation between protein insufficiency, as determined by plasma prealbumin levels, and linear growth impairment."
      explanation: Directly connects protein insufficiency to the growth-delay phenotype in children with PKU.
  - target: Plasma Prealbumin
    description: Plasma prealbumin is a monitoring readout for protein sufficiency during phenylalanine-restricted therapy.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:12183721
      reference_title: "Protein insufficiency and linear growth restriction in phenylketonuria."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "We suggest that a plasma prealbumin level of at least 20 mg/dL is necessary for optimal growth in children with PKU."
      explanation: Supports plasma prealbumin as a clinically relevant protein-sufficiency readout in treated children with PKU.
- name: Reduced Bone Mineral Density in PKU
  description: >-
    Adults and children with PKU have repeatedly been reported to have lower
    bone mineral density, with mechanisms still uncertain and likely involving
    diet composition, metabolic control, and other modifiers.
  biological_processes:
  - preferred_term: bone mineralization
    term:
      id: GO:0030282
      label: bone mineralization
    modifier: DECREASED
  evidence:
  - reference: PMID:25758373
    reference_title: "Bone health in phenylketonuria: a systematic review and meta-analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Patients with Phenylketonuria (PKU) reportedly have decreased bone mineral density (BMD)."
    explanation: Systematic review directly supports reduced BMD as a bone-health abnormality in PKU.
  - reference: PMID:25758373
    reference_title: "Bone health in phenylketonuria: a systematic review and meta-analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Ten out of 11 articles found BMD was significantly lower in patients with PKU."
    explanation: Summarizes the direction of BMD findings across included PKU studies.
  downstream:
  - target: Osteopenia
    description: Reduced bone mineral density is the quantitative substrate for osteopenia in the PKU phenotype spectrum.
    causal_link_type: DIRECT
    evidence:
    - reference: ORPHA:716
      reference_title: "Phenylketonuria (Orphanet structured-database record)"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0000938 | Osteopenia | Frequent (79-30%)"
      explanation: Orphanet records osteopenia as a frequent PKU phenotype.
    - reference: PMID:25758373
      reference_title: "Bone health in phenylketonuria: a systematic review and meta-analysis."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Ten out of 11 articles found BMD was significantly lower in patients with PKU."
      explanation: Supports lower BMD as the quantitative basis for osteopenia in the PKU bone-health evidence base.
  - target: Bone Mineral Density Z-score
    description: Bone mineral density Z-score is a quantitative readout of reduced bone density in PKU cohorts.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:39267130
      reference_title: "Meta-analysis of bone mineral density in adults with phenylketonuria."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Adults with PKU had lower BMD Z-scores than the reference (non-PKU) population but < 1 in 10 were below the expected range for age."
      explanation: Supports BMD Z-score as the quantitative biochemical/clinical readout of reduced bone mineral density in PKU.
- name: Maternal Hyperphenylalaninemia Teratogenicity
  description: >-
    In women with PKU or hyperphenylalaninemia, poor phenylalanine control during
    early pregnancy creates a fetal teratogenic exposure that is associated with
    congenital heart defects and other maternal PKU syndrome outcomes.
  chemical_entities:
  - preferred_term: L-phenylalanine
    term:
      id: CHEBI:58095
      label: L-phenylalanine zwitterion
    modifier: INCREASED
  biological_processes:
  - preferred_term: heart development
    term:
      id: GO:0007507
      label: heart development
    modifier: ABNORMAL
  evidence:
  - reference: PMID:10636975
    reference_title: "Maternal phenylketonuria syndrome: congenital heart defects, microcephaly, and developmental outcomes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "None of the women whose offspring had CHDs had blood Phe levels in control during the first 8 weeks of gestation."
    explanation: Directly supports poor early gestational phenylalanine control as the maternal PKU context for congenital heart defects.
  - reference: PMID:12193940
    reference_title: "Nutrient intake and congenital heart defects in maternal phenylketonuria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A significantly increased incidence of congenital heart defects was observed in offspring of mothers with hyperphenylalaninemia who had an elevated blood phenylalanine level >10 mg/dL at 0 to 8 weeks of gestation and a protein intake of < or = 50% of the recommended dietary allowance (P <.0013)."
    explanation: Supports the combined high-phenylalanine and maternal nutrition risk context for fetal cardiac malformations.
  downstream:
  - target: Abnormal Cardiovascular System Morphology
    description: Maternal PKU teratogenicity can cause congenital heart defects in offspring.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:10636975
      reference_title: "Maternal phenylketonuria syndrome: congenital heart defects, microcephaly, and developmental outcomes."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Thirty-one offspring had CHDs; of these, 17 also had microcephaly."
      explanation: Directly documents congenital heart defects among offspring in a maternal PKU cohort.
    - reference: PMID:12193940
      reference_title: "Nutrient intake and congenital heart defects in maternal phenylketonuria."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "An inadequate intake of protein during pregnancy in conjunction with elevated blood phenylalanine levels appear to have an additive effect in the incidence of congenital heart defects in the offspring of women with hyperphenylalaninemia."
      explanation: Supports congenital heart defects as a downstream fetal outcome of poorly controlled maternal hyperphenylalaninemia with inadequate protein intake.
- name: Relative Tyrosine Deficiency
  description: Decreased PAH flux lowers endogenous tyrosine generation from phenylalanine.
  chemical_entities:
  - preferred_term: L-tyrosine
    term:
      id: CHEBI:58315
      label: L-tyrosine zwitterion
    modifier: DECREASED
  biological_processes:
  - preferred_term: tyrosine metabolic process
    term:
      id: GO:0006570
      label: tyrosine metabolic process
    modifier: DECREASED
  evidence:
  - reference: PMID:29025426
    reference_title: "The complete European guidelines on phenylketonuria: diagnosis and treatment."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Phenylketonuria (PKU) is an autosomal recessive inborn error of phenylalanine metabolism caused by deficiency in the enzyme phenylalanine hydroxylase that converts phenylalanine into tyrosine."
    explanation: Impaired conversion from phenylalanine to tyrosine implies substrate deficiency downstream.
  - reference: PMID:21216643
    reference_title: "The effect of blood phenylalanine concentration on Kuvan™ response in phenylketonuria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Phenylketonuria (PKU) is caused by mutations in the phenylalanine hydroxylase gene (PAH) with consequent elevation of blood phenylalanine (Phe), reduction in tyrosine (Tyr) and elevation of Phe/Tyr ratio (P/T)."
    explanation: Human PKU cohort data directly reports reduced tyrosine associated with hyperphenylalaninemia.
  downstream:
  - target: Blood Tyrosine
    description: Reduced PAH-mediated conversion of phenylalanine to tyrosine is reflected by decreased blood tyrosine.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:30570999
      reference_title: "Phenylketonuria (PKU)."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Elevated blood Phe levels and decreased Tyr levels characterize PKU."
      explanation: Directly supports decreased blood tyrosine as the biochemical readout of relative tyrosine deficiency in PKU.
  - target: Phenylalanine to Tyrosine Ratio
    description: Reduced tyrosine availability contributes to the elevated phenylalanine-to-tyrosine ratio.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:21216643
      reference_title: "The effect of blood phenylalanine concentration on Kuvan™ response in phenylketonuria."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Phenylketonuria (PKU) is caused by mutations in the phenylalanine hydroxylase gene (PAH) with consequent elevation of blood phenylalanine (Phe), reduction in tyrosine (Tyr) and elevation of Phe/Tyr ratio (P/T)."
      explanation: Clinical data link reduced tyrosine with increased Phe/Tyr ratio in PKU.
  - target: Impaired Melanin Biosynthesis
    description: Reduced tyrosine supply limits melanin production.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:35854334
      reference_title: "Genetic etiology and clinical challenges of phenylketonuria."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Untreated PKU, also known as PAH deficiency, results in severe and irreversible intellectual disability, epilepsy, behavioral disorders, and clinical features such as acquired microcephaly, seizures, psychological signs, and generalized hypopigmentation of skin (including hair and eyes)."
      explanation: Clinical hypopigmentation supports impaired melanin synthesis downstream of tyrosine deficiency.
  - target: Reduced Dopamine Biosynthesis
    description: Lower tyrosine availability reduces substrate supply for catecholamine synthesis.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:6119011
      reference_title: "Serotonin and dopamine synthesis in phenylketonuria."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "In classical PKU, the serotonin and dopamine biosynthesis is inhibited by high L-phenylalanine in blood and tissues."
      explanation: Supports reduced dopamine biosynthesis in the PKU biochemical context.
- name: Competitive Large Neutral Amino Acid Transport at the Blood-Brain Barrier
  description: Large neutral amino acids, including phenylalanine, share competitive brain-entry transport.
  locations:
  - preferred_term: blood brain barrier
    term:
      id: UBERON:0000120
      label: blood brain barrier
  biological_processes:
  - preferred_term: neutral amino acid transport
    term:
      id: GO:0015804
      label: neutral amino acid transport
    modifier: DYSREGULATED
  chemical_entities:
  - preferred_term: L-phenylalanine
    term:
      id: CHEBI:58095
      label: L-phenylalanine zwitterion
    modifier: INCREASED
  - preferred_term: L-tyrosine
    term:
      id: CHEBI:58315
      label: L-tyrosine zwitterion
    modifier: DECREASED
  - preferred_term: L-tryptophan
    term:
      id: CHEBI:57912
      label: L-tryptophan zwitterion
    modifier: DECREASED
  evidence:
  - reference: PMID:987768
    reference_title: "Lowering brain phenylalanine levels by giving other large neutral amino acids. A new experimental therapeutic approach to phenylketonuria."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "The LNAA group of amino acids--phenylalanine, tyrosine, tryptophan, leucine, isoleucine, and valine--compete with each other for entry into brain by a common transport mechanism."
    explanation: Provides mechanistic support for competitive BBB amino acid transport.
  downstream:
  - target: Reduced Serotonin Biosynthesis
    description: Lower brain tryptophan availability contributes to impaired serotonin synthesis.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:6119011
      reference_title: "Serotonin and dopamine synthesis in phenylketonuria."
      supports: PARTIAL
      evidence_source: HUMAN_CLINICAL
      snippet: "In classical PKU, the serotonin and dopamine biosynthesis is inhibited by high L-phenylalanine in blood and tissues."
      explanation: Supports neurotransmitter biosynthesis inhibition; transporter-competition mechanism is an inferred intermediate.
  - target: Reduced Dopamine Biosynthesis
    description: Lower brain tyrosine availability contributes to impaired dopamine synthesis.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:6119011
      reference_title: "Serotonin and dopamine synthesis in phenylketonuria."
      supports: PARTIAL
      evidence_source: HUMAN_CLINICAL
      snippet: "In classical PKU, the serotonin and dopamine biosynthesis is inhibited by high L-phenylalanine in blood and tissues."
      explanation: Supports dopamine biosynthesis inhibition; transporter competition is an inferred upstream mechanism.
- name: Reduced Serotonin Biosynthesis
  description: High phenylalanine states inhibit serotonin production pathways.
  biological_processes:
  - preferred_term: serotonin biosynthetic process
    term:
      id: GO:0042427
      label: serotonin biosynthetic process
    modifier: DECREASED
  evidence:
  - reference: PMID:6119011
    reference_title: "Serotonin and dopamine synthesis in phenylketonuria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In classical PKU, the serotonin and dopamine biosynthesis is inhibited by high L-phenylalanine in blood and tissues."
    explanation: Human PKU data support reduced serotonin synthesis under high phenylalanine conditions.
  downstream:
  - target: Neurocognitive Dysfunction
    description: Monoamine deficits contribute to attention, executive, and behavioral impairment.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:34017006
      reference_title: "Phenylketonuria."
      supports: PARTIAL
      evidence_source: HUMAN_CLINICAL
      snippet: "Phenylketonuria (PKU; also known as phenylalanine hydroxylase (PAH) deficiency) is an autosomal recessive disorder of phenylalanine metabolism, in which especially high phenylalanine concentrations cause brain dysfunction."
      explanation: Supports brain dysfunction in PKU; specific attribution to serotonin deficit is mechanistically plausible but indirect in this source.
- name: Reduced Dopamine Biosynthesis
  description: High phenylalanine states inhibit dopamine production pathways.
  biological_processes:
  - preferred_term: dopamine biosynthetic process
    term:
      id: GO:0042416
      label: dopamine biosynthetic process
    modifier: DECREASED
  evidence:
  - reference: PMID:6119011
    reference_title: "Serotonin and dopamine synthesis in phenylketonuria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In classical PKU, the serotonin and dopamine biosynthesis is inhibited by high L-phenylalanine in blood and tissues."
    explanation: Human PKU data support reduced dopamine synthesis under high phenylalanine conditions.
  downstream:
  - target: Neurocognitive Dysfunction
    description: Dopaminergic dysfunction contributes to executive and cognitive deficits.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:34017006
      reference_title: "Phenylketonuria."
      supports: PARTIAL
      evidence_source: HUMAN_CLINICAL
      snippet: "Phenylketonuria (PKU; also known as phenylalanine hydroxylase (PAH) deficiency) is an autosomal recessive disorder of phenylalanine metabolism, in which especially high phenylalanine concentrations cause brain dysfunction."
      explanation: Supports PKU-related brain dysfunction; dopaminergic mediation is mechanistic interpretation.
  - target: Hypertonia
    description: Biogenic amine disruption in classical PKU can contribute to hypertonicity and spasticity.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - reduced biogenic amine neurotransmitter metabolites
    evidence:
    - reference: PMID:2516176
      reference_title: "Neurological deterioration in adult phenylketonuria."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Dietary therapy reduced serum phenylalanine levels, improved symptoms of hypertonicity, and cerebrospinal fluid neurotransmitter metabolites became normal."
      explanation: Links phenylalanine-lowering and normalization of neurotransmitter metabolites to improvement of hypertonicity.
- name: Brain Phenylalanine Toxicity
  description: Elevated phenylalanine in the CNS drives diffuse brain dysfunction.
  locations:
  - preferred_term: brain
    term:
      id: UBERON:0000955
      label: brain
  biological_processes:
  - preferred_term: nervous system development
    term:
      id: GO:0007399
      label: nervous system development
    modifier: ABNORMAL
  evidence:
  - reference: PMID:34017006
    reference_title: "Phenylketonuria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Phenylketonuria (PKU; also known as phenylalanine hydroxylase (PAH) deficiency) is an autosomal recessive disorder of phenylalanine metabolism, in which especially high phenylalanine concentrations cause brain dysfunction."
    explanation: Confirms high phenylalanine concentrations as a direct driver of brain dysfunction.
  downstream:
  - target: White Matter and Subcortical Structural Injury
    description: Brain phenylalanine toxicity contributes to persistent white-matter and subcortical abnormalities.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:37265600
      reference_title: "Compromised white matter is related to lower cognitive performance in adults with phenylketonuria."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "In conclusion, our findings demonstrate that white matter alterations in early-treated phenylketonuria persist into adulthood, are most prominent in the posterior white matter and are likely to be driven by axonal damage."
      explanation: Directly supports structural white-matter injury downstream of PKU brain pathology.
  - target: Microcephaly
    description: Untreated high-phenylalanine neurotoxicity can impair brain growth and cause acquired microcephaly.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - impaired brain development
    evidence:
    - reference: PMID:35854334
      reference_title: "Genetic etiology and clinical challenges of phenylketonuria."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Untreated PKU, also known as PAH deficiency, results in severe and irreversible intellectual disability, epilepsy, behavioral disorders, and clinical features such as acquired microcephaly, seizures, psychological signs, and generalized hypopigmentation of skin (including hair and eyes)."
      explanation: Supports acquired microcephaly as a downstream manifestation of untreated PAH-deficiency neurotoxicity.
  - target: Neurocognitive Dysfunction
    description: Brain dysfunction manifests clinically as cognitive impairment and executive deficits.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:34017006
      reference_title: "Phenylketonuria."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "If untreated, this brain dysfunction results in severe intellectual disability, epilepsy and behavioural problems."
      explanation: Links brain dysfunction directly to neurologic and cognitive outcomes.
  - target: Encephalopathy
    description: Severe phenylalanine-mediated brain dysfunction can manifest as encephalopathy.
    causal_link_type: DIRECT
    evidence:
    - reference: ORPHA:716
      reference_title: "Phenylketonuria (Orphanet structured-database record)"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0001298 | Encephalopathy | Occasional (29-5%)"
      explanation: Orphanet records encephalopathy in the PKU phenotype spectrum.
  - target: EEG Abnormality
    description: Phenylalanine-mediated brain dysfunction can be reflected by abnormal EEG findings.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: ORPHA:716
      reference_title: "Phenylketonuria (Orphanet structured-database record)"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0002353 | EEG abnormality | Frequent (79-30%)"
      explanation: Orphanet records EEG abnormality as a frequent PKU phenotype.
  - target: Tremor
    description: PKU brain dysfunction can include tremor as a motor manifestation.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:30570999
      reference_title: "Phenylketonuria (PKU)."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "These signs can include musty odor from skin and urine, fair skin, eczema, seizures, tremors, and hyperactivity."
      explanation: Clinical overview lists tremors among PKU signs.
  - target: Ataxia
    description: PKU neurologic involvement can include ataxia.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: ORPHA:716
      reference_title: "Phenylketonuria (Orphanet structured-database record)"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0001251 | Ataxia | Occasional (29-5%)"
      explanation: Orphanet records ataxia in the PKU phenotype spectrum.
- name: White Matter and Subcortical Structural Injury
  description: Treated adults still exhibit white-matter damage and subcortical volume loss associated with phenylalanine burden.
  cell_types:
  - preferred_term: oligodendrocyte
    term:
      id: CL:0000128
      label: oligodendrocyte
  locations:
  - preferred_term: white matter
    term:
      id: UBERON:0002316
      label: white matter
  biological_processes:
  - preferred_term: myelination
    term:
      id: GO:0042552
      label: myelination
    modifier: ABNORMAL
  evidence:
  - reference: PMID:37265600
    reference_title: "Compromised white matter is related to lower cognitive performance in adults with phenylketonuria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In conclusion, our findings demonstrate that white matter alterations in early-treated phenylketonuria persist into adulthood, are most prominent in the posterior white matter and are likely to be driven by axonal damage."
    explanation: Supports persistent white matter injury in adults with early-treated PKU.
  - reference: PMID:38907189
    reference_title: "Volumetric brain reductions in adult patients with phenylketonuria and their relationship with blood phenylalanine levels."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Moreover, these patients showed reduced global white matter volume as well as reductions in the volume of several subcortical grey matter structures, which might be related to the existence of underlying neurodevelopmental alterations."
    explanation: Independently confirms white matter and subcortical structural abnormalities.
  downstream:
  - target: Neurocognitive Dysfunction
    description: Structural brain injury is associated with lower cognitive performance.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:37265600
      reference_title: "Compromised white matter is related to lower cognitive performance in adults with phenylketonuria."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Furthermore, diffusion tensor imaging metrics in adults with phenylketonuria were related to performance in attention and executive functions."
      explanation: Connects white matter microstructure abnormalities to neurocognitive deficits.
  - target: Abnormal Cerebral White Matter Morphology
    description: Persistent white-matter injury is the mechanistic counterpart of the HPO white-matter morphology phenotype.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:37265600
      reference_title: "Compromised white matter is related to lower cognitive performance in adults with phenylketonuria."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "In conclusion, our findings demonstrate that white matter alterations in early-treated phenylketonuria persist into adulthood, are most prominent in the posterior white matter and are likely to be driven by axonal damage."
      explanation: Directly supports persistent cerebral white matter alterations in PKU.
  - target: Lower Limb Spasticity
    description: White-matter and subcortical motor-pathway injury can contribute to lower-limb spasticity.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: ORPHA:716
      reference_title: "Phenylketonuria (Orphanet structured-database record)"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0002061 | Lower limb spasticity | Occasional (29-5%)"
      explanation: Orphanet records lower-limb spasticity in the PKU phenotype spectrum.
  - target: Cerebral Visual Impairment
    description: Cerebral visual impairment is represented as an occasional neurologic manifestation downstream of brain structural injury.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: ORPHA:716
      reference_title: "Phenylketonuria (Orphanet structured-database record)"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0100704 | Cerebral visual impairment | Occasional (29-5%)"
      explanation: Orphanet records cerebral visual impairment in the PKU phenotype spectrum.
- name: Neurocognitive Dysfunction
  description: PKU causes global and executive cognitive impairment, especially when metabolic control is poor or untreated.
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  evidence:
  - reference: PMID:38907189
    reference_title: "Volumetric brain reductions in adult patients with phenylketonuria and their relationship with blood phenylalanine levels."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Adult patients with early-treated PKU showed significantly lower global intelligence than HC."
    explanation: Demonstrates measurable cognitive impairment in early-treated adult PKU cohorts.
  downstream:
  - target: Intellectual Disability
    description: Severe or untreated neurotoxicity can progress to intellectual disability.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:34017006
      reference_title: "Phenylketonuria."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "If untreated, this brain dysfunction results in severe intellectual disability, epilepsy and behavioural problems."
      explanation: Directly links PKU-related brain dysfunction to intellectual disability.
  - target: Seizures
    description: Severe untreated neurotoxicity can present with epilepsy/seizures.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:34017006
      reference_title: "Phenylketonuria."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "If untreated, this brain dysfunction results in severe intellectual disability, epilepsy and behavioural problems."
      explanation: Supports epilepsy as a downstream neurologic consequence.
  - target: Global Developmental Delay
    description: Untreated or poorly controlled PKU neurotoxicity can manifest as global developmental delay.
    causal_link_type: DIRECT
    evidence:
    - reference: ORPHA:716
      reference_title: "Phenylketonuria (Orphanet structured-database record)"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0001263 | Global developmental delay | Frequent (79-30%)"
      explanation: Orphanet records global developmental delay as a frequent PKU phenotype.
  - target: Specific Learning Disability
    description: Persistent cognitive and executive dysfunction can manifest as specific learning disability.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - reduced global intelligence and executive function.
    evidence:
    - reference: ORPHA:716
      reference_title: "Phenylketonuria (Orphanet structured-database record)"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0001328 | Specific learning disability | Frequent (79-30%)"
      explanation: Orphanet records specific learning disability as a frequent PKU phenotype.
  - target: Short Attention Span
    description: Adult PKU neurocognitive effects include attention and executive-function impairment.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:37265600
      reference_title: "Compromised white matter is related to lower cognitive performance in adults with phenylketonuria."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Furthermore, diffusion tensor imaging metrics in adults with phenylketonuria were related to performance in attention and executive functions."
      explanation: Human neuroimaging study links PKU white-matter metrics to attention and executive-function performance.
  - target: Atypical Behavior
    description: PKU brain dysfunction can present with behavioral problems.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:34017006
      reference_title: "Phenylketonuria."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "If untreated, this brain dysfunction results in severe intellectual disability, epilepsy and behavioural problems."
      explanation: Review directly links untreated PKU brain dysfunction to behavioral problems.
  - target: Anxiety
    description: Neuropsychiatric effects of PKU include anxiety in the phenotype spectrum.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: ORPHA:716
      reference_title: "Phenylketonuria (Orphanet structured-database record)"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0000739 | Anxiety | Occasional (29-5%)"
      explanation: Orphanet records anxiety in the PKU phenotype spectrum.
  - target: Depression
    description: Neuropsychiatric effects of PKU include depression in the phenotype spectrum.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: ORPHA:716
      reference_title: "Phenylketonuria (Orphanet structured-database record)"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0000716 | Depression | Occasional (29-5%)"
      explanation: Orphanet records depression in the PKU phenotype spectrum.
  - target: Dementia
    description: Severe chronic neurocognitive deterioration can manifest as dementia in some PKU patients.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: ORPHA:716
      reference_title: "Phenylketonuria (Orphanet structured-database record)"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0000726 | Dementia | Occasional (29-5%)"
      explanation: Orphanet records dementia in the PKU phenotype spectrum.
- name: Impaired Melanin Biosynthesis
  description: Reduced tyrosine availability limits melanin synthesis in untreated or poorly controlled disease.
  biological_processes:
  - preferred_term: melanin biosynthetic process
    term:
      id: GO:0042438
      label: melanin biosynthetic process
    modifier: DECREASED
  chemical_entities:
  - preferred_term: melanins
    term:
      id: CHEBI:25179
      label: melanins
    modifier: DECREASED
  evidence:
  - reference: PMID:30570999
    reference_title: "Phenylketonuria (PKU)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "These signs can include musty odor from skin and urine, fair skin, eczema, seizures, tremors, and hyperactivity."
    explanation: Fair skin in PKU is consistent with reduced pigmentation downstream of tyrosine deficit.
  downstream:
  - target: Hypopigmentation
    description: Reduced melanin production leads to fair skin and lighter pigmentation phenotypes.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:35854334
      reference_title: "Genetic etiology and clinical challenges of phenylketonuria."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Untreated PKU, also known as PAH deficiency, results in severe and irreversible intellectual disability, epilepsy, behavioral disorders, and clinical features such as acquired microcephaly, seizures, psychological signs, and generalized hypopigmentation of skin (including hair and eyes)."
      explanation: Supports hypopigmentation as a downstream manifestation of impaired pigmentation biology.
- name: Phenylketone Accumulation
  description: Alternative phenylalanine metabolism increases phenylketones such as phenylpyruvate.
  chemical_entities:
  - preferred_term: phenylpyruvate
    term:
      id: CHEBI:26008
      label: phenylpyruvate
    modifier: INCREASED
  evidence:
  - reference: PMID:21565303
    reference_title: "Study on urinary metabolic profile of phenylketonuria by micellar electrokinetic capillary chromatography with dual electrochemical detection--potential clinical application in fast diagnosis of phenylketonuria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The urinary metabolic marker compounds, namely phenylpyruvic acid (PPA), 2-hydroxyphenylacetic acid (oOPAA), 4-hydroxyphenylacetic acid (pOPAA), phenyllactic acid (PLA) and phenylacetic acid (PAA) of phenylketonuric individuals were detected"
    explanation: Confirms phenylketone metabolite accumulation in PKU urine profiles.
  downstream:
  - target: Musty Odor
    description: Phenylketone byproducts contribute to characteristic musty body odor.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:30570999
      reference_title: "Phenylketonuria (PKU)."
      supports: PARTIAL
      evidence_source: HUMAN_CLINICAL
      snippet: "These signs can include musty odor from skin and urine, fair skin, eczema, seizures, tremors, and hyperactivity."
      explanation: Supports musty odor phenotype; attribution to specific phenylketone species is mechanistic interpretation.
  - target: Eczema
    description: Eczematous dermatitis is associated with untreated or poorly controlled PKU through incompletely defined skin effects of PAH deficiency.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:30570999
      reference_title: "Phenylketonuria (PKU)."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "These signs can include musty odor from skin and urine, fair skin, eczema, seizures, tremors, and hyperactivity."
      explanation: Supports eczema as part of the clinical path downstream of PKU metabolism, though precise intermediates are not specified by this source.
  - target: Phenylalaninuria
    description: Urinary phenylalanine and phenylketone excretion reflects overflow alternative phenylalanine metabolism.
    causal_link_type: DIRECT
    evidence:
    - reference: ORPHA:716
      reference_title: "Phenylketonuria (Orphanet structured-database record)"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0032351 | Phenylalaninuria | Very frequent (99-80%)"
      explanation: Orphanet records phenylalaninuria as a very frequent PKU biochemical phenotype.
  - target: Phenylpyruvic Acid
    description: Phenylpyruvic acid is a measured urinary readout of phenylketone accumulation.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:21565303
      reference_title: "Study on urinary metabolic profile of phenylketonuria by micellar electrokinetic capillary chromatography with dual electrochemical detection--potential clinical application in fast diagnosis of phenylketonuria."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The urinary metabolic marker compounds, namely phenylpyruvic acid (PPA), 2-hydroxyphenylacetic acid (oOPAA), 4-hydroxyphenylacetic acid (pOPAA), phenyllactic acid (PLA) and phenylacetic acid (PAA) of phenylketonuric individuals were detected"
      explanation: Human urinary metabolite profiling supports phenylpyruvic acid as a phenylketone readout.
diagnosis:
- name: Newborn Screening for Hyperphenylalaninemia
  description: Initial diagnosis is made from heel-prick dried blood spot screening.
  evidence:
  - reference: PMID:21555948
    reference_title: "Phenylalanine hydroxylase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Phenylalanine hydroxylase deficiency can be diagnosed by newborn screening based on detection of the presence of hyperphenylalaninemia using the Guthrie microbial inhibition assay or other assays on a blood spot obtained from a heel prick."
    explanation: Defines newborn blood spot screening as the first-line diagnostic modality.
  - reference: PMID:34017006
    reference_title: "Phenylketonuria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Early diagnosis is based on newborn screening, and if treatment is started early and continued, intelligence is within normal limits with, on average, some suboptimal neurocognitive function."
    explanation: Independent review confirms newborn screening as the basis for early PKU diagnosis.
- name: Plasma Phenylalanine Monitoring
  description: Serial plasma phenylalanine and tyrosine measurement is required for diagnosis and longitudinal control.
  evidence:
  - reference: PMID:21555948
    reference_title: "Phenylalanine hydroxylase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Regular monitoring of plasma phenylalanine and tyrosine concentrations is necessary."
    explanation: Confirms biochemical monitoring as a core diagnostic and management component.
  - reference: PMID:39630157
    reference_title: "Phenylalanine hydroxylase deficiency diagnosis and management: A 2023 evidence-based clinical guideline of the American College of Medical Genetics and Genomics (ACMG)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We strongly recommend lifelong maintenance of Phe ≤360 μmol/L (using plasma or whole blood) for optimal intellectual outcomes and for reduced teratogenicity, utilizing all available and necessary dietary, pharmaceutical, and patient-educational modalities."
    explanation: ACMG guideline independently supports ongoing blood phenylalanine monitoring targets.
- name: PAH Molecular Genetic Testing
  description: Molecular testing confirms PAH deficiency and helps guide treatment selection.
  diagnosis_term:
    preferred_term: genetic testing
    term:
      id: MAXO:0000127
      label: genetic testing
  evidence:
  - reference: PMID:39630157
    reference_title: "Phenylalanine hydroxylase deficiency diagnosis and management: A 2023 evidence-based clinical guideline of the American College of Medical Genetics and Genomics (ACMG)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "genetic testing for PAH variants is recommended at birth to confirm diagnosis and guide therapy."
    explanation: ACMG guideline endorses early PAH genotyping for confirmation and treatment planning.
  - reference: PMID:21555948
    reference_title: "Phenylalanine hydroxylase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Molecular genetic testing of the phenylalanine hydroxylase gene is available for genetic counseling purposes to determine carrier status of at-risk relatives and for prenatal testing."
    explanation: GeneReviews confirms the role of PAH molecular testing in confirmatory and familial risk assessment.
differential_diagnoses:
- name: Hyperphenylalaninemia due to tetrahydrobiopterin deficiency
  description: BH4 cofactor defects can present as newborn-screen positive hyperphenylalaninemia and mimic PAH deficiency.
  disease_term:
    preferred_term: hyperphenylalaninemia due to tetrahydrobiopterin deficiency
    term:
      id: MONDO:0016543
      label: hyperphenylalaninemia due to tetrahydrobiopterin deficiency
  distinguishing_features:
  - Differential testing is required because BH4 deficiency can present with the same initial hyperphenylalaninemia signal as PKU.
  - Separation from PAH deficiency relies on pterin studies and DHPR enzyme activity testing.
  - Patients may develop neurologic abnormalities despite acceptable blood phenylalanine control.
  evidence:
  - reference: PMID:35952926
    reference_title: "Newborn screening and genetic features of patients with hyperphenylalaninemia in a southern Chinese population."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Newborn screening is an effective method for early detection of HPA, but differential diagnosis of BH4D is necessary."
    explanation: Explicitly states that BH4 deficiency must be differentiated from PAH-related hyperphenylalaninemia.
  - reference: PMID:8404969
    reference_title: "Differential diagnosis of hyperphenylalaninaemia by a combined phenylalanine-tetrahydrobiopterin loading test."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We describe a new fully reliable method for the differential diagnosis of tetrahydrobiopterin-dependent hyperphenylalaninaemia (HPA)."
    explanation: Supports dedicated differential workup for BH4-dependent forms.
- name: Dihydropteridine Reductase Deficiency
  description: A BH4 regeneration disorder causing hyperphenylalaninemia with monoamine neurotransmitter deficiency.
  disease_term:
    preferred_term: dihydropteridine reductase deficiency
    term:
      id: MONDO:0009862
      label: dihydropteridine reductase deficiency
  distinguishing_features:
  - DHPR activity testing on dried blood spots is recommended during differential diagnosis.
  - Distinguishing this disorder from PAH deficiency changes treatment strategy beyond phenylalanine restriction alone.
  evidence:
  - reference: PMID:3930839
    reference_title: "Differential diagnosis of tetrahydrobiopterin deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Measurement of DHPR activity in blood spots on Guthrie cards is recommended."
    explanation: Confirms DHPR enzyme testing as a key discriminator in hyperphenylalaninemia workup.
  - reference: PMID:8404969
    reference_title: "Differential diagnosis of hyperphenylalaninaemia by a combined phenylalanine-tetrahydrobiopterin loading test."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "It should be performed together with the measurement of dihydropteridine reductase (DHPR) activity in blood."
    explanation: Reinforces that differential diagnosis requires specific DHPR testing.
- name: BH4-deficient hyperphenylalaninemia A
  description: PTS-related BH4 synthesis deficiency that phenotypically overlaps with PKU on newborn screening.
  disease_term:
    preferred_term: BH4-deficient hyperphenylalaninemia A
    term:
      id: MONDO:0009863
      label: BH4-deficient hyperphenylalaninemia A
  distinguishing_features:
  - Caused by BH4 pathway defects (including PTS variants) rather than PAH enzyme deficiency.
  - Requires BH4-focused biochemical and/or genetic testing to identify correctly.
  evidence:
  - reference: PMID:35952926
    reference_title: "Newborn screening and genetic features of patients with hyperphenylalaninemia in a southern Chinese population."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Of the 296 newborns who tested HPA positive, 56 were diagnosed with HPA, including 47 with phenylalanine hydroxylase deficiency and nine with tetrahydrobiopterin deficiency (BH4D)."
    explanation: Demonstrates a real newborn-screen cohort where BH4-deficient cases coexist with PAH deficiency and require distinction.
  - reference: PMID:35952926
    reference_title: "Newborn screening and genetic features of patients with hyperphenylalaninemia in a southern Chinese population."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Thirty-three PAH variants and five PTS variants were detected in HPA patients;"
    explanation: Supports genetic differentiation between PAH-related PKU and PTS-related BH4 deficiency.
- name: Mild Hyperphenylalaninemia
  description: A milder PAH-spectrum condition with lower untreated phenylalanine burden and lower neurologic risk than classic PKU.
  disease_term:
    preferred_term: mild hyperphenylalaninemia
    term:
      id: MONDO:0019335
      label: mild hyperphenylalaninemia
  distinguishing_features:
  - Lower baseline phenylalanine elevations and substantially reduced risk of severe cognitive impairment compared with classic PKU.
  - Phenylalanine thresholds for lifelong intensive treatment differ from classic PKU-range disease.
  evidence:
  - reference: PMID:21555948
    reference_title: "Phenylalanine hydroxylase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Mild phenylketonuria and mild hyperphenylalaninemia are associated with lower risk of impaired cognitive development in the absence of treatment."
    explanation: Supports lower neurodevelopmental risk profile relative to classic untreated PKU.
  - reference: PMID:39630157
    reference_title: "Phenylalanine hydroxylase deficiency diagnosis and management: A 2023 evidence-based clinical guideline of the American College of Medical Genetics and Genomics (ACMG)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "treatment for PAH deficiency should be lifelong for individuals with untreated phenylalanine (Phe) levels >360 μmol/L"
    explanation: Guideline threshold helps distinguish lower-range hyperphenylalaninemia from classic PKU requiring strict lifelong treatment targets.
phenotypes:
- name: Intellectual Disability
  category: Neurological
  frequency: VERY_FREQUENT
  diagnostic: true
  notes: >-
    Develops in untreated PKU and is preventable with early dietary treatment.
    The Orphanet phenotype row documents severe intellectual disability as
    frequent, while this general phenotype entry retains VERY_FREQUENT for
    untreated intellectual disability risk.
  phenotype_term:
    preferred_term: Intellectual Disability
    term:
      id: HP:0001249
      label: Intellectual disability
  evidence:
  - reference: PMID:34017006
    reference_title: "Phenylketonuria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "If untreated, this brain dysfunction results in severe intellectual disability, epilepsy and behavioural problems."
    explanation: The Nature Reviews Primer confirms severe intellectual disability as a key untreated phenotype.
  - reference: PMID:38907189
    reference_title: "Volumetric brain reductions in adult patients with phenylketonuria and their relationship with blood phenylalanine levels."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "Adult patients with PKU showed significantly lower performance than HC in Full Scale IQ"
    explanation: Even early-treated adults show lower IQ compared to healthy controls.
  - reference: ORPHA:716
    reference_title: "Phenylketonuria (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0010864 | Intellectual disability, severe | Frequent (79-30%)"
    explanation: >-
      Orphanet's HPO annotation supports severe intellectual disability as
      frequent in PKU; the broader intellectual disability phenotype remains
      very frequent for untreated disease.
- name: Seizures
  category: Neurological
  frequency: FREQUENT
  notes: Common in untreated patients
  phenotype_term:
    preferred_term: Seizures
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: PMID:29025426
    reference_title: "The complete European guidelines on phenylketonuria: diagnosis and treatment."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "If left untreated, PKU results in increased phenylalanine concentrations in blood and brain, which cause severe intellectual disability, epilepsy and behavioural problems."
    explanation: European guidelines confirm epilepsy as a major untreated manifestation.
  - reference: ORPHA:716
    reference_title: "Phenylketonuria (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001250 | Seizure | Frequent (79-30%)"
    explanation: Orphanet's curated HPO frequency annotation supports seizures as frequent in PKU.
- name: Microcephaly
  category: Neurological
  frequency: FREQUENT
  notes: Result of impaired brain development
  phenotype_term:
    preferred_term: Microcephaly
    term:
      id: HP:0000252
      label: Microcephaly
  evidence:
  - reference: PMID:17092471
    reference_title: "Phenylketonuria in pediatric neurology practice: a series of 146 cases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In addition to well-known findings such as mental retardation, autistic features, microcephaly, and tremor, motor retardation was common and responded promptly to dietary treatment."
    explanation: Pediatric PKU case series documents microcephaly among established neurologic manifestations.
  - reference: PMID:35854334
    reference_title: "Genetic etiology and clinical challenges of phenylketonuria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Untreated PKU, also known as PAH deficiency, results in severe and irreversible intellectual disability, epilepsy, behavioral disorders, and clinical features such as acquired microcephaly, seizures, psychological signs, and generalized hypopigmentation of skin (including hair and eyes)."
    explanation: Review abstract independently supports acquired microcephaly in untreated PKU.
  - reference: ORPHA:716
    reference_title: "Phenylketonuria (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000252 | Microcephaly | Frequent (79-30%)"
    explanation: Orphanet's curated HPO frequency annotation supports microcephaly as frequent in PKU.
- name: Hypertonia
  category: Neurological
  frequency: OCCASIONAL
  notes: Reported in untreated/poorly controlled disease; less frequent than hypotonia in pediatric series.
  phenotype_term:
    preferred_term: Hypertonia
    term:
      id: HP:0001276
      label: Hypertonia
  evidence:
  - reference: PMID:17092471
    reference_title: "Phenylketonuria in pediatric neurology practice: a series of 146 cases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Hypotonia and diminished reflexes were more frequent findings than hypertonia."
    explanation: Confirms hypertonia occurs in PKU while indicating lower relative frequency.
  - reference: PMID:2516176
    reference_title: "Neurological deterioration in adult phenylketonuria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Dietary therapy reduced serum phenylalanine levels, improved symptoms of hypertonicity, and cerebrospinal fluid neurotransmitter metabolites became normal."
    explanation: Adult PKU report supports clinically significant hypertonicity as a neurologic manifestation.
- name: Hypopigmentation
  category: Dermatological
  frequency: FREQUENT
  notes: Fair skin, light hair, blue eyes due to melanin deficiency
  phenotype_term:
    preferred_term: Hypopigmentation
    term:
      id: HP:0001010
      label: Hypopigmentation of the skin
  evidence:
  - reference: PMID:35854334
    reference_title: "Genetic etiology and clinical challenges of phenylketonuria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Untreated PKU, also known as PAH deficiency, results in severe and irreversible intellectual disability, epilepsy, behavioral disorders, and clinical features such as acquired microcephaly, seizures, psychological signs, and generalized hypopigmentation of skin (including hair and eyes)."
    explanation: Supports generalized skin, hair, and eye hypopigmentation as a PKU phenotype.
  - reference: PMID:30570999
    reference_title: "Phenylketonuria (PKU)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "These signs can include musty odor from skin and urine, fair skin, eczema, seizures, tremors, and hyperactivity."
    explanation: Fair skin in PKU is consistent with clinical hypopigmentation.
  - reference: ORPHA:716
    reference_title: "Phenylketonuria (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001010 | Hypopigmentation of the skin | Frequent (79-30%)"
    explanation: Orphanet's curated HPO frequency annotation supports hypopigmentation as frequent in PKU.
- name: Eczema
  category: Dermatological
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Eczema
    term:
      id: HP:0000964
      label: Eczematoid dermatitis
  evidence:
  - reference: PMID:30570999
    reference_title: "Phenylketonuria (PKU)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "These signs can include musty odor from skin and urine, fair skin, eczema, seizures, tremors, and hyperactivity."
    explanation: Clinical overview explicitly lists eczema among PKU manifestations.
  - reference: ORPHA:716
    reference_title: "Phenylketonuria (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000964 | Eczematoid dermatitis | Frequent (79-30%)"
    explanation: Orphanet's curated HPO frequency annotation supports eczematoid dermatitis as frequent in PKU.
- name: Musty Odor
  category: Other
  frequency: FREQUENT
  notes: Due to phenylacetic acid in sweat and urine
  phenotype_term:
    preferred_term: Musty Odor
    term:
      id: HP:0410021
      label: Musty odor
  evidence:
  - reference: PMID:30570999
    reference_title: "Phenylketonuria (PKU)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "These signs can include musty odor from skin and urine, fair skin, eczema, seizures, tremors, and hyperactivity."
    explanation: Clinical overview directly supports musty body odor as a characteristic PKU sign.
  - reference: ORPHA:716
    reference_title: "Phenylketonuria (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0410021 | Musty odor | Frequent (79-30%)"
    explanation: Orphanet's curated HPO frequency annotation supports musty odor as frequent in PKU.
- name: Phenylalaninuria
  category: Biochemical
  frequency: VERY_FREQUENT
  notes: Urinary phenylalanine/phenylketone abnormality reflected in the disease name.
  phenotype_term:
    preferred_term: Phenylalaninuria
    term:
      id: HP:0032351
      label: Phenylalaninuria
  evidence:
  - reference: ORPHA:716
    reference_title: "Phenylketonuria (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0032351 | Phenylalaninuria | Very frequent (99-80%)"
    explanation: Orphanet's HPO annotation classifies phenylalaninuria as very frequent in PKU.
- name: Hyperphenylalaninemia
  category: Biochemical
  frequency: FREQUENT
  notes: Elevated blood phenylalanine is the defining biochemical abnormality.
  phenotype_term:
    preferred_term: Hyperphenylalaninemia
    term:
      id: HP:0004923
      label: Hyperphenylalaninemia
  evidence:
  - reference: ORPHA:716
    reference_title: "Phenylketonuria (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0004923 | Hyperphenylalaninemia | Frequent (79-30%)"
    explanation: Orphanet's HPO annotation supports hyperphenylalaninemia as a frequent PKU phenotype.
- name: Abnormal Cerebral White Matter Morphology
  category: Neurological
  frequency: FREQUENT
  notes: White-matter abnormalities are reported in PKU, including early-treated adults.
  phenotype_term:
    preferred_term: Abnormal cerebral white matter morphology
    term:
      id: HP:0002500
      label: Abnormal cerebral white matter morphology
  evidence:
  - reference: ORPHA:716
    reference_title: "Phenylketonuria (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002500 | Abnormal cerebral white matter morphology | Frequent (79-30%)"
    explanation: Orphanet's HPO annotation supports cerebral white-matter abnormality as frequent in PKU.
- name: EEG Abnormality
  category: Neurological
  frequency: FREQUENT
  phenotype_term:
    preferred_term: EEG abnormality
    term:
      id: HP:0002353
      label: EEG abnormality
  evidence:
  - reference: ORPHA:716
    reference_title: "Phenylketonuria (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002353 | EEG abnormality | Frequent (79-30%)"
    explanation: Orphanet's HPO annotation supports EEG abnormality as frequent in PKU.
- name: Global Developmental Delay
  category: Neurodevelopmental
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Global developmental delay
    term:
      id: HP:0001263
      label: Global developmental delay
  evidence:
  - reference: ORPHA:716
    reference_title: "Phenylketonuria (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001263 | Global developmental delay | Frequent (79-30%)"
    explanation: Orphanet's curated HPO annotation supports global developmental delay as a frequent PKU phenotype.
- name: Atypical Behavior
  category: Behavioral
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Atypical behavior
    term:
      id: HP:0000708
      label: Atypical behavior
  evidence:
  - reference: ORPHA:716
    reference_title: "Phenylketonuria (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000708 | Atypical behavior | Frequent (79-30%)"
    explanation: Orphanet's curated HPO annotation supports atypical behavior as frequent in PKU.
- name: Specific Learning Disability
  category: Neurodevelopmental
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Specific learning disability
    term:
      id: HP:0001328
      label: Specific learning disability
  evidence:
  - reference: ORPHA:716
    reference_title: "Phenylketonuria (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001328 | Specific learning disability | Frequent (79-30%)"
    explanation: Orphanet's curated HPO annotation supports specific learning disability as frequent in PKU.
- name: Growth Delay
  category: Growth
  frequency: FREQUENT
  description: >-
    Growth delay in PKU can reflect nutrition-sensitive linear growth
    impairment during phenylalanine-restricted dietary therapy.
  phenotype_term:
    preferred_term: Growth delay
    term:
      id: HP:0001510
      label: Growth delay
  evidence:
  - reference: ORPHA:716
    reference_title: "Phenylketonuria (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001510 | Growth delay | Frequent (79-30%)"
    explanation: Orphanet's curated HPO annotation supports growth delay as frequent in PKU.
  - reference: PMID:12183721
    reference_title: "Protein insufficiency and linear growth restriction in phenylketonuria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "There is a strong relation between protein insufficiency, as determined by plasma prealbumin levels, and linear growth impairment."
    explanation: Human PKU cohort data support linear growth impairment tied to protein insufficiency.
- name: Osteopenia
  category: Musculoskeletal
  frequency: FREQUENT
  description: >-
    Osteopenia reflects the lower bone mineral density reported across PKU bone
    health studies, although causal contributors remain incompletely resolved.
  phenotype_term:
    preferred_term: Osteopenia
    term:
      id: HP:0000938
      label: Osteopenia
  evidence:
  - reference: ORPHA:716
    reference_title: "Phenylketonuria (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000938 | Osteopenia | Frequent (79-30%)"
    explanation: Orphanet's curated HPO annotation supports osteopenia as frequent in PKU.
  - reference: PMID:25758373
    reference_title: "Bone health in phenylketonuria: a systematic review and meta-analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Ten out of 11 articles found BMD was significantly lower in patients with PKU."
    explanation: Systematic review evidence supports lower BMD as the clinical substrate for osteopenia in PKU.
- name: Ataxia
  category: Neurological
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Ataxia
    term:
      id: HP:0001251
      label: Ataxia
  evidence:
  - reference: ORPHA:716
    reference_title: "Phenylketonuria (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001251 | Ataxia | Occasional (29-5%)"
    explanation: Orphanet's curated HPO annotation supports ataxia as an occasional PKU phenotype.
- name: Tremor
  category: Neurological
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Tremor
    term:
      id: HP:0001337
      label: Tremor
  evidence:
  - reference: ORPHA:716
    reference_title: "Phenylketonuria (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001337 | Tremor | Occasional (29-5%)"
    explanation: Orphanet's curated HPO annotation supports tremor as an occasional PKU phenotype.
- name: Short Attention Span
  category: Behavioral
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Short attention span
    term:
      id: HP:0000736
      label: Short attention span
  evidence:
  - reference: ORPHA:716
    reference_title: "Phenylketonuria (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000736 | Short attention span | Occasional (29-5%)"
    explanation: Orphanet's curated HPO annotation supports short attention span as an occasional PKU phenotype.
- name: Anxiety
  category: Psychiatric
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Anxiety
    term:
      id: HP:0000739
      label: Anxiety
  evidence:
  - reference: ORPHA:716
    reference_title: "Phenylketonuria (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000739 | Anxiety | Occasional (29-5%)"
    explanation: Orphanet's curated HPO annotation supports anxiety as an occasional PKU phenotype.
- name: Depression
  category: Psychiatric
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Depression
    term:
      id: HP:0000716
      label: Depression
  evidence:
  - reference: ORPHA:716
    reference_title: "Phenylketonuria (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000716 | Depression | Occasional (29-5%)"
    explanation: Orphanet's curated HPO annotation supports depression as an occasional PKU phenotype.
- name: Dementia
  category: Neurological
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Dementia
    term:
      id: HP:0000726
      label: Dementia
  evidence:
  - reference: ORPHA:716
    reference_title: "Phenylketonuria (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000726 | Dementia | Occasional (29-5%)"
    explanation: Orphanet's curated HPO annotation supports dementia as an occasional PKU phenotype.
- name: Encephalopathy
  category: Neurological
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Encephalopathy
    term:
      id: HP:0001298
      label: Encephalopathy
  evidence:
  - reference: ORPHA:716
    reference_title: "Phenylketonuria (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001298 | Encephalopathy | Occasional (29-5%)"
    explanation: Orphanet's curated HPO annotation supports encephalopathy as an occasional PKU phenotype.
- name: Lower Limb Spasticity
  category: Neurological
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Lower limb spasticity
    term:
      id: HP:0002061
      label: Lower limb spasticity
  evidence:
  - reference: ORPHA:716
    reference_title: "Phenylketonuria (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002061 | Lower limb spasticity | Occasional (29-5%)"
    explanation: Orphanet's curated HPO annotation supports lower limb spasticity as an occasional PKU phenotype.
- name: Cerebral Visual Impairment
  category: Ocular
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Cerebral visual impairment
    term:
      id: HP:0100704
      label: Cerebral visual impairment
  evidence:
  - reference: ORPHA:716
    reference_title: "Phenylketonuria (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0100704 | Cerebral visual impairment | Occasional (29-5%)"
    explanation: Orphanet's curated HPO annotation supports cerebral visual impairment as an occasional PKU phenotype.
- name: Abnormal Cardiovascular System Morphology
  category: Cardiovascular
  frequency: OCCASIONAL
  notes: >-
    In PKU, cardiac malformations arise primarily in offspring of mothers with
    poorly controlled PKU (maternal PKU syndrome), rather than as a direct
    phenotype of affected individuals. Orphanet annotates this phenotype at
    occasional frequency.
  phenotype_term:
    preferred_term: Abnormal cardiovascular system morphology
    term:
      id: HP:0030680
      label: Abnormal cardiovascular system morphology
  evidence:
  - reference: ORPHA:716
    reference_title: "Phenylketonuria (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0030680 | Abnormal cardiovascular system morphology | Occasional (29-5%)"
    explanation: >-
      Orphanet's curated HPO annotation records abnormal cardiovascular system
      morphology at occasional frequency; the clinical context for PKU is
      primarily maternal PKU syndrome, as noted above.
  - reference: PMID:10636975
    reference_title: "Maternal phenylketonuria syndrome: congenital heart defects, microcephaly, and developmental outcomes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Thirty-one offspring had CHDs; of these, 17 also had microcephaly."
    explanation: Human maternal PKU cohort evidence supports congenital heart defects as the cardiovascular morphology context for this phenotype.
biochemical:
- name: Blood Phenylalanine
  presence: Elevated
  context: Greater than 120 micromol/L, often greater than 1200 micromol/L in classic PKU
  biomarker_term:
    preferred_term: L-phenylalanine
    term:
      id: CHEBI:58095
      label: L-phenylalanine zwitterion
  readouts:
  - target: Hyperphenylalaninemia
    relationship: READOUT_OF
    direction: POSITIVE
    endpoint_context: DIAGNOSTIC
    interpretation: Elevated blood phenylalanine reports impaired PAH-dependent phenylalanine clearance.
  - target: Maternal Hyperphenylalaninemia Teratogenicity
    relationship: READOUT_OF
    direction: POSITIVE
    endpoint_context: PROGNOSTIC
    interpretation: Elevated maternal blood phenylalanine during early gestation predicts fetal congenital-heart-defect risk in maternal PKU syndrome.
  evidence:
  - reference: PMID:24385074
    reference_title: "Phenylalanine hydroxylase deficiency: diagnosis and management guideline."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Phenylalanine hydroxylase deficiency, traditionally known as phenylketonuria, results in the accumulation of phenylalanine in the blood of affected individuals and was the first inborn error of metabolism to be identified through population screening."
    explanation: Supports elevated blood phenylalanine as the defining biochemical abnormality.
  - reference: PMID:21216643
    reference_title: "The effect of blood phenylalanine concentration on Kuvan™ response in phenylketonuria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Phenylketonuria (PKU) is caused by mutations in the phenylalanine hydroxylase gene (PAH) with consequent elevation of blood phenylalanine (Phe), reduction in tyrosine (Tyr) and elevation of Phe/Tyr ratio (P/T)."
    explanation: Independent human cohort evidence confirms elevated blood phenylalanine in PKU.
- name: Treatment-Induced Plasma Phenylalanine Reduction
  presence: Treatment-induced
  context: >-
    Plasma phenylalanine concentration measured during pharmacotherapy with
    phenylalanine hydroxylase activators (sapropterin) or phenylalanine-
    metabolizing enzyme therapy (pegvaliase). Distinct from baseline diagnostic
    hyperphenylalaninemia. Plasma phenylalanine is recognized by the FDA as a
    validated surrogate endpoint supporting traditional approval of PKU drugs.
  biomarker_term:
    preferred_term: plasma phenylalanine measurement
    term:
      id: NCIT:C81280
      label: Phenylalanine Measurement
  synonyms:
  - plasma Phe
  - blood phenylalanine concentration
  readouts:
  - target: Hyperphenylalaninemia
    relationship: PHARMACODYNAMIC_MARKER_OF
    direction: NEGATIVE
    endpoint_context: PHARMACODYNAMIC
    regulatory_endpoint_refs:
    - FDA-SE-adult-noncancer-087
    - FDA-SE-pediatric-noncancer-057
    interpretation: >-
      Reductions in plasma phenylalanine during treatment with phenylalanine
      hydroxylase activators (sapropterin) or phenylalanine-metabolizing enzyme
      therapy (pegvaliase) report pharmacodynamic correction at the
      hyperphenylalaninemia node and underpin the FDA surrogate-endpoint basis
      for traditional approval of PKU drugs.
    evidence:
    - reference: PMID:17693179
      reference_title: "Efficacy of sapropterin dihydrochloride (tetrahydrobiopterin, 6R-BH4) for reduction of phenylalanine concentration in patients with phenylketonuria: a phase III randomised placebo-controlled study."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The primary endpoint was mean change from baseline in concentration of phenylalanine in blood after 6 weeks."
      explanation: >-
        The pivotal randomized placebo-controlled trial of sapropterin used
        blood phenylalanine concentration as its primary endpoint, establishing
        plasma Phe as the pharmacodynamic readout for PAH-activator efficacy.
    - reference: PMID:17693179
      reference_title: "Efficacy of sapropterin dihydrochloride (tetrahydrobiopterin, 6R-BH4) for reduction of phenylalanine concentration in patients with phenylketonuria: a phase III randomised placebo-controlled study."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "After 6 weeks of treatment, patients given sapropterin had a decrease in mean blood phenylalanine of 236 (257) micromol/L, compared with a 3 (240) micromol/L increase in the placebo group (p<0.0001)."
      explanation: >-
        Plasma phenylalanine declined significantly with sapropterin therapy
        versus placebo, confirming Phe as a treatment-responsive pharmacodynamic
        marker.
    - reference: PMID:29653686
      reference_title: "Pegvaliase for the treatment of phenylketonuria: Results of a long-term phase 3 clinical trial program (PRISM)."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Mean (SD) blood Phe was 1232.7 (386.4) μmol/L at baseline, 564.5 (531.2) μmol/L at 12 months, and 311.4 (427) μmol/L at 24 months, a decrease from baseline of 51.1% and 68.7%, respectively."
      explanation: >-
        PRISM-1/2 pivotal phase 3 trials of pegvaliase report pharmacodynamic
        reduction of plasma phenylalanine, supporting plasma Phe as the
        pharmacodynamic readout for phenylalanine-metabolizing enzyme
        substitution therapy.
  evidence:
  - reference: PMID:17693179
    reference_title: "Efficacy of sapropterin dihydrochloride (tetrahydrobiopterin, 6R-BH4) for reduction of phenylalanine concentration in patients with phenylketonuria: a phase III randomised placebo-controlled study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We aimed to test the efficacy of sapropterin, a synthetic form of tetrahydrobiopterin (BH4), for reduction of blood phenylalanine concentration."
    explanation: >-
      Establishes plasma phenylalanine reduction as the treatment-effect
      endpoint for sapropterin in PKU.
  - reference: PMID:29653686
    reference_title: "Pegvaliase for the treatment of phenylketonuria: Results of a long-term phase 3 clinical trial program (PRISM)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Pegvaliase, PEGylated recombinant Anabaena variabilis phenylalanine ammonia lyase (PAL), converts Phe to trans-cinnamic acid and ammonia, and is a potential enzyme substitution therapy to lower blood Phe in adults with PKU."
    explanation: >-
      Establishes the pharmacodynamic basis: pegvaliase enzymatically degrades
      phenylalanine, with plasma Phe as the measurable response.
- name: Blood Tyrosine
  presence: Decreased
  context: Low due to blocked conversion from phenylalanine
  biomarker_term:
    preferred_term: L-tyrosine
    term:
      id: CHEBI:58315
      label: L-tyrosine zwitterion
  readouts:
  - target: Relative Tyrosine Deficiency
    relationship: READOUT_OF
    direction: NEGATIVE
    endpoint_context: DIAGNOSTIC
    interpretation: Lower blood tyrosine reports reduced PAH-mediated conversion of phenylalanine to tyrosine.
  evidence:
  - reference: PMID:30570999
    reference_title: "Phenylketonuria (PKU)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Elevated blood Phe levels and decreased Tyr levels characterize PKU."
    explanation: Directly supports low tyrosine as a characteristic biochemical feature.
  - reference: PMID:21216643
    reference_title: "The effect of blood phenylalanine concentration on Kuvan™ response in phenylketonuria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Phenylketonuria (PKU) is caused by mutations in the phenylalanine hydroxylase gene (PAH) with consequent elevation of blood phenylalanine (Phe), reduction in tyrosine (Tyr) and elevation of Phe/Tyr ratio (P/T)."
    explanation: Independent cohort data explicitly reports reduced tyrosine in PKU.
- name: Phenylalanine to Tyrosine Ratio
  presence: Elevated
  context: Diagnostic marker
  readouts:
  - target: Hyperphenylalaninemia
    relationship: READOUT_OF
    direction: POSITIVE
    endpoint_context: DIAGNOSTIC
    interpretation: Elevated Phe/Tyr ratio reports combined phenylalanine accumulation and reduced tyrosine production.
  - target: Relative Tyrosine Deficiency
    relationship: READOUT_OF
    direction: POSITIVE
    endpoint_context: DIAGNOSTIC
    interpretation: Elevated Phe/Tyr ratio reports the biochemical imbalance produced by impaired PAH flux.
  evidence:
  - reference: PMID:35952926
    reference_title: "Newborn screening and genetic features of patients with hyperphenylalaninemia in a southern Chinese population."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "All patients had elevated Phe and Phe/Tyr levels."
    explanation: Supports elevation of the phenylalanine:tyrosine index in diagnosed HPA/PKU cohorts.
  - reference: PMID:21216643
    reference_title: "The effect of blood phenylalanine concentration on Kuvan™ response in phenylketonuria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Phenylketonuria (PKU) is caused by mutations in the phenylalanine hydroxylase gene (PAH) with consequent elevation of blood phenylalanine (Phe), reduction in tyrosine (Tyr) and elevation of Phe/Tyr ratio (P/T)."
    explanation: Independent clinical data supports elevated Phe/Tyr ratio as a core PKU biochemical marker.
- name: Phenylpyruvic Acid
  presence: Elevated
  context: Alternative metabolite in urine
  biomarker_term:
    preferred_term: phenylpyruvate
    term:
      id: CHEBI:26008
      label: phenylpyruvate
  readouts:
  - target: Phenylketone Accumulation
    relationship: READOUT_OF
    direction: POSITIVE
    endpoint_context: DIAGNOSTIC
    interpretation: Elevated urinary phenylpyruvic acid reports diversion of excess phenylalanine into phenylketone metabolites.
  evidence:
  - reference: PMID:21565303
    reference_title: "Study on urinary metabolic profile of phenylketonuria by micellar electrokinetic capillary chromatography with dual electrochemical detection--potential clinical application in fast diagnosis of phenylketonuria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The urinary metabolic marker compounds, namely phenylpyruvic acid (PPA), 2-hydroxyphenylacetic acid (oOPAA), 4-hydroxyphenylacetic acid (pOPAA), phenyllactic acid (PLA) and phenylacetic acid (PAA) of phenylketonuric individuals were detected"
    explanation: Supports urinary phenylpyruvic acid elevation as part of the PKU metabolite profile.
- name: Plasma Prealbumin
  presence: Decreased
  context: Low plasma prealbumin marks protein insufficiency during PKU dietary therapy.
  readouts:
  - target: Protein Insufficiency During Dietary Therapy
    relationship: READOUT_OF
    direction: NEGATIVE
    endpoint_context: MONITORING
    interpretation: Lower plasma prealbumin reports protein insufficiency associated with impaired linear growth in treated PKU children.
  evidence:
  - reference: PMID:12183721
    reference_title: "Protein insufficiency and linear growth restriction in phenylketonuria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We suggest that a plasma prealbumin level of at least 20 mg/dL is necessary for optimal growth in children with PKU."
    explanation: Supports plasma prealbumin as a monitoring readout for protein sufficiency and growth risk in children with PKU.
- name: Bone Mineral Density Z-score
  presence: Decreased
  context: Lower BMD Z-scores summarize the quantitative bone-density abnormality reported in PKU cohorts.
  readouts:
  - target: Reduced Bone Mineral Density in PKU
    relationship: READOUT_OF
    direction: NEGATIVE
    endpoint_context: MONITORING
    interpretation: Decreased BMD Z-score reports reduced bone mineral density in PKU bone-health assessment.
  evidence:
  - reference: PMID:39267130
    reference_title: "Meta-analysis of bone mineral density in adults with phenylketonuria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Adults with PKU had lower BMD Z-scores than the reference (non-PKU) population but < 1 in 10 were below the expected range for age."
    explanation: Meta-analysis supports lower BMD Z-scores as a quantitative readout of PKU bone mineral density.
genetic:
- name: PAH
  gene_term:
    preferred_term: PAH
    term:
      id: hgnc:8582
      label: PAH
  association: Causative
  notes: >-
    Autosomal recessive; multiple pathogenic PAH variants are reported across
    populations. Severe/null or near-null variant combinations drive the classic
    PKU path, while hypomorphic residual-function combinations underlie milder
    phenotypes and potential BH4 responsiveness.
  evidence:
  - reference: PMID:35854334
    reference_title: "Genetic etiology and clinical challenges of phenylketonuria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "PKU, an autosomal recessive disease, is an inborn error of phenylalanine (Phe) metabolism caused by pathogenic variants in the phenylalanine hydroxylase (PAH) gene."
    explanation: Directly supports PAH as the causative gene in classical PKU.
  - reference: PMID:35952926
    reference_title: "Newborn screening and genetic features of patients with hyperphenylalaninemia in a southern Chinese population."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Thirty-three PAH variants and five PTS variants were detected in HPA patients; 80.6 % PAH variants and 100 % PTS variants were classified as pathogenic or likely pathogenic."
    explanation: Provides cohort-level evidence for multiple pathogenic PAH variants in HPA/PKU.
  - reference: CGGV:assertion_5a617cb4-94ec-4f34-b97e-10d9808a1581-2020-04-24T160000.000Z
    reference_title: "PAH / phenylketonuria (Definitive)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "PAH | HGNC:8582 | phenylketonuria | MONDO:0009861 | AR | Definitive"
    explanation: ClinGen classifies the PAH-phenylketonuria gene-disease relationship as definitive with autosomal recessive inheritance.
  variants:
  - name: Severe PAH variant combinations
    description: >-
      Biallelic severe PAH variant combinations produce complete or near-complete
      PAH activity loss and map to the classic PKU mutation-to-phenotype path.
    gene:
      preferred_term: PAH
      term:
        id: hgnc:8582
        label: PAH
    type: null_or_severe_hypomorphic_variant_combination
    clinical_significance: PATHOGENIC
    functional_effects:
    - function: phenylalanine hydroxylase activity
      type: loss_of_function
      regulatory_category: LOF
      description: Severe combinations cause complete or near-complete PAH activity deficiency.
    evidence:
    - reference: PMID:21555948
      reference_title: "Phenylalanine hydroxylase deficiency."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Classic phenylketonuria is caused by a complete or near-complete deficiency of phenylalanine hydroxylase activity and without dietary restriction of phenylalanine most children will develop profound and irreversible intellectual disability."
      explanation: Supports the severe variant-class branch from PAH activity loss to classic PKU and intellectual disability.
    - reference: PMID:35854334
      reference_title: "Genetic etiology and clinical challenges of phenylketonuria."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Severe phenotypes are classic PKU, and less severe forms of PAH deficiency are moderate PKU, mild PKU, mild hyperphenylalaninaemia (HPA), or benign HPA."
      explanation: Supports the severity gradient used to separate classic PKU from residual-function phenotypes.
  - name: Residual-function PAH variant combinations
    description: >-
      Hypomorphic PAH variant combinations retain enough PAH activity to produce
      milder PKU or mild hyperphenylalaninemia and can permit sapropterin/BH4
      responsiveness.
    gene:
      preferred_term: PAH
      term:
        id: hgnc:8582
        label: PAH
    type: hypomorphic_or_residual_function_variant_combination
    clinical_significance: PATHOGENIC
    functional_effects:
    - function: phenylalanine hydroxylase activity
      type: partial_loss_of_function
      regulatory_category: LOF
      description: Residual PAH activity lowers phenotype severity and can be pharmacologically activated by BH4 analog therapy.
    evidence:
    - reference: PMID:34017006
      reference_title: "Phenylketonuria."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Pharmacological treatments are available, such as tetrahydrobiopterin, which is effective in only a minority of patients (usually those with milder PKU)"
      explanation: Supports the residual-function/BH4-responsive branch in milder PKU.
    - reference: PMID:35854334
      reference_title: "Genetic etiology and clinical challenges of phenylketonuria."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The synthetic BH4 analog, sapropterin hydrochloride (i.e., Kuvan®, BioMarin), is another potential treatment that activates residual PAH, thus decreasing Phe concentrations in the blood of PKU patients."
      explanation: Directly supports residual PAH activity as the pharmacological target for sapropterin response.
environmental:
- name: Dietary Phenylalanine
  notes: Primary determinant of metabolic control
  evidence:
  - reference: PMID:24385074
    reference_title: "Phenylalanine hydroxylase deficiency: diagnosis and management guideline."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Treatment has predominantly been dietary manipulation, and use of low protein and phenylalanine medical foods is likely to remain a major component of therapy for the immediate future."
    explanation: Supports that phenylalanine intake control through diet is central to metabolic management.
  - reference: PMID:35854334
    reference_title: "Genetic etiology and clinical challenges of phenylketonuria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Dietary treatment, including natural protein restriction and Phe-free supplements, must be used to maintain blood Phe concentrations of 120-360 μmol/L throughout the life span."
    explanation: Independent review supports dietary phenylalanine restriction as a central environmental determinant of metabolic control.
- name: Mammalian Meat Intake
  notes: Representative high-protein phenylalanine-rich food source requiring restriction
  food_source:
    preferred_term: mammalian meat food product
    term:
      id: FOODON:00001006
      label: mammalian meat food product
- name: Dairy Intake
  notes: Milk and related dairy foods contribute to dietary phenylalanine burden
  food_source:
    preferred_term: milk
    term:
      id: FOODON:03302116
      label: cow milk (liquid)
- name: Nut Intake
  notes: Nuts are concentrated protein sources that contribute to dietary phenylalanine burden
  food_source:
    preferred_term: nut
    term:
      id: FOODON:03303171
      label: nut
- name: Aspartame
  notes: Contains phenylalanine, must be avoided
  evidence:
  - reference: PMID:33672234
    reference_title: "Accidental Consumption of Aspartame in Phenylketonuria: Patient Experiences."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Aspartame is a phenylalanine containing sweetener, added to foods and drinks, which is avoided in phenylketonuria (PKU)."
    explanation: Directly supports aspartame avoidance as a relevant environmental exposure issue in PKU.
  - reference: PMID:3291200
    reference_title: "Aspartame: review of recent experimental and observational data."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Persons suffering from phenylketonuria (PKU-homozygotes) on a phenylalanine-restricted diet should avoid consumption of aspartame."
    explanation: Independent review supports specific aspartame avoidance guidance in PKU.
treatments:
- name: Phenylalanine-Restricted Diet
  description: Lifelong dietary restriction of phenylalanine intake, mainstay of treatment.
  treatment_term:
    preferred_term: dietary intervention
    term:
      id: MAXO:0000088
      label: dietary intervention
    dietary_modifications:
    - action: RESTRICT
      food:
        preferred_term: mammalian meat food product
        term:
          id: FOODON:00001006
          label: mammalian meat food product
    - action: RESTRICT
      food:
        preferred_term: milk
        term:
          id: FOODON:03302116
          label: cow milk (liquid)
    - action: RESTRICT
      food:
        preferred_term: nut
        term:
          id: FOODON:03303171
          label: nut
  target_mechanisms:
  - target: Hyperphenylalaninemia
    treatment_effect: INHIBITS
    description: Restricting dietary phenylalanine lowers and maintains blood phenylalanine concentrations.
    evidence:
    - reference: PMID:35854334
      reference_title: "Genetic etiology and clinical challenges of phenylketonuria."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Dietary treatment, including natural protein restriction and Phe-free supplements, must be used to maintain blood Phe concentrations of 120-360 μmol/L throughout the life span."
      explanation: Supports dietary phenylalanine restriction as acting on the hyperphenylalaninemia node.
  evidence:
  - reference: PMID:34017006
    reference_title: "Phenylketonuria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Dietary restriction of phenylalanine has been the mainstay of treatment for over 60 years and has been highly successful, although outcomes are still suboptimal and patients can find the treatment difficult to adhere to."
    explanation: Confirms diet as the primary and long-standing treatment approach.
  - reference: PMID:21555948
    reference_title: "Phenylalanine hydroxylase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The mainstay of treatment for hyperphenylalaninemia involves a low-protein diet and use of a phenylalanine-free medical formula."
    explanation: Independent clinical review confirms low-protein dietary treatment as standard of care.
- name: Medical Formula
  description: Phenylalanine-free amino acid supplements to provide protein needs.
  treatment_term:
    preferred_term: dietary intervention
    term:
      id: MAXO:0000088
      label: dietary intervention
  target_mechanisms:
  - target: Hyperphenylalaninemia
    treatment_effect: MODULATES
    description: Phenylalanine-free formula supports protein requirements while limiting phenylalanine burden.
    evidence:
    - reference: PMID:21555948
      reference_title: "Phenylalanine hydroxylase deficiency."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The mainstay of treatment for hyperphenylalaninemia involves a low-protein diet and use of a phenylalanine-free medical formula."
      explanation: GeneReviews supports phenylalanine-free medical formula as part of hyperphenylalaninemia management.
  evidence:
  - reference: PMID:21555948
    reference_title: "Phenylalanine hydroxylase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The mainstay of treatment for hyperphenylalaninemia involves a low-protein diet and use of a phenylalanine-free medical formula."
    explanation: Directly supports phenylalanine-free medical formula as standard PKU therapy.
  - reference: PMID:35854334
    reference_title: "Genetic etiology and clinical challenges of phenylketonuria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Dietary treatment, including natural protein restriction and Phe-free supplements, must be used to maintain blood Phe concentrations of 120-360 μmol/L throughout the life span."
    explanation: Independent review confirms ongoing use of Phe-free supplementation in PKU management.
- name: Sapropterin (Kuvan)
  description: BH4 cofactor replacement for responsive patients, allows dietary liberalization.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: sapropterin
      term:
        id: CHEBI:59560
        label: sapropterin
  target_mechanisms:
  - target: Residual PAH Activity and BH4 Responsiveness
    treatment_effect: ACTIVATES
    description: Sapropterin/BH4 activates residual PAH activity in responsive patients.
    evidence:
    - reference: PMID:35854334
      reference_title: "Genetic etiology and clinical challenges of phenylketonuria."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The synthetic BH4 analog, sapropterin hydrochloride (i.e., Kuvan®, BioMarin), is another potential treatment that activates residual PAH, thus decreasing Phe concentrations in the blood of PKU patients."
      explanation: Directly supports residual PAH activation as the mechanism targeted by sapropterin.
  evidence:
  - reference: PMID:34017006
    reference_title: "Phenylketonuria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Pharmacological treatments are available, such as tetrahydrobiopterin, which is effective in only a minority of patients (usually those with milder PKU)"
    explanation: Confirms sapropterin (BH4) effectiveness in a subset of patients with milder disease.
  - reference: PMID:17693179
    reference_title: "Efficacy of sapropterin dihydrochloride (tetrahydrobiopterin, 6R-BH4) for reduction of phenylalanine concentration in patients with phenylketonuria: a phase III randomised placebo-controlled study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In some patients with phenylketonuria who are responsive to BH4, sapropterin treatment to reduce blood phenylalanine could be used as an adjunct to a restrictive low-phenylalanine diet, and might even replace the diet in some instances."
    explanation: Phase III trial evidence supports sapropterin efficacy in BH4-responsive PKU.
- name: Pegvaliase (Palynziq)
  description: Enzyme substitution therapy using PEGylated phenylalanine ammonia lyase.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: pegvaliase
      term:
        id: NCIT:C174744
        label: Pegvaliase
  target_mechanisms:
  - target: Hyperphenylalaninemia
    treatment_effect: INHIBITS
    description: Pegvaliase reduces blood phenylalanine concentrations by substituting an alternative phenylalanine-catabolizing enzyme activity.
    evidence:
    - reference: PMID:29628378
      reference_title: "Pegvaliase for the treatment of phenylketonuria: A pivotal, double-blind randomized discontinuation Phase 3 clinical trial."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Results from this study confirmed the efficacy of pegvaliase in maintaining reduced blood Phe concentrations with a manageable safety profile for most participants."
      explanation: Supports pegvaliase as acting on the hyperphenylalaninemia node by maintaining reduced blood phenylalanine.
  evidence:
  - reference: PMID:34017006
    reference_title: "Phenylketonuria."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "pegylated phenylalanine ammonia lyase, which requires daily subcutaneous injections and causes adverse immune responses"
    explanation: Confirms pegvaliase as an available treatment, noting its route and immunogenicity concerns.
  - reference: PMID:29628378
    reference_title: "Pegvaliase for the treatment of phenylketonuria: A pivotal, double-blind randomized discontinuation Phase 3 clinical trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Results from this study confirmed the efficacy of pegvaliase in maintaining reduced blood Phe concentrations with a manageable safety profile for most participants."
    explanation: Pivotal Phase 3 trial independently supports pegvaliase efficacy and tolerability profile.
- name: Large Neutral Amino Acids
  description: Compete with phenylalanine for brain transport, adjunctive therapy.
  treatment_term:
    preferred_term: dietary intervention
    term:
      id: MAXO:0000088
      label: dietary intervention
  target_mechanisms:
  - target: Competitive Large Neutral Amino Acid Transport at the Blood-Brain Barrier
    treatment_effect: MODULATES
    description: Large neutral amino acid supplementation competes with phenylalanine transport into brain.
    evidence:
    - reference: PMID:35854334
      reference_title: "Genetic etiology and clinical challenges of phenylketonuria."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Additional treatments include the casein glycomacropeptide (GMP), which contains very limited aromatic amino acids and may improve immunological function, and large neutral amino acid (LNAA) supplementation to prevent plasma Phe transport into the brain."
      explanation: Supports LNAA supplementation as targeting the BBB neutral amino acid transport mechanism.
  evidence:
  - reference: PMID:987768
    reference_title: "Lowering brain phenylalanine levels by giving other large neutral amino acids. A new experimental therapeutic approach to phenylketonuria."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Increasing the serum concentrations of amino acids competitive with phenylalanine for transport across the blood brain barrier might form an alternative approach to effective dietary treatment of PKU."
    explanation: Supports LNAA supplementation rationale as an adjunctive PKU dietary strategy.
  - reference: PMID:35854334
    reference_title: "Genetic etiology and clinical challenges of phenylketonuria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Additional treatments include the casein glycomacropeptide (GMP), which contains very limited aromatic amino acids and may improve immunological function, and large neutral amino acid (LNAA) supplementation to prevent plasma Phe transport into the brain."
    explanation: Human PKU review independently supports LNAA supplementation as an adjunctive treatment strategy.
datasets:
- accession: geo:GSE294755
  title: "Whole transcriptome comparison between two groups of PKU patients: Non-carriers vs. Carriers of rs113883650"
  description: Transcriptomic profiling dataset comparing PKU carrier/non-carrier groups under differing phenylalanine exposure conditions.
  organism:
    preferred_term: Homo sapiens
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: MICROARRAY
  sample_types:
  - preferred_term: patient-derived cells
    term:
      id: CL:0000000
      label: cell
  sample_count: 19
  conditions:
  - PKU non-carrier group
  - PKU carrier group (rs113883650)
  - high phenylalanine condition
  - low phenylalanine condition
  publication: PMID:41387948
  evidence:
  - reference: geo:GSE294755
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "We demonstrated a decrease of expression of proteasome pathway (KEGG) incells treated with high Phe concentrations."
    explanation: Dataset-level summary supports relevance to PKU high-phenylalanine cellular response.
  findings:
  - statement: High-phenylalanine conditions in this cohort were associated with reduced expression of proteasome pathway genes.
    evidence:
    - reference: geo:GSE294755
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "We demonstrated a decrease of expression of proteasome pathway (KEGG) incells treated with high Phe concentrations."
      explanation: GEO summary reports pathway-level transcriptomic changes under high phenylalanine exposure.
- accession: geo:GSE112108
  title: Does early treatment of PKU patients with sapropterin dihydrochloride affect brain development?
  description: RNA-seq from organotypic rat brain cultures exposed to sepiapterin/BH4 to model developmental effects relevant to early PKU treatment contexts.
  organism:
    preferred_term: Rattus norvegicus
    term:
      id: NCBITaxon:10116
      label: Rattus norvegicus
  data_type: BULK_RNA_SEQ
  sample_types:
  - preferred_term: organotypic brain cell culture
    term:
      id: CL:0000000
      label: cell
    tissue_term:
      preferred_term: brain
      term:
        id: UBERON:0000955
        label: brain
  sample_count: 23
  conditions:
  - sepiapterin-treated
  - untreated control
  - early developmental stage
  - later developmental stage
  evidence:
  - reference: geo:GSE112108
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "RNAseq analyses revealed a number of significantly affected genes."
    explanation: Supports utility of this dataset for transcriptomic analysis of early PKU-treatment-relevant brain effects.
  findings:
  - statement: Early-stage sepiapterin exposure showed transcriptomic and cellular evidence of disturbed neural development, with increased apoptosis and altered glial/axonal markers.
    evidence:
    - reference: geo:GSE112108
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "RNAseq analyses revealed a number of significantly affected genes."
      explanation: Dataset summary confirms measurable transcriptional perturbations in treated developing brain cultures.
    - reference: geo:GSE112108
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "Immunofluorescence for activated caspase-3 revealed an increased apoptosis rate."
      explanation: Summary links treatment exposure to increased apoptosis in the early developmental stage.
- accession: geo:GSE55148
  title: Mildly compromised tetrahydrobiopterin biosynthesis mouse mutants exhibit abnormal body fat distribution and abdominal obesity
  description: Mouse expression profiling study of reduced BH4 biosynthesis (Pts mutant models), relevant to BH4-deficient hyperphenylalaninemia mechanisms.
  organism:
    preferred_term: Mus musculus
    term:
      id: NCBITaxon:10090
      label: Mus musculus
  data_type: MICROARRAY
  sample_types:
  - preferred_term: brain tissue
    term:
      id: UBERON:0000955
      label: brain
  - preferred_term: liver tissue
    term:
      id: UBERON:0002107
      label: liver
  sample_count: 16
  conditions:
  - Pts mutant mice
  - wild-type controls
  evidence:
  - reference: geo:GSE55148
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "BH4 deficiency due to an autosomal recessive defect in its biosynthetic enzyme 6-pyruvoyltetrahydropterin synthase (PTPS, encoded by the PTS gene) leads to a variant form of hyperphenylalaninemia concomitant with severe deficiency of brain monoamine neurotransmitters."
    explanation: Dataset-level summary supports relevance to BH4-associated hyperphenylalaninemia mechanisms.
  findings:
  - statement: BH4-biosynthesis impairment in this model produced metabolic phenotypes relevant to BH4-associated hyperphenylalaninemia.
    evidence:
    - reference: geo:GSE55148
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "BH4 deficiency due to an autosomal recessive defect in its biosynthetic enzyme 6-pyruvoyltetrahydropterin synthase (PTPS, encoded by the PTS gene) leads to a variant form of hyperphenylalaninemia concomitant with severe deficiency of brain monoamine neurotransmitters."
      explanation: Summary supports translational relevance of BH4-pathway models to differential hyperphenylalaninemia biology.
clinical_trials:
- name: NCT00838435
  phase: PHASE_III
  status: COMPLETED
  description: >-
    Phase 3b open-label Kuvan study in young children with PKU evaluating safety,
    neurocognitive outcomes, blood phenylalanine maintenance, and growth.
  target_phenotypes:
  - preferred_term: Intellectual Disability
    term:
      id: HP:0001249
      label: Intellectual disability
  evidence:
  - reference: clinicaltrials:NCT00838435
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This multicenter, open label study is designed to evaluate the safety of Kuvan® and its effect on neurocognitive function, blood Phe concentration, and growth in children with PKU who are 0-6 years old."
    explanation: Trial synopsis confirms explicit clinical endpoints relevant to PKU neurocognitive disease burden.
- name: NCT01212744
  phase: PHASE_II
  status: COMPLETED
  description: >-
    Phase 2 open-label trial of daily subcutaneous rAvPAL-PEG evaluating safety,
    tolerability, and efficacy for blood phenylalanine reduction in PKU.
  target_phenotypes:
  - preferred_term: Intellectual Disability
    term:
      id: HP:0001249
      label: Intellectual disability
  - preferred_term: Seizures
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: clinicaltrials:NCT01212744
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The purpose of this study is to evaluate the effect of daily administration of rAvPAL-PEG on the reduction of blood Phe concentrations in subjects with PKU."
    explanation: Confirms interventional targeting of the core biochemical driver in PKU.
- name: NCT04534842
  phase: PHASE_II
  status: COMPLETED
  description: >-
    Open-label Phase 2 SynPheny-1 trial assessing efficacy and safety of
    SYNB1618/SYNB1934 oral biotherapeutic regimens in PKU.
  target_phenotypes:
  - preferred_term: Intellectual Disability
    term:
      id: HP:0001249
      label: Intellectual disability
  evidence:
  - reference: clinicaltrials:NCT04534842
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This Phase 2 study in patients with phenylketonuria (PKU) will be an open-label, dual-arm study of either a SYNB1618 or SYNB1934 dose-ramp regimen."
    explanation: Confirms active interventional evaluation of novel PKU therapeutics in a defined patient cohort.
computational_models:
- name: Multi-compartment PKU FBA Model
  description: Three-compartment FBA model with explicit blood-brain barrier transport for aromatic amino acids
  model_type: FLUX_BALANCE_ANALYSIS
  base_model: Recon-derived
  perturbations:
  - preferred_term: PAH
    term:
      id: hgnc:8582
      label: PAH
    modifier: ABSENT
  publication: PMID:36880400
  evidence:
  - reference: PMID:36880400
    reference_title: "Competitive, multi-objective, and compartmented Flux Balance Analysis for addressing tissue-specific inborn errors of metabolism."
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: "We built a three-compartment model, made the common transport across the BBB explicit, and included dopamine and serotonin synthesis as parts of the brain function to be delivered by FBA."
    explanation: Directly supports model architecture and PKU-relevant mechanistic scope.
  modeled_mechanisms:
  - target: Competitive Large Neutral Amino Acid Transport at the Blood-Brain Barrier
    description: The FBA model explicitly represents shared BBB aromatic amino acid transport.
  - target: Reduced Dopamine Biosynthesis
    description: The FBA model includes dopamine synthesis as a brain-function objective affected by PKU metabolic constraints.
  - target: Reduced Serotonin Biosynthesis
    description: The FBA model includes serotonin synthesis as a brain-function objective affected by PKU metabolic constraints.
  notes: Explains brain-specific pathology and why Phe restriction outperforms Tyr supplementation
- name: Recon3D with PAH knockout
  description: Human genome-scale metabolic model simulating phenylalanine hydroxylase deficiency
  model_type: GENOME_SCALE_METABOLIC
  base_model: Recon3D
  repository_url: https://github.com/VirtualMetabolicHuman/Recon
  model_id: Recon3D
  model_software: COBRApy
  model_format: SBML
  perturbations:
  - preferred_term: PAH
    term:
      id: hgnc:8582
      label: PAH
    modifier: ABSENT
  publication: PMID:29457794
  evidence:
  - reference: PMID:29457794
    reference_title: "Recon3D enables a three-dimensional view of gene variation in human metabolism."
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: "Recon3D represents the most comprehensive human metabolic network model to date, accounting for 3,288 open reading frames (representing 17% of functionally annotated human genes), 13,543 metabolic reactions involving 4,140 unique metabolites, and 12,890 protein structures."
    explanation: Supports use of Recon3D as a genome-scale computational base model for metabolic disease simulation.
  modeled_mechanisms:
  - target: Hepatic PAH Enzyme Deficiency
    description: PAH knockout in Recon3D models the primary PAH-deficiency reaction defect.
  - target: Hyperphenylalaninemia
    description: PAH knockout is used to simulate the metabolic consequence of impaired phenylalanine clearance.
- name: Harvey Whole-Body PKU Model
  description: Sex-specific whole-body model for organ-resolved IEM biomarker prediction.
  model_type: GENOME_SCALE_METABOLIC
  base_model: Harvey 1.0
  repository_url: https://www.vmh.life/
  perturbations:
  - preferred_term: PAH
    term:
      id: hgnc:8582
      label: PAH
    modifier: ABSENT
  publication: PMID:32463598
  evidence:
  - reference: PMID:32463598
    reference_title: "Personalized whole-body models integrate metabolism, physiology, and the gut microbiome."
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: "We developed a new metabolic network reconstruction approach that used organ-specific information from literature and omics data to generate two sex-specific whole-body metabolic (WBM) reconstructions."
    explanation: Supports whole-body sex-specific metabolic reconstruction framework underlying Harvey/Harvetta-style models.
  - reference: PMID:32463598
    reference_title: "Personalized whole-body models integrate metabolism, physiology, and the gut microbiome."
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: "We also illustrate that the WBM models can predict known biomarkers of inherited metabolic diseases in different biofluids."
    explanation: Supports biomarker prediction capability relevant to PKU and related IEM applications.
  modeled_mechanisms:
  - target: Hepatic PAH Enzyme Deficiency
    description: Whole-body PAH absence models the inherited metabolic block across organs.
  - target: Hyperphenylalaninemia
    description: Whole-body modeling is used for inherited metabolic disease biomarker prediction, including phenylalanine-related biomarkers.
  notes: Whole-body WBM framework supports organ-resolved biomarker prediction in inherited metabolic disease.
references:
- reference: PMID:21555948
  title: "Phenylalanine hydroxylase deficiency."
  tags:
  - GeneReviews
  findings: []
classifications:
  harrisons_chapter:
  - classification_value: GENETICS_ENVIRONMENT_DISEASE
    evidence:
    - reference: PMID:21555948
      reference_title: "Phenylalanine hydroxylase deficiency."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Phenylalanine hydroxylase deficiency is an autosomal recessive disorder that results in intolerance to the dietary intake of the essential amino acid phenylalanine."
      explanation: Supports classification of PKU as a hereditary disease.

📚

References & Deep Research

References

1

PMID:21555948

Phenylalanine hydroxylase deficiency.

No top-level findings curated for this source.

Deep Research

1

Falcon ▸

1. Disease Information

Edison Scientific Literature 33 citations 2026-04-25T22:29:02.069035

1. Disease Information

1.1 What is the disease?

PKU is defined in authoritative guideline and review literature as an autosomal recessive defect of phenylalanine metabolism due to phenylalanine hydroxylase (PAH) deficiency, causing elevated Phe in blood/brain and (if untreated) severe neurodevelopmental sequelae. (spronsen2017keyeuropeanguidelines pages 1-1, martinez2024state‐of‐the‐art2023on pages 1-3)

Direct abstract quote (European guideline): “Phenylketonuria (PKU) is an autosomal recessive inborn error of phenylalanine metabolism caused by deficiency in the enzyme phenylalanine hydroxylase that converts phenylalanine into tyrosine.” (spronsen2017keyeuropeanguidelines pages 1-1)

1.2 Key identifiers (requested: OMIM, Orphanet, ICD-10/ICD-11, MeSH, MONDO)

OMIM: 261600 (explicitly cited as “PKU, OMIM 261600” in recent clinical literature). (cunningham2023nutritionmanagementof pages 1-2, maissenabgottspon2023healthrelatedqualityof pages 1-2)
Orphanet / ICD / MeSH / MONDO: Not directly extractable from the currently retrieved full texts; additional direct database queries (e.g., Orphanet, MONDO, MeSH Browser, ICD-11) would be required for authoritative IDs.

1.3 Synonyms and alternative names

Frequently used equivalents include: * PAH deficiency / phenylalanine hydroxylase deficiency (common in guidelines and mechanistic reviews). (spronsen2017keyeuropeanguidelines pages 1-1, martinez2024state‐of‐the‐art2023on pages 1-3) * Hyperphenylalaninemia (HPA) is often used as an umbrella phenotype category; PKU is typically reserved for higher untreated Phe ranges or clinically significant disease requiring treatment. (pinto2024bloodphenylalaninelevels pages 2-3, hofman2018dietaryadherencein pages 41-45)

1.4 Evidence sources: individual vs aggregated resources

Most core disease knowledge (definition, targets, thresholds) is derived from aggregated guideline and consensus processes (systematic evidence grading plus Delphi methods) as in the European guidelines. (spronsen2017keyeuropeanguidelines pages 1-1)

2. Etiology

2.1 Disease causal factors

Primary cause (genetic/mechanistic): biallelic PAH variants → reduced PAH enzyme activity → increased Phe and altered Tyr availability; PAH uses tetrahydrobiopterin (BH4) as a cofactor. (pinto2024bloodphenylalaninelevels pages 2-3, spronsen2017keyeuropeanguidelines pages 1-1)

2.2 Risk factors

Genetic: pathogenic PAH variants (many alleles; an example allele specifically noted in a recent European cohort paper is c.1222C>T (p.Arg408Trp)). (pinto2024bloodphenylalaninelevels pages 2-3)
Environmental / behavioral: the dominant modifiable “risk factor” for clinical deterioration is chronic exposure to elevated blood Phe, largely driven by difficulty adhering to restrictive diet over time. Age-related deterioration of metabolic control is documented in large European real-world data. (pinto2024bloodphenylalaninelevels pages 2-3)

2.3 Protective factors

Early detection by NBS and early treatment is protective against the classic severe neurodevelopmental phenotype. (spronsen2017keyeuropeanguidelines pages 1-1)
More frequent blood Phe monitoring is associated with better control (likely enabling faster dietary/therapy adjustments). (pinto2024bloodphenylalaninelevels pages 2-3)

2.4 Gene–environment interaction

PKU is a canonical gene–environment interaction disease: the genotype (residual PAH function; BH4 responsiveness) interacts with dietary Phe exposure to determine blood Phe and outcomes; guideline targets are operationalized as blood Phe thresholds for lifelong management. (spronsen2017keyeuropeanguidelines pages 1-1, spronsen2017keyeuropeanguidelines pages 4-5)

3. Phenotypes (clinical spectrum)

3.1 Phenotype spectrum and laboratory phenotype categories

A commonly used severity schema (based on untreated Phe) includes: * Mild hyperphenylalaninemia: ~120–600 µmol/L * Classic PKU: often >1200 µmol/L These categorical thresholds are summarized in recent literature and reviews. (alfadhel2024firstsuccessfuloutcomes pages 1-2, yu2025advancinggenetherapy pages 2-4)

3.2 Major clinical manifestations (with suggested HPO terms)

Untreated/late-treated PKU is associated with severe neurodevelopmental outcomes (intellectual disability, seizures/epilepsy, behavioral problems). (spronsen2017keyeuropeanguidelines pages 1-1)

Early-treated PKU (lifelong care): subtle but clinically relevant outcomes can persist, especially with higher Phe exposure: * Executive dysfunction (HP:0000726) * Attention deficit (HP:0007018) * Memory impairment (HP:0002354) * Anxiety (HP:0000739) * Depressive mood (HP:0000716) * Ataxia (HP:0001251) / tremor (HP:0001337) These associations are emphasized in cohort and guideline discussions linking blood Phe to neuropsychological and neurological outcomes. (pinto2024bloodphenylalaninelevels pages 2-3, spronsen2017keyeuropeanguidelines pages 4-5)

3.3 Age of onset, progression, and frequency

Onset: congenital; clinically silent at birth; adverse outcomes emerge with sustained feeding/accumulation without treatment (hence NBS importance). (spronsen2017keyeuropeanguidelines pages 1-1)
Progression: metabolic control commonly deteriorates after childhood/adolescence and into adulthood, with a clear age gradient in real-world data. (pinto2024bloodphenylalaninelevels pages 2-3)

3.4 Quality of life (QoL) impact (recent primary data)

In a cross-sectional European study of 124 adults with early-treated classical PKU, most QoL domains showed “little or no impact,” and “more than three-quarters” rated their health status as good/very good/excellent; however, fatigue (“tiredness”), guilt about dietary non-adherence, and pregnancy-related Phe concerns were salient. (maissenabgottspon2023healthrelatedqualityof pages 1-2)

4. Genetic / Molecular Information

4.1 Causal genes

PAH is the principal causal gene for classic PKU / PAH deficiency. (spronsen2017keyeuropeanguidelines pages 1-1, martinez2024state‐of‐the‐art2023on pages 1-3)

4.2 Pathogenic variants (current understanding)

A comprehensive variant catalogue is not present in the retrieved texts, but recent gene-therapy-oriented reviews note very large allelic heterogeneity (thousands of reported PAH variants) and population-specific common alleles; example common alleles are listed (e.g., R408W). (yu2025advancinggenetherapy pages 2-4)

4.3 BH4 responsiveness (therapeutic stratifier)

BH4 responsiveness is central to precision management: * European guidelines note that “some patients benefit from tetrahydrobiopterin (BH4).” (spronsen2017keyeuropeanguidelines pages 1-1) * Expert consensus highlights substantial non-responsiveness in more severe phenotypes; one expert consensus summary states “about 50–80% of patients, especially those with a more severe disease phenotype, are unresponsive to sapropterin.” (rocha2023expertconsensuson pages 1-2)

4.4 Modifier genes / epigenetics / chromosomal abnormalities

Not extractable from the currently retrieved texts.

5. Environmental Information

The dominant environmental determinant of phenotype severity is dietary phenylalanine exposure (and adherence to medical nutrition therapy), rather than exogenous toxins or infections. Restrictive dietary therapy itself can influence broader physiology (e.g., nutrient status), motivating ongoing monitoring and therapy optimization. (rocha2023expertconsensuson pages 1-2, pinto2024bloodphenylalaninelevels pages 2-3)

6. Mechanism / Pathophysiology

6.1 Causal chain (upstream → downstream)

PAH deficiency reduces hepatic conversion of Phe → Tyr (BH4-dependent). (spronsen2017keyeuropeanguidelines pages 1-1, pinto2024bloodphenylalaninelevels pages 2-3)
Elevated blood Phe and altered amino-acid balance leads to brain exposure.
Neurotoxicity mechanisms include reduced transport of other large neutral amino acids across the blood–brain barrier and downstream neurotransmitter synthesis disruption.

Guidelines explicitly note that high Phe causes neurocognitive impairment via “reduced LNAA transport and decreases in neurotransmitter synthesis (↓Trp→↓serotonin; ↓Tyr→↓dopamine).” (spronsen2017keyeuropeanguidelines pages 4-5)

6.2 Neuroimaging/brain structure outcomes (recent studies)

Adult treated PKU still shows structural brain differences in contemporary cohorts: * In a neurodevelopmental disorders study (PKU n=35; controls n=22), adults with PKU had lower Full Scale IQ and reduced volumes in pallidum, hippocampus, amygdala, brainstem, and total cerebral white matter; blood Phe correlated negatively with pallidum and brainstem volumes. (pinto2024bloodphenylalaninelevels pages 2-3)

6.3 Suggested ontology terms

GO biological processes: phenylalanine catabolic process; aromatic amino acid family metabolic process; neurotransmitter biosynthetic process.
UBERON anatomical sites: liver (primary metabolic defect), brain/white matter/subcortical structures (major affected targets).
CHEBI: phenylalanine; tyrosine; tetrahydrobiopterin.

(These ontology mappings are consistent with the mechanistic chain described in guidelines and cohort papers, though explicit ontology annotations are not contained in the retrieved texts.) (pinto2024bloodphenylalaninelevels pages 2-3, spronsen2017keyeuropeanguidelines pages 4-5)

7. Anatomical Structures Affected

Primary organ (disease origin): liver (hepatic PAH deficiency). (spronsen2017keyeuropeanguidelines pages 1-1)
Primary target organ (toxicity): brain (white matter and subcortical structures) with correlations to blood Phe. (pinto2024bloodphenylalaninelevels pages 2-3)

8. Temporal Development

Congenital onset with potential for severe outcomes if untreated.
Lifelong course: guideline targets are lifelong, and real-world data show deterioration of metabolic control with age, implying ongoing vulnerability across the lifespan. (pinto2024bloodphenylalaninelevels pages 2-3, spronsen2017keyeuropeanguidelines pages 1-1)

9. Inheritance and Population

9.1 Inheritance

Autosomal recessive inheritance is consistently stated in guidelines and contemporary reviews. (spronsen2017keyeuropeanguidelines pages 1-1, martinez2024state‐of‐the‐art2023on pages 1-3)

9.2 Epidemiology / prevalence / incidence

Not extractable from the currently retrieved texts.

9.3 Real-world metabolic-control statistics (Europe 2012–2018)

A 9-centre European/Turkish retrospective study of 1323 patients (age 1–57 years) reported that the percentage of Phe values within target declined with increasing age, with a particularly low proportion in older adults (≥41 years: 40%). (pinto2024bloodphenylalaninelevels pages 2-3)

10. Diagnostics

10.1 Screening

Newborn screening is the standard population screening approach for early identification and prevention of severe sequelae. (spronsen2017keyeuropeanguidelines pages 1-1)

10.2 Key diagnostic biomarker and targets

Blood phenylalanine (Phe) is the core biomarker for diagnosis and management. (spronsen2017keyeuropeanguidelines pages 1-1, pinto2024bloodphenylalaninelevels pages 2-3)

European 2017 guideline targets and treatment thresholds: * Targets: 120–360 µmol/L (0–12 years and maternal PKU) and 120–600 µmol/L (>12 years, non-pregnant). (spronsen2017keyeuropeanguidelines pages 1-1, spronsen2017keyeuropeanguidelines pages 4-5) * Threshold logic: no intervention if untreated Phe <360 µmol/L; treat to age 12 when untreated Phe is 360–600 µmol/L; lifelong treatment if untreated Phe >600 µmol/L. (spronsen2017keyeuropeanguidelines pages 1-1)

11. Outcome / Prognosis

11.1 Prognostic factors

Blood Phe exposure is repeatedly emphasized as the key modifiable prognostic factor; higher Phe is associated with worse neurocognitive and some structural brain outcomes. (pinto2024bloodphenylalaninelevels pages 2-3, spronsen2017keyeuropeanguidelines pages 4-5)

11.2 Maternal PKU (teratogenic risk)

European guidelines specify tighter pregnancy targets (120–360 µmol/L) and note that women with untreated Phe <360 µmol/L may not require lowering for pregnancy, reflecting the established fetal risk from elevated maternal Phe. (spronsen2017keyeuropeanguidelines pages 4-5)

12. Treatment (current practice, 2023–2024 developments)

12.1 Medical nutrition therapy (MNT)

MNT (low-Phe diet + protein substitutes/medical foods) remains foundational. Expert consensus in adults (Delphi panel) concluded MNT has limited long-term effectiveness, is associated with high treatment burden, and many adults cannot achieve adequate metabolic control on diet alone—supporting an “unmet need” in adult PKU. (rocha2023expertconsensuson pages 1-2)

Expert opinion signal: The same consensus notes an 85% agreement statement that adults should be offered pharmacologic options when available. (rocha2023expertconsensuson pages 4-5)

12.2 Sapropterin (BH4 analogue)

Sapropterin (BH4) is used for responsive patients with residual PAH activity. In the European cohort (n=1323), sapropterin-treated patients (n=222) had statistically lower mean Phe and higher proportion within target than diet-only, though the mean difference was modest. (pinto2024bloodphenylalaninelevels pages 2-3)

12.3 Pegvaliase (enzyme substitution therapy)

A 2023 update of the web-based GMDI/SERN PKU nutrition management guideline incorporated pegvaliase implementation and monitoring, noting regulatory approvals (FDA 2018; EMA 2019) and the possibility of substantial diet liberalization with successful therapy. (cunningham2023nutritionmanagementof pages 1-2)

Quantitative efficacy and safety (PAL-003 extension): In a long-term phase 2 extension (n=68 entering extension), mean Phe decreased ~59% to ~542 µmol/L at Week 48; thresholds ≤120, ≤360, and ≤600 µmol/L were achieved by ~79–83% of participants. Injection-site reactions, erythema, headache, and arthralgia were common; most AEs were mild/moderate. (longo2018longtermsafetyand pages 1-2)

12.4 Emerging therapies (2024–2026 clinical development)

JNT-517 (oral small-molecule; Otsuka) — clinical trials

NCT06971731 (Phase 3 adults; n≈120): randomized placebo-controlled trial with primary endpoint percent change in plasma Phe at Weeks 2/4/6 for 150 mg BID; includes responder thresholds such as <600, <360, <120 µmol/L. (NCT06971731 chunk 1)
NCT06637514 (Phase 2 adolescents 12–<18; n≈10): primary objectives safety/tolerability/PK; secondary outcomes include changes in plasma and urinary Phe. (NCT06637514 chunk 1)
NCT05781399 (First-in-human, healthy + PKU adults): includes urinary amino-acid change measures and PK comparisons. (NCT05781399 chunk 2)
NCT06628128 (Phase 3 open-label extension): long-term safety (TEAEs) and metabolic outcomes (plasma/urinary Phe; dietary intake). (NCT06628128 chunk 1)

AAV gene therapy (liver-directed PAH gene addition) — clinical trials

BMN 307 (BioMarin) — NCT04480567 (Phase 1/2; open-label; dose escalation; n≈100): primary outcome is change from baseline in mean plasma Phe at Week 12; secondary outcomes include Phe and dietary protein intake at Week 96 and TEAEs up to 5 years. (NCT04480567 chunk 1)
Reviews of gene therapy note ongoing/terminated AAV programs and highlight safety concerns (e.g., transaminase elevations) and challenges for long-term expression, particularly in younger patients. (martinez2024state‐of‐the‐art2023on pages 10-12, yu2025advancinggenetherapy pages 11-12)

12.5 Suggested MAXO terms (examples)

Dietary phenylalanine restriction / medical nutrition therapy (MAXO: dietary therapy)
Sapropterin pharmacotherapy (MAXO: pharmacotherapy)
Pegvaliase enzyme therapy (MAXO: enzyme replacement/enzyme substitution therapy)
AAV-based gene transfer (MAXO: gene therapy)

(Explicit MAXO identifiers were not present in retrieved texts; these are conceptual mappings.)

13. Prevention

Secondary prevention: NBS + early treatment initiation prevents severe irreversible neurodevelopmental injury. (spronsen2017keyeuropeanguidelines pages 1-1)
Tertiary prevention: lifelong metabolic monitoring and maintaining target Phe ranges; more frequent monitoring is associated with improved control. (pinto2024bloodphenylalaninelevels pages 2-3)
Maternal PKU prevention: pregnancy target Phe 120–360 µmol/L per European guidelines. (spronsen2017keyeuropeanguidelines pages 4-5)

14. Other species / natural disease

Not addressed in the retrieved evidence.

15. Model organisms

A 2024 gene-therapy review notes that murine models replicate key aspects of human pathology and are extensively used for liver-directed gene therapy proof-of-principle, including multiple vector/editing approaches; a classic model referenced is the homozygous enu2/2 mouse. (martinez2024state‐of‐the‐art2023on pages 10-12)

Recent developments (prioritizing 2023–2024)

Guideline/practice update for pegvaliase nutrition management (Jun 2023) with implementation toolkits for initiation, monitoring, and special populations. URL: https://doi.org/10.1186/s13023-023-02751-0 (cunningham2023nutritionmanagementof pages 1-2)
Delphi expert consensus (Sep 2023) highlighting limitations/burden of lifelong diet therapy in adults and recommending pharmacologic options when available. URL: https://doi.org/10.3390/nu15183940 (rocha2023expertconsensuson pages 4-5)
Large multi-centre real-world European dataset (Jun 2024) quantifying age-associated deterioration in metabolic control and association of monitoring frequency with control. URL: https://doi.org/10.3390/nu16132064 (pinto2024bloodphenylalaninelevels pages 2-3)
Gene therapy state-of-the-art (Aug 2024) summarizing AAV, lentiviral, and nonviral/LNP mRNA approaches and the translational barriers. URL: https://doi.org/10.1002/jimd.12651 (martinez2024state‐of‐the‐art2023on pages 1-3)

Data gaps vs requested template

Several template elements could not be completed from the currently retrieved texts, notably: MONDO/MeSH/Orphanet/ICD identifiers; prevalence/incidence and carrier frequencies; detailed PAH variant spectra with ClinVar/gnomAD frequencies; modifier genes/epigenetics; comprehensive organ-system comorbidity statistics from the 2024 somatic comorbidity SLR (full numeric extraction was not available in the retrieved snippets); and detailed cross-species natural disease information. Where these items are essential for a knowledge base entry, direct database retrieval (Orphanet/MONDO/MeSH/ICD; ClinVar; gnomAD; registry epidemiology sources) and full-text extraction of the SLR’s included primary studies would be required. (whitehall2024systematicliteraturereview pages 49-49)

References

(pinto2024bloodphenylalaninelevels pages 2-3): Alex Pinto, Kirsten Ahring, Manuela Ferreira Almeida, Catherine Ashmore, Amaya Bélanger-Quintana, Alberto Burlina, Turgay Coşkun, Anne Daly, Esther van Dam, Ali Dursun, Sharon Evans, François Feillet, Maria Giżewska, Hulya Gökmen-Özel, Mary Hickson, Yteke Hoekstra, Fatma Ilgaz, Richard Jackson, Alicja Leśniak, Christian Loro, Katarzyna Malicka, Michał Patalan, Júlio César Rocha, Serap Sivri, Iris Rodenburg, Francjan van Spronsen, Kamilla Strączek, Ayşegül Tokatli, and Anita MacDonald. Blood phenylalanine levels in patients with phenylketonuria from europe between 2012 and 2018: is it a changing landscape? Nutrients, 16:2064, Jun 2024. URL: https://doi.org/10.3390/nu16132064, doi:10.3390/nu16132064. This article has 14 citations.
(spronsen2017keyeuropeanguidelines pages 1-1): Francjan J van Spronsen, Annemiek MJ van Wegberg, Kirsten Ahring, Amaya Bélanger-Quintana, Nenad Blau, Annet M Bosch, Alberto Burlina, Jaime Campistol, Francois Feillet, Maria Giżewska, Stephan C Huijbregts, Shauna Kearney, Vincenzo Leuzzi, Francois Maillot, Ania C Muntau, Fritz K Trefz, Margreet van Rijn, John H Walter, and Anita MacDonald. Key european guidelines for the diagnosis and management of patients with phenylketonuria. The Lancet Diabetes & Endocrinology, 5:743-756, Sep 2017. URL: https://doi.org/10.1016/s2213-8587(16)30320-5, doi:10.1016/s2213-8587(16)30320-5. This article has 551 citations and is from a highest quality peer-reviewed journal.
(martinez2024state‐of‐the‐art2023on pages 1-3): Michael Martinez, Cary O. Harding, Gerald Schwank, and Beat Thöny. State‐of‐the‐art 2023 on gene therapy for phenylketonuria. Journal of Inherited Metabolic Disease, 47:80-92, Aug 2024. URL: https://doi.org/10.1002/jimd.12651, doi:10.1002/jimd.12651. This article has 43 citations and is from a peer-reviewed journal.
(cunningham2023nutritionmanagementof pages 1-2): Amy Cunningham, Fran Rohr, Patricia Splett, Shideh Mofidi, Heather Bausell, Adrya Stembridge, Aileen Kenneson, and Rani H. Singh. Nutrition management of pku with pegvaliase therapy: update of the web-based pku nutrition management guideline recommendations. Orphanet Journal of Rare Diseases, Jun 2023. URL: https://doi.org/10.1186/s13023-023-02751-0, doi:10.1186/s13023-023-02751-0. This article has 32 citations and is from a peer-reviewed journal.
(maissenabgottspon2023healthrelatedqualityof pages 1-2): Stephanie Maissen-Abgottspon, Raphaela Muri, Michel Hochuli, Péter Reismann, András Gellért Barta, Ismail Mucahit Alptekin, Álvaro Hermida-Ameijeiras, Alessandro P. Burlina, Alberto B. Burlina, Chiara Cazzorla, Jessica Carretta, Roman Trepp, and Regula Everts. Health-related quality of life in a european sample of adults with early-treated classical pku. Orphanet Journal of Rare Diseases, Sep 2023. URL: https://doi.org/10.1186/s13023-023-02917-w, doi:10.1186/s13023-023-02917-w. This article has 14 citations and is from a peer-reviewed journal.
(spronsen2017keyeuropeanguidelines pages 4-5): Francjan J van Spronsen, Annemiek MJ van Wegberg, Kirsten Ahring, Amaya Bélanger-Quintana, Nenad Blau, Annet M Bosch, Alberto Burlina, Jaime Campistol, Francois Feillet, Maria Giżewska, Stephan C Huijbregts, Shauna Kearney, Vincenzo Leuzzi, Francois Maillot, Ania C Muntau, Fritz K Trefz, Margreet van Rijn, John H Walter, and Anita MacDonald. Key european guidelines for the diagnosis and management of patients with phenylketonuria. The Lancet Diabetes & Endocrinology, 5:743-756, Sep 2017. URL: https://doi.org/10.1016/s2213-8587(16)30320-5, doi:10.1016/s2213-8587(16)30320-5. This article has 551 citations and is from a highest quality peer-reviewed journal.
(rocha2023expertconsensuson pages 1-2): Júlio César Rocha, Kirsten K. Ahring, Heather Bausell, Deborah A. Bilder, Cary O. Harding, Anita Inwood, Nicola Longo, Ania C. Muntau, André L. Santos Pessoa, Fran Rohr, Serap Sivri, and Álvaro Hermida. Expert consensus on the long-term effectiveness of medical nutrition therapy and its impact on the outcomes of adults with phenylketonuria. Nutrients, 15:3940, Sep 2023. URL: https://doi.org/10.3390/nu15183940, doi:10.3390/nu15183940. This article has 15 citations.
(rocha2023expertconsensuson pages 4-5): Júlio César Rocha, Kirsten K. Ahring, Heather Bausell, Deborah A. Bilder, Cary O. Harding, Anita Inwood, Nicola Longo, Ania C. Muntau, André L. Santos Pessoa, Fran Rohr, Serap Sivri, and Álvaro Hermida. Expert consensus on the long-term effectiveness of medical nutrition therapy and its impact on the outcomes of adults with phenylketonuria. Nutrients, 15:3940, Sep 2023. URL: https://doi.org/10.3390/nu15183940, doi:10.3390/nu15183940. This article has 15 citations.
(martinez2024state‐of‐the‐art2023on pages 10-12): Michael Martinez, Cary O. Harding, Gerald Schwank, and Beat Thöny. State‐of‐the‐art 2023 on gene therapy for phenylketonuria. Journal of Inherited Metabolic Disease, 47:80-92, Aug 2024. URL: https://doi.org/10.1002/jimd.12651, doi:10.1002/jimd.12651. This article has 43 citations and is from a peer-reviewed journal.
(hofman2018dietaryadherencein pages 41-45): DL Hofman. Dietary adherence in phenylketonuria (pku) and effects on cognitive function and quality of life. Unknown journal, 2018.
(alfadhel2024firstsuccessfuloutcomes pages 1-2): Majid Alfadhel and Rayyan Albarakati. First successful outcomes of pegvaliase (palynziq) in children. BMC Medical Genomics, Mar 2024. URL: https://doi.org/10.1186/s12920-024-01847-1, doi:10.1186/s12920-024-01847-1. This article has 3 citations and is from a peer-reviewed journal.
(yu2025advancinggenetherapy pages 2-4): In-sun Yu and Jaemin Jeong. Advancing gene therapy for phenylketonuria: from precision editing to clinical translation. International Journal of Molecular Sciences, 26:8722, Sep 2025. URL: https://doi.org/10.3390/ijms26178722, doi:10.3390/ijms26178722. This article has 3 citations.
(longo2018longtermsafetyand pages 1-2): Nicola Longo, Roberto Zori, Melissa P. Wasserstein, Jerry Vockley, Barbara K. Burton, Celeste Decker, Mingjin Li, Kelly Lau, Joy Jiang, Kevin Larimore, and Janet A. Thomas. Long-term safety and efficacy of pegvaliase for the treatment of phenylketonuria in adults: combined phase 2 outcomes through pal-003 extension study. Orphanet Journal of Rare Diseases, Jul 2018. URL: https://doi.org/10.1186/s13023-018-0858-7, doi:10.1186/s13023-018-0858-7. This article has 37 citations and is from a peer-reviewed journal.
(NCT06971731 chunk 1): A Study to Evaluate the Safety and Efficacy of JNT-517 in Participants With Phenylketonuria (PKU). Otsuka Pharmaceutical Development & Commercialization, Inc.. 2025. ClinicalTrials.gov Identifier: NCT06971731
(NCT06637514 chunk 1): A Phase 2 Study of JNT-517 in Adolescent Participants With Phenylketonuria. Otsuka Pharmaceutical Development & Commercialization, Inc.. 2025. ClinicalTrials.gov Identifier: NCT06637514
(NCT05781399 chunk 2): First-in-Human, Multiple Part Clinical Study of JNT-517 in Healthy Participants and in Participants With Phenylketonuria. Otsuka Pharmaceutical Development & Commercialization, Inc.. 2022. ClinicalTrials.gov Identifier: NCT05781399
(NCT06628128 chunk 1): A Study to Evaluate the Long-Term Safety and Efficacy of JNT-517 in Participants With Phenylketonuria. Otsuka Pharmaceutical Development & Commercialization, Inc.. 2025. ClinicalTrials.gov Identifier: NCT06628128
(NCT04480567 chunk 1): AAV Gene Therapy Study for Subjects with PKU. BioMarin Pharmaceutical. 2020. ClinicalTrials.gov Identifier: NCT04480567
(yu2025advancinggenetherapy pages 11-12): In-sun Yu and Jaemin Jeong. Advancing gene therapy for phenylketonuria: from precision editing to clinical translation. International Journal of Molecular Sciences, 26:8722, Sep 2025. URL: https://doi.org/10.3390/ijms26178722, doi:10.3390/ijms26178722. This article has 3 citations.
(whitehall2024systematicliteraturereview pages 49-49): Kaleigh B. Whitehall, Sarah Rose, Gillian E. Clague, Kirsten K. Ahring, Deborah A. Bilder, Cary O. Harding, Álvaro Hermida, Anita Inwood, Nicola Longo, François Maillot, Ania C. Muntau, André L. S. Pessoa, Júlio C. Rocha, Fran Rohr, Serap Sivri, Jack Said, Sheun Oshinbolu, and Gillian C. Sibbring. Systematic literature review of the somatic comorbidities experienced by adults with phenylketonuria. Orphanet Journal of Rare Diseases, Aug 2024. URL: https://doi.org/10.1186/s13023-024-03203-z, doi:10.1186/s13023-024-03203-z. This article has 12 citations and is from a peer-reviewed journal.

Ask OpenScientist

OpenScientist Report

Classifications

Mappings

Definitions

Inheritance

Subtypes

Mechanistic Hypotheses

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Medical Actions

Environmental Factors

Biochemical Markers

Differential Diagnoses

Related Datasets

Clinical Trials

Computational Models

Source YAML

References & Deep Research

References

Deep Research

1. Disease Information

1.1 What is the disease?

1.2 Key identifiers (requested: OMIM, Orphanet, ICD-10/ICD-11, MeSH, MONDO)

1.3 Synonyms and alternative names

1.4 Evidence sources: individual vs aggregated resources

2. Etiology

2.1 Disease causal factors

2.2 Risk factors

2.3 Protective factors

2.4 Gene–environment interaction

3. Phenotypes (clinical spectrum)

3.1 Phenotype spectrum and laboratory phenotype categories

3.2 Major clinical manifestations (with suggested HPO terms)

3.3 Age of onset, progression, and frequency

3.4 Quality of life (QoL) impact (recent primary data)

4. Genetic / Molecular Information

4.1 Causal genes

4.2 Pathogenic variants (current understanding)

4.3 BH4 responsiveness (therapeutic stratifier)

4.4 Modifier genes / epigenetics / chromosomal abnormalities

5. Environmental Information

6. Mechanism / Pathophysiology

6.1 Causal chain (upstream → downstream)

6.2 Neuroimaging/brain structure outcomes (recent studies)

6.3 Suggested ontology terms

7. Anatomical Structures Affected

8. Temporal Development

9. Inheritance and Population

9.1 Inheritance

9.2 Epidemiology / prevalence / incidence

9.3 Real-world metabolic-control statistics (Europe 2012–2018)

10. Diagnostics

10.1 Screening

10.2 Key diagnostic biomarker and targets

11. Outcome / Prognosis

11.1 Prognostic factors

11.2 Maternal PKU (teratogenic risk)

12. Treatment (current practice, 2023–2024 developments)

12.1 Medical nutrition therapy (MNT)

12.2 Sapropterin (BH4 analogue)

12.3 Pegvaliase (enzyme substitution therapy)

12.4 Emerging therapies (2024–2026 clinical development)

JNT-517 (oral small-molecule; Otsuka) — clinical trials

AAV gene therapy (liver-directed PAH gene addition) — clinical trials

12.5 Suggested MAXO terms (examples)

13. Prevention

14. Other species / natural disease

15. Model organisms

Recent developments (prioritizing 2023–2024)

Data gaps vs requested template